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Background: Patients often experience changes to their medicines regimen while 
they are in hospital, and it is healthcare policy in the UK to ensure that patients’ 
medicines are managed optimally after discharge from secondary care. However, 
research suggests that a substantial proportion of patients who have been discharged 
from hospital subsequently experience medicines-related problems and require 
support. Patient medicines helpline services (PMHS) have been set up by some 
National Health Service (NHS) Trusts in England, with the aim of providing 
medicines-related support to discharged patients. However, to date, little high-quality 
research has been conducted to examine the impact of PMHS upon service users 
and healthcare organisations. 
 
Aims: The aim of this doctoral research was to address the following question: What 
is the impact of National Health Service patient medicines helpline services upon 
service users and healthcare organisations? In order to achieve this, the RE-AIM 
framework was used throughout the research. RE-AIM comprises five dimensions 
which are considered important for evaluating the impact of interventions (Reach, 
Effectiveness, Adoption, Implementation, and Maintenance). 
 
Methods: A mixed-methods approach was adopted, and five studies were conducted. 
In study one, an online survey was sent to pharmacy professionals at all 226 acute, 
mental health, specialist, and community NHS Trusts in England in 2017. Its aim was 
to obtain key data concerning the provision and usage of PMHS in NHS Trusts in 
England. Studies two and three were systematic reviews. Study two systematically 
examined the available literature regarding the effectiveness of medicines information 
services for patients and the general public. Study three systematically examined the 
available literature regarding the characteristics of users of PMHS, and the types of 
enquiries they make. Studies four and five were qualitative. Study four explored thirty-
four pharmacy professionals’ perceptions and experiences of providing PMHS, and its 
data were analysed using Framework Analysis. Study five explored forty service 
users’ experiences of contacting PMHS, and its data were analysed using Inductive 




Main findings: The findings suggest that PMHS have the potential to provide timely 
medicines-related support to patients and carers when they are feeling vulnerable 
during the transition from secondary to primary care. Additionally, PMHS are 
perceived as effective and valued from the perspectives of pharmacy professionals 
who provide them, and patients and carers who use them (e.g., satisfaction ratings 
are excellent, and users typically rate that the advice was followed). However, the 
evidence regarding the effectiveness of PMHS is limited by primarily consisting of 
subjective experiences and perceptions (e.g., survey and interview data) rather than 
hard outcomes (e.g., symptoms, disease recurrence, readmission rates). The findings 
also show that, despite their perceived benefits, the limited adoption, implementation, 
and reach of PMHS hinders their overall impact. For example, approximately only fifty 
percent of Trusts provide this service, and of those that do, on average only five 
enquiries are received per week per Trust. Additionally, the availability and promotion 
of extant PMHS could be improved. The limited adoption, implementation, and reach 
of PMHS is largely a consequence of limited resources and staffing to adequately 
provide this service. However, despite this, the findings suggest that once adopted, 
PMHS are likely to become a relatively stable service for NHS Trusts.  
 
Conclusions: Based upon the findings of this doctoral research, practice 
recommendations have been made to improve the delivery of extant PMHS, in order 
to provide a more valued and efficient service. This has largely focussed upon 
improving the availability and promotion of PMHS, and for pharmacy professionals 
who provide a PMHS to share their learning with the wider MI community regarding 
ways to provide a PMHS with limited resources. However, since PMHS are currently 
provided suboptimally (e.g., they are only provided by half of NHS Trusts, and they 
are provided in a way that does not meet national standards), and since research has 
not been conducted to establish their cost-effectiveness, another recommendation is 
for stakeholders to consider the best way to support patients with their medicines 
following discharge from secondary care. Thus, research recommendations from this 
doctoral research focus upon exploring the future of PMHS, and establishing the best 
way to support all patients who need help with their medicines following discharge 
from secondary care, which is efficient and cost-effective yet without diminishing 
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Chapter 1: Structure of thesis 
 
1.1 Overview of Chapter 1 
 
This introductory chapter provides a summary of the doctoral research, including 
the overarching research question being addressed, and the chapters comprising this 
thesis. 
 
1.2 Summary of doctoral research topic 
 
National Health Service (NHS) policies regarding hospital discharges within the 
United Kingdom (UK) predominantly focus upon the issue of delayed transfers of 
care, with the aim of discharging patients as soon as possible (1-4). However, 
although rarely mentioned in NHS England and Department of Health policy 
documents, it is also essential to improve the safety of transitions for patients 
between different healthcare services and settings (5, 6). A suboptimal transition from 
hospital to home can be risky for a patient, and medicines-related problems may 
result in rehospitalisation, adverse medical events, and even death (7, 8). Hospital 
discharge has the potential to be a confusing and/or risky period for patients who 
have recently experienced changes to their medicines. Many patients leave hospital 
with gaps in their knowledge about their medicines (9-14), and a sizeable percentage 
of patients subsequently experience medicines-related errors and require support 
with medicines-related problems (15-22).  
 
Patient medicines helpline services (PMHS) have been set up at some NHS 
Trusts in the UK, with the aim of providing an information and advice service to 
recently discharged hospital patients and their carers who have questions or 
concerns about the patient’s prescribed medicines. Providing a PMHS accords with 
healthcare policy recommendations regarding the importance of not only providing 
patients with information, but also giving patients the opportunity to seek information 
about their care (23, 24). For example, providing a PMHS accords with World Health 
Organisation (WHO) policy, which states that offering information on medicines via 
Medicines Information (MI) centres, and providing public education about medicines, 




Despite the first PMHS being established in 1992, prior to this doctoral research, 
PMHS had not been evaluated in a rigorous way. The small number of studies that 
had been published were mainly service evaluations conducted by providers of 
PMHS who had evaluated their own service, and therefore may be biased (e.g., 
selection and measurement bias) and lack generalisability (25-28). Findings 
suggested that service users are typically satisfied with the service, and that PMHS 
may provide an avenue for improving services within the Trust (e.g., improving 
discharge summaries, based upon the content of PMHS enquiries). Additionally, two 
surveys had been conducted to establish the provision of PMHS (25, 29). These 
surveys found that not all hospitals in the UK provide a PMHS, and that PMHS are 
provided in different ways (e.g., different hours of availability). Such differences in the 
provision of PMHS may affect the overall impact of this service to achieve its aim – to 
provide medicines-related support to patients following their discharge from 
secondary to primary care. Thus, the aim of this doctorate was to conduct high-quality 
research that examines the impact of PMHS on service users and healthcare 
organisations. 
 
1.3 Research question for this doctoral research 
 
The overarching research question to be addressed was: What is the impact of 
National Health Service (NHS) patient medicines helpline services upon service users 
and healthcare organisations? 
 
The RE-AIM evaluation framework was used throughout the doctoral research in 
order to answer this question (30). Whereas most studies focus upon evaluating the 
effectiveness of an intervention to establish its impact, RE-AIM comprises five 
dimensions that are conceptualised as being important for evaluating the impact of 
interventions. These are: Reach (proportion and representativeness of the population 
receiving the intervention), Effectiveness (assessment of the positive and negative 
consequences of an intervention), Adoption (proportion and representativeness of 
settings that adopt an intervention), Implementation (extent to which an intervention is 
delivered as intended), and Maintenance (extent to which an intervention becomes a 
relatively stable, enduring part of the behavioural repertoire of an 
individual/organisation). RE-AIM was chosen since all five dimensions are relevant for 





1.4 Summary of chapters in this thesis 
 
This thesis represents a PhD by publication, and is therefore structured by five 
papers that have either been published, or have been accepted for publication. The 
only chapters that do not contain papers are Chapter 1 (Structure of thesis), Chapter 
2 (Overview of literature), Chapter 3 (Methodology), and Chapter 9 (General 
discussion). Chapters 4 to 8 contain the papers as published/accepted, in order of 
date of publication.  
 
Chapter 2 provides an overview of the literature pertaining to the research topic at 
the start of the doctorate. Thus, Chapter 2 provides a rationale for the doctoral 
research, and outlines its aims. A systematic literature review is not presented here, 
since two systematic literature reviews were conducted and published later during the 
doctoral research process (see Chapters 5 and 6).  
 
Chapter 3 outlines the methodology used within this doctoral research. A rationale 
is presented for the theoretical framework used throughout this research (RE-AIM), 
and for the need to explore this topic using mixed methods. The ontological and 
epistemological positions used for this doctoral research are also presented. 
 
Chapter 4 presents a cross-sectional survey study exploring current practice in 
the operation of PMHS in England. Since similar previously conducted studies were 
out-of-date (25, 29), the primary aim of this study was to establish a current baseline 
regarding the operation of PMHS that could be used to inform the development of 
subsequent studies. In this study, all five dimensions of the RE-AIM framework are 
used to examine PMHS (Reach, Effectiveness, Adoption, Implementation, and 
Maintenance). Specifically, this study aimed to (1) establish the percentage of NHS 
Trusts in England that provide a PMHS, and explore the reasons why some Trusts do 
not provide this service; 2) examine how PMHS are operated in England, by 
comparing how current practice meets with national standards for operating PMHS; 3) 
establish the average number of years that Trusts have operated PMHS, and the 
reasons why some Trusts stopped operating a helpline; 4) establish for whom PMHS 
are available, and the average number of enquiries received per week; and 5) 
establish pharmacy professionals’ perceptions as to the benefits that their PMHS can 
have. The latter was considered important, since to date the perceived benefits of 
PMHS have been devised by a small working group of MI pharmacists for use within 
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guidelines aimed at increasing the provision of PMHS within the UK (31). This survey 
study was published in BMC Health Services Research in November 2018. 
 
Chapter 5 presents a systematic review examining the literature pertaining to the 
effectiveness of MI services for patients and the general public. Therefore, this study 
examined PMHS by focussing upon the Effectiveness dimension of the RE-AIM 
framework. The aim of this study was to address the following research question: 
What is the available evidence regarding the effectiveness of PMHS and medicines 
information services for the general public? The findings of this systematic review are 
presented, and recommendations are made regarding improving clinical practice and 
future research endeavours. The published evidence found in this review are also 
useful in comparison to pharmacy professionals’ perceived benefits of PMHS as 
established in the survey study (Chapter 4), in order to identify evidence gaps for 
future research. Thus, the findings of this review influenced the decision to primarily 
adopt a qualitative approach for the remainder of this PhD (see Chapters 7 and 8), 
since this was a noticeable gap within the literature. This systematic review was 
accepted for publication in the International Journal of Pharmacy Practice in July 
2019. 
 
Chapter 6 presents a systematic review examining the characteristics of users of 
PMHS, and the types of enquiries they make. Therefore, this study examined PMHS 
by focussing upon the Reach dimension of the RE-AIM framework. This was 
important, since the survey study (Chapter 4) found that the reach of PMHS could be 
improved, and a systematic review of extant literature would enable greater 
exploration of this. The aim of this study was to address the following research 
questions: What are the characteristics of people who use PMHS? What are the 
characteristics of enquiries made to PMHS? The findings of this systematic review 
are more generalisable to PMHS throughout the UK than individual service 
evaluations alone, and the findings are useful for establishing whether PMHS are 
under-used by any types of patients, and for also understanding patients’ MI needs. 
This work has highlighted areas for the improvement of PMHS, and the chapter ends 
with relevant recommendations. This systematic review was accepted for publication 
in the European Journal of Hospital Pharmacy in October 2019.  
 
Chapter 7 presents the findings of a qualitative study of pharmacy professionals’ 
perceptions of providing a PMHS. The aim of this study was to address the following 
research question: What are pharmacy professionals’ experiences and perceptions of 
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providing an NHS PMHS? In this study, all five dimensions of the RE-AIM framework 
are used to examine PMHS (Reach, Effectiveness, Adoption, Implementation, and 
Maintenance), from the perspectives of pharmacy professionals who provide a 
PMHS. This was important, since the survey study (Chapter 4) also examined all 
dimensions of the RE-AIM framework, albeit using survey methods. Therefore, this 
qualitative study provided PMHS providers the opportunity to describe the provision of 
PMHS in their own words, without the constraints of pre-specified survey questions 
and answer options. The chapter begins with a rationale for examining healthcare 
professionals’ perceptions of healthcare services, and why this is important for 
PMHS. The findings from thirty-four interviews with pharmacy professionals are 
presented, along with a discussion as to the relevance of the findings. Based upon 
the findings, recommendations for improving PMHS are presented. This study was 
accepted for publication in BMC Health Services Research in April 2020. 
 
Chapter 8 presents the findings of a qualitative study examining patients’ and 
carers’ experiences of using a PMHS. The aim of this study was to address the 
following research question: What are patients’ and carers’ experiences of using an 
NHS PMHS? In this study, the examination of PMHS primarily focussed upon the 
Effectiveness and Implementation dimensions of the RE-AIM framework. This is 
because service users are ideally placed to describe the effect that their PMHS had, 
and to use their experiences of contacting a PMHS to describe how it could be 
improved. The chapter begins with a rationale for examining service users’ 
experiences of contacting PMHS. This was important since the systematic review 
examining the effectiveness of PMHS (Chapter 5) found that, to date, service users’ 
experiences of PMHS had only been collected using survey methods. The findings 
from forty interviews with service users are presented, along with a discussion as to 
the relevance of the findings. Based upon the findings, recommendations for 
improving PMHS are presented. This study has been submitted to BMJ Open. 
Following peer review, it has recently been revised and resubmitted.  
 
Chapter 9 presents the overall discussion and conclusions of this body of 
research. This includes the implications of the research for hospital-based pharmacy 
practice, and recommendations for improving PMHS and the provision of medicines-
related support following discharge from secondary care. The chapter also includes 




1.5 Chapter 1 summary 
 
This introductory chapter presented a summary of the doctoral research and the 
chapters comprising this thesis. Next, an overview of relevant research literature 
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Chapter 2: Overview of literature 
 
2.1 Overview of Chapter 2 
 
This chapter provides a rationale for the doctoral research, which examines 
the impact of National Health Service (NHS) patient medicines helpline services 
(PMHS). The chapter begins with a description of how medicines use is increasing, 
how patients have a need for medicines-related support following hospital 
discharge, and how managing patients’ medicines-related issues after discharge 
can be burdensome for healthcare services. Next is a description of medicines 
information services as an intervention to provide medicines-related support to 
patients, with a focus upon PMHS. An overview of evidence pertaining to PMHS at 
the start of this doctoral research is then provided. Finally, this chapter ends with a 
description of the aims of this doctoral research. 
 
2.2 Patients’ need for support with medicines following discharge from 
secondary care 
 
2.2.1 Medication use is increasing 
 
Prescription and over-the-counter medications are both fundamental and 
commonplace components of healthcare worldwide, and are used to prevent, treat 
or manage illness and to improve patients’ quality of life (1). Approximately half of 
people in both the United Kingdom and the United States of America take at least 
one prescribed medication on a regular basis (2, 3). Additionally, the use of 
medications is increasing. Between 2006 and 2016, the average number of 
prescriptions per head of the UK population increased from 14.8 to 20.0 per annum, 
and there has also been an increase of 46.8% in the total number of prescription 
items dispensed in the community (752.0 million in 2006, and 1,104.1 million in 
2016) (4).  
 
Polypharmacy is also growing in the general population. Polypharmacy is 
often defined as the concomitant use of five or more medicines (5). In a large 
Scottish cohort study, the proportion of adults prescribed five or more medications 
increased from 11.4% in 1995 to 20.8% in 2010 (6). Findings also suggest that 
polypharmacy is more common in the elderly population (6-8). In the UK, over half of 
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people over 65 years old take more than three prescribed medicines (9), and one in 
six people over the age of 65 take ten or more prescribed medicines (10). This is 
because as life expectancy increases, more chronic diseases are likely to co-occur 
over time, resulting in a growing need for pharmacological treatments for these 
diseases, and a higher number of prescriptions per individual (1). Research 
suggests that there are many risks associated with polypharmacy. Polypharmacy 
increases the risk of prescribing errors (11), adverse drug reactions (12), drug-drug 
interactions (6), suboptimal adherence (13), emergency department visits (14), 
unplanned hospital admissions (15, 16), and readmissions (17, 18). Polypharmacy 
also increases the likelihood that patients will lack knowledge or understanding of 
their medicines (19, 20). Medicines optimisation is an approach to safe and effective 
medicines use, with the aim of ensuring that people get the best possible outcomes 
from their medicines, using the best available evidence to guide decisions about 
care whilst also taking into account patients’ needs, preferences and values (1, 21). 
Ensuring that a patient’s medicines are optimised is important for increasing the 
likelihood that patients take their medicines as intended, and is especially useful 
regarding the management of polypharmacy in order to minimise the above risks (1, 
22). Population projections produced by the Office for National Statistics suggest 
that the population of older people will significantly increase in the next two decades 
(23). This may indicate an increased need for interventions and services in the 
future to provide medicines-related support for this growing older population.  
 
2.2.2 Patients’ knowledge about medicines following discharge from hospital 
 
Patients who have been discharged from secondary care healthcare settings 
have often experienced recent changes to their medicines regimen, including the 
addition of new medicines (22, 24-26). For example, during a hospital stay, 
approximately 60% of patients experience three or more changes to their medicines 
regimen (26). However, a growing body of evidence highlights that patients in the 
UK and internationally often lack knowledge of their medications following discharge 
from hospital (27-29). For example, Holloway et al. carried out an interview study 
with patients on five wards of a teaching hospital in Glasgow on the morning of their 
discharge (27). This study found that 60% of patients could not name at least one of 
their medicines, only 25% knew the prescribed dose of at least one of their 





Lacking knowledge of medicines may not be problematic, if patients have 
received clear written information about their medicines that they are able to 
understand and follow. However, evidence highlights that discharged hospital 
patients in the UK also often report not being able to recall receiving important 
information about their medications (27, 30-33). For example, results from the UK 
NHS annual Adult Inpatient Survey found that, between 2013 and 2017, 29-30% of 
patients (n range = 40000-55923) reported that they were not provided with 
completely clear written or printed information about their medicines. Additionally, 
42-44% of patients (n range = 38384-52554) did not recall receiving any information 
from staff about side effects to look out for when they returned home (30). 
Dissatisfaction with information received about side effects accords with findings 
from research studies, such as a survey of 140 patients at an NHS Trust in the UK, 
conducted by Auyeung et al. (34). They found that 42% (n = 59) of participants were 
dissatisfied with information they received pertaining to the risks of developing side 
effects, and 40% (n = 56) were dissatisfied with information pertaining to what to do 
if a side effect occurs.  
 
The above findings from the UK correspond with findings from international 
studies that also suggest that patients often lack medicines-related knowledge 
following discharge, particularly around side effects (35-39), and that patients often 
report not being able to recall receiving important medicines-related information (40-
44). Qualitative and survey studies suggest that patients’ lack of knowledge of their 
medicines following hospital discharge may be a consequence of healthcare 
professionals not always having the time to provide adequate discharge counselling 
(45-47).  
 
2.2.3 Medicines-related problems following discharge from hospital 
 
As well as often requiring information about medicines, a substantial 
proportion of patients who have been discharged from hospital will subsequently 
experience medicines-related problems, as evidenced by studies conducted in the 
UK (48-51) and internationally (52-54). As well as the potential to cause harm, 
medicines-related problems can cause patients to become non-adherent (55). 
Medicines-related problems are typically defined as events or circumstances 
pertaining to patients’ medication that can potentially or actually reduce desired 
health outcomes (56). Medicines-related problems particularly pertain to adverse 
drug reactions (an unwanted or harmful reaction that occurs after the administration 
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of a drug or drugs), medication errors (mishaps that occur during prescribing, 
transcribing, dispensing, administering, adherence, or monitoring a drug), and 
adverse drug events (an injury resulting from the use of a drug, which includes 
adverse drug reactions and medication errors) (57, 58).  
 
Two studies have been conducted that followed up cohorts of patients after 
being discharged from hospital within the UK in order to explore the percentages of 
patients that subsequently experienced medicines-related problems (48, 59). Marvin 
et al. (48) carried out a survey study that involved contacting patients three weeks 
after being discharged for a short-stay admission from a hospital in London. They 
found that 44% (n = 12) of the 27 patients in the study had experienced medicines-
related problems, mainly around side effects and administration. Similarly, 
Mackridge et al. subsequently conducted a study that involved surveying ninety-nine 
patients by telephone approximately two weeks after discharge from one of six 
acute hospitals in the North-West of England (49, 59). They found that 35% (n = 35) 
of patients experienced medicines-related problems following discharge, mainly 
around adverse effects (63%, n = 22). Also, 59% (n = 59) of patients reported that 
they had sought information or help with their medicines following discharge, mostly 
from GPs. This shows how medicines-related problems following hospital discharge 
can have an impact upon other healthcare services, particularly primary care. 
However, both the study by Marvin et al. and the study by Mackridge et al. are 
limited by their small sample sizes, and the findings may not be generalisable since 
participants were recruited from one department at one NHS Trust (Marvin et al.) 
and one region within the UK (Marvin et al. and Mackridge et al.). 
 
Whilst acknowledging the limitations of the studies by Marvin et al. and 
Mackridge et al., extrapolating from their findings, it seems plausible that 
approximately 36-44% of patients who are discharged from hospital in England may 
experience medicines-related problems.  
 
2.2.4 Medicines-related harm following discharge from hospital 
 
Studies have also been conducted to specifically examine patients’ 
experiences of medicines-related harm following discharge from hospital. A recently 
conducted, multicentre prospective cohort study by Parekh et al., (60), published in 
2018, examined medicines-related harm following hospital discharge. In this study, 
medicine-related harm was defined as an adverse drug reaction, or harm arising 
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from non-adherence. One thousand one-hundred and sixteen older adults were 
followed up for eight weeks after being discharged from one of five hospitals in 
Southern England. Assessment of harm was conducted by research pharmacists at 
sites, with all cases of medicines-related harm subsequently reviewed and 
confirmed or rejected by an independent group of experts (three senior Geriatricians 
and a senior researcher in clinical pharmacy). Therefore, a thorough approach was 
taken to establish incidents of medicines-related harm in this study. Using a 
combination of data collection methods (telephone interviews with participants, 
general practitioner records, and prospective review of hospital readmission 
records), Perekh et al. found that 37% (n = 413) of patients experienced medicines-
related harm. Of these patients, 81% (n = 336) were considered to experience 
serious harm, and 52% (n = 214) of harms were potentially preventable. However, 
only 10% were classified as definitely preventable, and 41% were classified as 
possibly preventable. Four participants experienced fatal harm (e.g., one participant 
suffered a stroke associated with non-adherence to warfarin, and another patient 
died following a fall associated with lorazepam use; however, the latter was not 
described in enough detail establish how the fall was known to definitely be 
attributed to the use of lorazepam). Seventy-nine percent (n = 328) of participants 
who experienced medicines-related harm sought the help of healthcare 
professionals during the eight-week period, again showing how avoidable 
medicines-related issues following hospital discharge increase the demand upon 
other healthcare services.  
 
Prior to the above study by Parekh et al., evidence pertaining to medicines-
related harm following hospital discharge can be found in two systematic reviews 
(61, 62). Alqenae et al. found that, out of 35 studies, the median rate of adverse 
drug reactions for adults and elderly patients was 22%, and the median rate of 
adverse drug events was 18.8% (62). In the second systematic review, Parekh et al. 
found that, out of eight studies, the range of older adults experienced medicines-
related harm (defined as experiencing an adverse drug reaction or an adverse drug 
event) following hospital discharge was 0.4% to 51.2% (61). An average was not 
conducted, due to the substantial methodological variation between the eight 
studies. Additionally, Parekh et al. found that between 35% and 59% of these 
incidences of medicines-related harm were considered to be avoidable (61). The 
findings combined illustrate that a substantial proportion of patients experience 
medicines-related harm following hospital discharge, particularly elderly patients, 
and many of these are considered avoidable. However, it is important to note that 
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the methodological quality of the studies in the systematic review by Parekh et al. 
were found to be moderate, and in five of the eight studies, there was a high risk of 
bias (61). Additionally, definitions of medicines-related harm differed across the 
included studies, and two did not report the definition that they used. Methodological 
quality of studies in the systematic review by Alqenae, was found to be mostly low 
and moderate (62). Such limitations may therefore affect the conclusions drawn 
from the above findings.  
 
In 2017, the World Health Organisation launched a global patient safety 
challenge, which aimed to reduce severe and avoidable medicines-related harm by 
50% over the next five years (63). Providing evidence-based healthcare 
interventions and services to patients in order to reduce medicines-related harm will 
be important in order to achieve this.    
 
2.2.5 Medication errors during the hospital discharge process 
 
Medication errors have been defined as a preventable event that may lead to 
inappropriate medication use or patient harm (64). Patients may experience 
medication errors during the hospital discharge process, including prescribing errors 
and incorrect or missing information on discharge summary documents (64-69). Two 
systematic reviews have recently been conducted that explore medication error 
rates following discharge from hospital (62, 70). In the first, published in 2016, 
Aldhwaihi et al. identified that dispensing error rates in hospital pharmacies were 
between 0.015% and 34% of dispensed items (70). This finding comes from fifteen 
studies, conducted in four countries (UK, United States of America, Brazil, and 
France), with six studies conducted within the UK. However, a limitation of this 
review is that the authors did not provide a breakdown of the error rates by country, 
and therefore the error rate for the studies conducted in the UK is unknown. 
Additionally, the authors did not conduct a grey literature search as part of the 
review, which may have excluded some relevant studies, and those studies that 
were included were not assessed for risk of bias. In the second systematic review, 
published in 2020, Alqenae et al. found the average medication error rate 
experienced by older adults following hospital discharge to be 53%, across five 
studies (62). However, Alqenae et al. did not report the denominator for this error 
rate, nor whether any of the five studies were conducted within the UK. They also 
did not provide a breakdown as to the error rates for different types of medication 
errors (e.g., prescribing, dispensing). Therefore, the reporting of findings from the 
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above systematic reviews does not provide any useful information pertaining to 
medication error rates within the UK. 
 
A review of the prevalence of medication errors in the NHS in England was 
published in 2018 by Elliott et al. (64). This review identified four studies that 
examined medication error rates during the transition of care from hospital discharge 
(three with a retrospective design, one with a prospective design) (71-74). The 
prevalence of errors ranged from 0.2% to 81%, with the authors suggesting that the 
wide range possibly being a consequence of the broad definitions of medication 
error used in some of the studies. For example, the study that found an 81% error 
rate included prescribing errors, clerical errors, and errors regarding medicines 
stopped during admissions, and the definitions for each of these were considered to 
be broad (71). This highlights a limitation of the measurement of medication errors, 
since the use of different definitions and coding categories may influence study 
findings. From two studies, prescribing error rates ranged from 0.2% to 20.8% (n = 
10/509; n = 54/259) (71, 73). From one study, the rate of potentially inappropriate 
medications was 26.7% (n = 52/195). In one study, 43% (n = 18/42) of patients were 
identified as having an error or discrepancy on their discharge summary. Three of 
the four studies examined the clinical relevance and severity of the medication 
errors. One study measured hospital readmission within thirty days of discharge. 
However, this study was limited by a small sample size, and of 42 participants, three 
experienced a hospital readmission. Of these three, two were found to have 
discrepancies in their discharge medication prescription. Although, a further 
limitation of this study is that no causal link can be made between the discrepancy 
and the readmission. In the two other studies that examined the clinical relevance 
and severity of errors, errors were assessed for their potential to cause harm to 
patients. In one study, out of 74 errors, 73% (n = 54) were potentially clinically 
relevant for patients, with 5.4% (n = 4) associated with potentially serious harm. In 
the other study, of 51 errors, one had the potential to cause temporary harm 
(0.02%).  
 
Combined, the four studies in the review by Elliott et al. suggest that 
medication errors may be common, and some have the potential to cause harm to 
patients. However, Elliott et al. acknowledge a number of limitations with these 
studies, and study quality was variable (64). As noted, one study had a small 
sample size. Another study was conducted at a single centre, which was a specialist 
older people’s unit of a hospital, thereby limiting its representativeness. In two other 
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studies, data were collected from just one hospital setting, which also limit their 
generalisability. Additionally, it was not clear that the methods of assessing errors 
was consistently applied in three of the four studies.  
 
2.2.6 Medicines-related hospital readmissions 
 
Until recently, NHS Trusts in England would experience restrictions on 
payments for readmission that occurred within 30 days of discharge from a previous 
(index) admission (75). Readmissions account for a significant amount of hospital 
expenditure, with a report from the National Audit Office in 2014 estimating that the 
annual cost of emergency readmissions within thirty days of discharge is £2.4 billion 
(76). Therefore, avoiding rehospitalisation is a priority for healthcare policy makers 
in the UK. Additionally, recent figures suggest that the numbers of readmissions 
within 30 days of discharge are increasing. Between 2013/14 and 2017/18, the rate 
of emergency readmissions increased from 12.4% to 13.7% (77). However, it is 
unknown how many of these were medicines-related. The following studies suggest 
that the proportion of emergency readmissions that are medicines-related may be 
substantial.  
 
A recent systematic review of nineteen studies by El Morabet et al., 
published in 2018, found that rates of hospital readmissions due to medicines varied 
from 3% to 64% (median = 21%). Additionally, up to 87% (median 69%) of these 
medicines-related readmissions were deemed preventable (78). Two studies within 
this systematic review were conducted within the UK. One was a study conducted 
by Davies et al., which was published in 2010 (51). They found that approximately 
20% of hospital readmissions within one year of the index admission were due to 
ADRs, with 57% judged to be avoidable (51). The second study was conducted by 
Witherington et al. and published in 2008. They found a 30-day hospital readmission 
rate of 38% that was attributable to medication in a sample of patients aged 75 
years and older, with 61% considered to be preventable (65).  
 
A recently-conducted, multicentre prospective cohort study, published in 
2018, followed up 1280 older adults for eight weeks after being discharged from one 
of five hospitals in Southern England (60). The incidence of hospital readmission as 
a result of medicines-related harm was 78 per 1000 discharges. Additionally, the 
authors estimated that medicines-related harm in older adults costs the NHS £396 
million annually, and £243 million of that is potentially preventable (£51.6 million 
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were classified as ‘definitely preventable’). Of these amounts, 90% were attributed 
to hospital readmissions (i.e., £356.4 million annually, with £218.7 million being 
potentially preventable). These findings are based upon the cost of NHS service use 
associated with each case of medicines-related harm. Where there was uncertainty, 
a more cautious approach was taken, suggesting that these amounts may be an 
underestimation.  
 
2.3 Providing support to patients after discharge from secondary care 
 
2.3.1 The provision of medicines information services 
 
It is healthcare policy and procedure in the UK to ensure that patients’ 
medicines are managed optimally during the transition of care period, after they 
have been discharged from secondary care to primary care (1, 79, 80). 
Recommendations by the National Institute for Health and Care Excellence include 
sending a patient’s medicines discharge information to their nominated community 
pharmacy, and arranging for additional support for certain at risk groups (e.g., 
patients’ taking multiple medicines or with chronic or long-term conditions, and older 
people) such as pharmacist counselling, telephone follow-up, and GP or nurse 
home visits (1). A growing body of evidence highlights the potential effectiveness of 
community pharmacist involvement on 30-day hospital readmissions (e.g., hospital 
referral of patients to community pharmacies for medication reviews), as established 
in a systematic review and meta-analysis by Lussier et al. (81). However, this 
systematic review is limited by high heterogeneity (e.g., varied study designs and 
methods of analysis, and degree of pharmacist involvement in the interventions), 
and the inclusion of ten studies, six of which were rated as having a high or serious 
risk of bias. Research also suggests a potential benefit of timely electronic transfer 
of discharge documentation to community pharmacies (82, 83), and targeted 
counselling follow-up telephone calls to at risk patients conducted by hospital 
pharmacist (48, 84, 85).  
 
However, for the above interventions, the onus is largely upon the healthcare 
professional to offer support to patients, particularly those deemed to be at-risk. 
Services are also available that enable the patient to seek help, should they feel 
they require it. This is important, since the above findings show that medicines-
related issues following hospital discharge are not just experienced by at-risk 
patients (e.g., medication errors). World Health Organisation policy states that 
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offering information on medicines via Medicines Information centres, and providing 
public education about medicines, are two of twelve essential interventions to 
promote the rational use of medicines (86). Therefore, medicines information (MI) 
services have been established in many countries to support patients and the public 
who have questions regarding their medications (87-91). 
 
2.3.2 NHS patient medicines helpline services 
 
In the UK, a network of local and regional medicines information services, 
collectively known as UKMi, are based in the pharmacy departments of many NHS 
Trusts (92). The initial aim of these medicines information services was to provide 
medicines-related information and advice to healthcare staff regarding 
pharmacotherapy for their patients (93, 94). However, in response to evidence that 
patients often have unmet needs regarding their medications following hospital 
discharge, in 1992 the first patient medicines helpline service (PMHS) was 
established at an NHS Trust in the UK (95, 96). Since then, PMHS have become 
available at many NHS Trusts throughout the UK, to provide patients with a means 
of accessing medicines-related information and support following discharge (97). In 
2014 a survey study was conducted that found that approximately 55% of hospital-
based MI Centres provide a PMHS (97). Although there are ten regional MI Centres 
within England, these provide MI for healthcare professionals rather than patients. 
Therefore, PMHS are typically a local service, provided by NHS Trusts primarily for 
their own patients.  
 
Providing a PMHS accords with healthcare policy recommendations 
regarding the importance of giving patients the opportunity to seek information about 
their care and to be involved in decisions about their care (98-101).  
 
2.3.3 Medicines information services outside of the UK 
 
The UK is unique, since other countries do not typically provide medicines 
helplines that are operated by a network of hospital pharmacy services specifically 
for their recently discharged patients to speak to a pharmacy professional about 
their medicines. In most countries, helplines are provided for the general public (also 
referred to in published literature as ‘consumers’, ‘public’, and ‘laypeople’) rather 
than patients of a specific hospital. Also, the services are typically provided from 
Drug Information Centers or Drug and Poison Information Centers, which are often 
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regional or national (91, 102-105). For example, in 2009 in the United States there 
were 89 Centers that served the general public, and these were typically situated in 
community hospitals, university hospitals, federal government hospitals, tertiary care 
facilities, and schools of pharmacy (106-108). Similarly, in the Scandinavian 
countries, Drug Information Centers are regional, and are affiliated with clinical 
pharmacology services at university hospitals (109-111). In the Netherlands there is 
a national drug information service (112). Additionally, consumers in some non-UK 
countries such as the United States may also have the option of acquiring medicines 
information from services which provide alternative communication methods to 
telephone helplines, such as online drug information services (113-115). 
 
2.4 Overview of evidence pertaining to patient medicines helpline services at 
the start of this doctoral research 
 
2.4.1 Proposed benefits of patient medicines helpline services 
 
Although PMHS were initially set up to improve patients’ knowledge and use 
of their medicines, guidelines for their implementation have suggested other 
benefits, for both service users and healthcare organisations (116). Potential 
advantages include improving patient adherence, reducing patient harm, highlighting 
medication errors so that healthcare staff can learn from them and put systems in 
place to reduce their future likelihood, reducing patients’ avoidable use of other 
healthcare services (e.g., GP visits, Accident & Emergency visits, and hospital 
readmissions), and improving the patient experience of healthcare services (e.g., 
patient satisfaction with care) (117, 118).  Table 2.1 provides an overview of the 
proposed benefits of PMHS by some of the main proponents of PMHS.  
 
As seen in Table 1, PMHS are therefore perceived to be beneficial not only 
for service users, but also healthcare organisations in terms of learning from patient 
experiences (e.g., using information about errors to improve healthcare services) 
and reducing the burden on other services. However, further research is needed to 
ascertain whether these proposed benefits can be evidenced. Additionally, the 
proposed benefits were developed by a small working group of MI pharmacists, and 
therefore, there may be other perceived benefits of PMHS that are not included 




Table 2.1. Summary of the potential benefits of providing a patient medicines helpline service, 
proposed by Wills et al. (116) 
Benefits for patients   
Benefits for NHS Trust and other healthcare 
services 
Provides support during transition of 
care, when patients can experience 
information gaps. 
 
Reduced readmission rates (i.e., 
improvement in Trust targets; avoiding 
penalties for emergency readmissions). 
Ability to access professional support 
from home. 
 
Provides a back-up to discharge counselling. 
Patients may avoid harm. 
 
Assurance to staff that patients have access 
to professional contact once home. 
Medicines may be optimised, so that 
patients obtain the best possible 
outcomes from their medicines. 
 
Patients' opinion of Trust may improve (i.e., 
satisfaction ratings). 
Interactions are avoided. 
 
Helpline is positive message from Trust to 
local media. 
Provides personalised patient advice. 
 
Early warning for Trust about areas of risk. 
Patients have a right to information 
about their treatments. 
 
Prevention of complains and litigation. 
  
Picks up critical incidents and errors (i.e., 
ability to learn from adverse patient 




Service is inexpensive to run, and meets 
needs of a large population. 
 
Engaging the local community is a key 
aspect of a Foundation Trust's role. 
  
Putting patients' needs at the heart of 
services (a core NHS value). 
  
May reduce burden on primary care. 
    May reduce attendances to Accident & 
Emergency departments. 





2.4.2 Types of enquiries answered by patient medicines helpline services 
 
In their examination of sixty-nine PMHS in the UK, Raynor et al. found that 
the most common enquiries related to adverse effects (41%), dosage and 
administration (27%), and interactions (21%) (119). However, this study was 
published in 2000 (year of data collection unknown) and therefore may not be 
representative of the types of calls received to PMHS currently. More recently, in 
their 12-month review of calls received to their helpline, Bramley et al. found that the 
most common reason for calling was a lack of appropriate information on the 
discharge letter (24%), followed by drug interactions with other drugs or medical 
conditions (11%), adverse drug reactions (10%), supply (8%), general information 
about side effects (7%), error (6%) and advice about medicines changes (6%) (97). 
However, these findings come from 413 enquiries received to only one helpline and 
may not be generalisable. Additionally, collecting data pertaining to the type of 
enquiries received does not provide evidence as to the quality of the information 
provided, nor whether the enquiries received were even able to be dealt with by the 
PMHS. For example, in the study by Raynor et al., adverse effects comprised 41% 
of enquiries. It may be that PMHS are able to provide information pertaining to 
potential side effects to look out for, yet their role may be limited if a patient contacts 
the service and is actually experiencing side effects. Therefore, research is needed 
to establish not only the types of enquiries received to PMHS, but whether the 
service was even able to help the patient.  
Furthermore, in the Bramley et al. study (97), most enquiries received to their 
PMHS pertained to a lack of appropriate information on the discharge letter (24%). 
Thus, by providing additional appropriate information to patients’ discharge letters, 
the number of enquiries to their service would reduce by 24%. This suggests that 
providing a PMHS may be a mechanism for establishing ways to improve patients’ 
care earlier in their care pathway, therefore reducing their need to contact the 
hospital for help after being discharged. Relatedly, a study by Marvin et all found 
that, of 500 calls to their PMHS, 34% pertained to medication errors (120). This 
suggests that if mechanisms were put in place to reduce the number of medication 
errors that occur, the number of calls to PMHS may reduce. Research is needed to 
establish whether this is the case. This is important, since earlier in the chapter the 
evidence pertaining to medicines-related errors during the transfer from secondary 
to primary care in the UK suggested that such errors may be fairly common (64). 
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Earlier in the chapter, it was also noted that the proportion of medicines-
related harm following hospital discharge may also be substantial (i.e., 
approximately 37% in a cohort of 1116 older adults by Parekh et al.; (60)). 
Relatedly, Marvin et al. (2011) found that, of 500 calls to their PMHS, 48% were 
concerned with harm or judged to have the potential for harm had professional 
information not been available. One percent of calls were considered to pertain to 
serious harm, defined as requiring intervention and referral. These findings suggest 
that PMHS have the potential to be of benefit for preventing harm (albeit not serious 
harm in most cases) to approximately 37% of older patients who have been 
discharged from hospital. However, this is dependent upon patients being aware 
that they have an issue with their medicines, being aware that PMHS exist, and 
choosing to use this service. Therefore, the percentage of older patients who may 
avoid medicines-related harm through contacting a PMHS would likely be much 
lower. Additionally, the finding by Marvin et al. was established from data collected 
at one site, and where the provider of the service also coded the enquiries in terms 
of potential for harm. Therefore, measurement bias may have occurred (i.e., coding 
the enquiries in such a way to make the service seem more useful than it actually 
is). The study also does not provide detail as to exactly how the PMHS was able to 
prevent harm to patients. Further research is needed to establish this, and establish 
the generalisability of these findings, through research that is conducted 
independently of the sites being examined.  
2.4.3 Prevalence of patient medicines helpline services 
 
Establishing the prevalence of NHS PMHS in the UK is useful to gauge the 
uptake of this service by pharmacy teams from the time that the first helpline was 
set up approximately 28 years ago. At the start of this doctoral research, four studies 
had been published that described the prevalence of PMHS (97, 121-123). 
However, these studies measured the number of helplines in slightly different ways, 
rendering them difficult to compare to one another in order to establish change in 

































































































































































































































































































































































































































































































































































































































































































































































Overall, the findings suggest that approximately half of NHS Trusts may 
provide a PMHS. The most recent study was published in 2014 and was conducted 
by Bramley et al. (97). They found that PMHS were provided by 102 out of 184 UK 
Medicines Information (MI) teams (55%). However, by only surveying MI teams, 
Bramley et al. may not have included all NHS secondary care PMHS in the UK. For 
example, Raynor et al. (119) found that, in 33% of hospitals, the medicines helpline 
telephone was located in the dispensary. If any of these hospitals did not have an MI 
team, then it may be possible that they would not have been identified in the survey 
by Bramley et al.  Furthermore, since the study by Bramley et al. was conducted, 
guidelines and national standards have been published to provide guidance to 
hospital pharmacy and MI teams in the UK in order to set up and operate their own 
PMHS (116, 118). It therefore seems plausible that the finding by Bramley et al. is 
an underestimation of the number of medicines helplines currently in operation in 
the UK.  
 
The findings by Bramley et al. are also difficult to compare to the findings by 
the Healthcare Commission, published in 2007, which measured the number of NHS 
Trusts that operated a helpline (122, 123).  Some MI teams provide their services to 
more than one NHS Trust (i.e., via a service level agreement), since some Trusts do 
not have their own MI team. Additionally, some NHS Trusts have more than one MI 
team, such as one at each hospital within the Trust. These factors may account for 
why the proportion of PMHS found by Bramley et al. is lower than that found by the 
Healthcare Commission, which was published seven years earlier. Therefore, it may 
be beneficial to establish the current provision of PMHS, using NHS Trusts as the 
unit of measurement, thus generating data that can be compared to the findings of 
the Healthcare Commission approximately ten years ago. Additionally, individuals 
become patients of NHS Trusts rather than MI Centres, and so the provision of 
PMHS at NHS Trusts would be more important to patients, rather than the provision 
of PMHS at MI Centres. 
 
2.4.4 The operation of patient medicines helpline services 
 
Surveys examining the operation of medicines helplines in the UK describe, 
for example, the number of calls received per week, the hours and days of 
availability of the service, the methods of accessing the service, the methods of 
advertising the service, the occupation/qualifications of staff who deal with enquiries, 
the use of guidelines/procedures, and the use of auditing/monitoring procedures (97, 
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119). At the start of this doctoral research, two studies had been published that 
examined the operation of PMHS, and both used cross-sectional surveys completed 
by healthcare professionals (97, 119). However, the most recent was published in 
2014 (year of data collection not reported) (97), and the first was published in 2000 
(119). Therefore, the operation of PMHS in the UK at the start of this doctoral 
research was unknown. Additionally, since 2014, national standards have been 
published and endorsed by the UKMI to provide guidance as to what constitutes 
acceptable and commendable provision of PMHS (118). Therefore, it would also be 
beneficial to explore whether providers of PMHS are specifically meeting these 
standards.  
 
2.5 The aim of this doctoral research 
 
The NHS is committed to providing evidence-based patient care (124). 
However, so far only a paucity of descriptive data exists to attempt to answer 
whether PMHS are effective at delivering what their proponents suggest are benefits 
of operating such a helpline (117, 118). Studies examining PMHS have primarily 
been service evaluations where the providers of PMHS have evaluated their own 
services, which may have biased their findings (e.g., selection and measurement 
bias). Additionally, many findings are likely to be out-of-date (e.g., those examining 
the provision and operation of PMHS). 
 
The aim of this doctoral research was therefore to examine the current 
impact of NHS PMHS. As described in more detail in the following chapter, the 
impact of PMHS was examined throughout this doctoral research using the RE-AIM 
evaluation framework (125). RE-AIM conceptualises ‘impact’ as being the product of 
an intervention’s reach, effectiveness, adoption, implementation, and maintenance 
(125).  
  
Due to the lack of high-quality research to date, much of this doctoral 
research constituted providing the foundations for future research on this topic, and 
establishing gaps in the evidence-base. Therefore, a survey was conducted to 
establish the percentage of NHS Trusts that provide a PMHS, and to explore current 
practice in the operation of PMHS. Also, two systematic reviews were conducted; 
one examining the evidence regarding the effectiveness of MI services for patients 
and the general public, and a second examining the characteristics of PMHS 
enquirers and the enquiries they make. Based upon this initial work, the final two 
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studies were designed to address gaps in the literature. Both are qualitative studies; 
one examined pharmacy professionals’ perceptions of providing a PMHS, the other 
examined patients/carers experiences of using a PMHS.  
 
Throughout this doctoral research, the findings of each study have resulted 
in the development of recommendations for improving current practice regarding the 
provision of PMHS (summarised in Chapter 9: General discussion). Adding to the 
limited evidence that was available at the start of this doctoral research has helped 
to establish whether PMHS achieve what they aim to achieve (i.e., provide 
medicines-related support to patients and carers during the transition from 
secondary to primary care), and whether the provision of PMHS may be improved to 
ensure that the needs of service users are being met. Additionally, proponents of 
PMHS suggest that PMHS may also function to be of benefit to healthcare 
organisations (e.g., provide NHS Trusts the opportunity to learn from errors 
identified via helpline enquiries, and reduce the burden upon other healthcare 
services such as GPs). Thus, this doctoral research provided the opportunity to also 
explore whether PMHS have an impact upon healthcare organisations. 
 
2.6 Chapter 2 summary 
 
 This chapter introduced the topic for this doctoral research, including why 
such research is needed. Patients and carers have a need for medicines-related 
support following discharge from secondary to primary care. Patient medicines 
helpline services have been established at some NHS Trusts to enable patients and 
carers to seek support with their medicines. However, little high-quality research has 
been conducted to examine this service. Therefore, the aim of this research was to 
conduct high-quality research to examine the impact of PMHS. The RE-AIM 
evaluation framework was used throughout this research, which conceptualises that 
the impact of an intervention is the product of its reach, effectiveness, adoption, 
implementation, and maintenance.  
 
 The following chapter explores the methodological approach used for this 
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Chapter 3: Methodology 
 
3.1 Overview of Chapter 3 
 
Chapter 3 outlines the methodology used in this doctoral research. The 
chapter begins with the overarching research question for this doctoral research, 
and then describes the research approach used to answer this question – mixed 
methods, using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and 
Maintenance) evaluation framework. Next, pragmatism is described as the main 
philosophical approach that has been endorsed by mixed methods researchers, and 
the reasons why it was chosen for this doctoral research.  
 
3.2 Research question for this doctoral research 
 
As stated in Chapter 1, the overarching question that this doctoral research 
addressed is: What is the impact of National Health Service (NHS) patient 
medicines helpline services upon service users and healthcare organisations? 
 
3.3 Defining ‘patient medicines helpline services’ 
 
Although some studies have been conducted to examine PMHS, to date a 
definition of PMHS does not exist. For this doctoral research, PMHS will be defined 
in the following way. 
 
- A service providing medicines information and advice, and not general 
clinical information and advice; 
- A service for patients and/or carers of patients who received care from the 
NHS Trust within the UK that provides the PMHS, and not for a specific 
subset of patients and/or their carers; and 
- A service involving distance communication, via any means, between the 
service user and service provider, instigated by the service user.  
 
At the start of this doctoral research, this definition was reviewed by four 





3.4 Methodology of this doctoral research 
 
3.4.1 Using the RE-AIM evaluation framework to examine the impact of patient 
medicines helpline services 
 
The aim of this research is to examine the impact of PMHS. To examine the 
impact of PMHS, the RE-AIM evaluation framework will be used throughout this 
doctoral research. The RE-AIM framework was first published in 1999 by Glasgow 
et al., and aims to identify the different ways that an intervention has impact (1). The 
framework developed out of a need for improved research and reporting of findings 
pertaining to the implementation and validity of health interventions, and to facilitate 
the translation of research findings so that effective interventions are more widely 
adopted. However, Glasgow et al. acknowledge that the way in which RE-AIM is 
applied can vary, and that the framework has and will continue to evolve to meet the 
needs of its users (2). Being twenty years old, RE-AIM is a well-established 
framework for evaluating the impact of health interventions (3, 4).  
 
RE-AIM is based upon the work of Abrams et al. (5) who defined the impact 
of an intervention as the product of a programme’s reach (the percentage of the 
population receiving the intervention) and its efficacy (assessment of both positive 
and negative consequences of an intervention). Glasgow et al. (1) expand on this 
conceptualisation of the impact of an intervention to develop RE-AIM, by adding 
three dimensions that apply to the settings in which research is conducted. The 
three other dimensions are Adoption (the absolute number, proportion, and 
representativeness of settings and people who are willing to initiate a program, and 
why), Implementation (the extent to which an intervention is delivered as intended, 
the time and cost of the intervention, and adaptations made to the intervention), and 
Maintenance (the extent to which an intervention becomes a relatively stable, 
enduring part of the behavioural repertoire of an individual/organisation; the long-
term effects of a service or intervention on its users after it has been completed). 
Glasgow et al. also expanded the definition of Reach (the absolute number, 
proportion, and representativeness of individuals who are willing to participate in a 
given initiative, intervention, or program, and reasons why or why not). Additionally, 
Glasgow et al. suggest that ‘efficacy’ could be replaced with ‘effectiveness’, 
depending on the stage of research and/or the intervention being investigated, in 
order to assess its impact in terms of actual changes in real-life conditions (6). The 
definition of Efficacy/Effectiveness was also expanded (the impact of an intervention 
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on important individual outcomes, including potential negative effects, and broader 
impact including quality of life and economic outcomes; and variability across 
subgroups). 
 
Glasgow et al. emphasise the importance of focusing on all five dimensions 
of the framework in order to fully evaluate the impact of an intervention, and that this 
is more likely to result in research findings being translated into practice  (2, 4). The 
‘RE’ dimensions are primarily concerned with the impact on the individual (e.g., is 
an intervention beneficial for the people receiving it, and are all individuals who can 
benefit from the intervention receiving it?). The ‘AIM’ dimensions are primarily 
concerned with the impact of an intervention at the level of the intervention setting 
(e.g., are sites which could offer the intervention, actually offering it? If a site offers 
the intervention, is it being offered as intended? And if so, is this stable over time?). 
Glasgow et al. suggest that the ‘AIM’ dimensions are less often studied but are 
equally important factors in determining an intervention’s impact (4, 7).  
 
Although originally the focus of RE-AIM was upon assessing the impact of 
an intervention using quantitative data, the framework has been expanded to 
emphasise the importance of qualitative data to understand the framework’s 
different dimensions (2, 4). For example, Kessler et al. (2) propose that the use of 
qualitative data are important for understanding the reasons for not adopting the 
intervention (adoption) and for non-participation in the intervention (reach), and for 
further exploring the outcomes of an intervention (efficacy/effectiveness). The RE-
AIM framework therefore accords with the mixed methods approach, whereby 
qualitative findings can elucidate quantitative findings, by generating knowledge that 
cannot be generated via quantitative methods alone. The use of mixed methods are 
encouraged by the developers of RE-AIM (2).  
 
Other frameworks have been developed for the purpose of evaluating 
healthcare interventions and services, such as APEASE (comprising of six criteria: 
affordability, practicability, effectiveness, acceptability, side effects/safety, and 
equity; (8)) and the Medical Research Council (MRC) guidance for developing and 
evaluating complex interventions (9). PMHS are not a complex intervention, and so 
the MRC guidance is not appropriate to evaluate this service. The APEASE criteria 
is a relatively recent framework, first published in 2014 (8). Therefore, at the time of 
choosing a framework at the start of this doctoral research, the APEASE criteria had 
not been widely used (a search for literature at the time showed that only a few 
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studies had used it, primarily to develop interventions rather than evaluate them), 
whereas the RE-AIM framework had been widely used, and in a variety of contexts 
(4). Relatedly, the APEASE criteria did not appear to be evidence-based; its 
developers did not provide detail as to how the criteria were developed. However, 
the criteria appear to be similar to other previously developed frameworks for 
evaluating the quality of healthcare services and interventions, such as those by 
Donabedian, Maxwell, and Higginson (all four frameworks include the dimensions 
effectiveness, acceptability, and equity, and three of the four also include 
accessibility) (10-12). Additionally, the RE-AIM is the only framework that purports 
to examine the impact of interventions and services. The APEASE criteria, and the 
frameworks proposed by Donabedian, Maxwell, and Higginson are described as 
examining the quality of healthcare interventions and services. Therefore, the RE-
AIM framework seemed more of an appropriate fit for answering the overarching 
research question for this PhD (i.e., Examining the impact of NHS PMHS on service 
users and healthcare organisations). Despite this, it is important to acknowledge 
that the RE-AIM conceptualisation of impact is not absolute. Impact is a construct, 
and it has been conceptualised by the developers of RE-AIM as consisting of an 
intervention’s reach, effectiveness, adoption, impact and maintenance, by a small 
group of academics (1).  
 
Nevertheless, the RE-AIM framework is a useful tool for examining PMHS, 
since all five of the framework’s dimensions are relevant. Therefore, the knowledge 
generated from this doctoral research will be enhanced, rather than solely focusing 
upon, for example, the examination of the effectiveness of PMHS. PMHS could 
potentially be adopted by all NHS Trusts with the aim of being available for all of a 
Trust’s patients (RE-AIM Adoption and Reach, respectively). Additionally, national 
standards for setting up and operating a PMHS in the UK have recently been 
developed, and are endorsed by the Royal Pharmaceutical Society [46]. This 
provides the opportunity to evaluate the extent that current practice in the provision 
of PMHS meets these standards (RE-AIM Implementation). The longevity of PMHS 
could be examined by establishing for how long PMHS have been provided, and 
reasons for their continuation or their closure at certain sites (RE-AIM Maintenance). 
Additionally, the longer-term impact that the helpline advice may have upon service 
users could also be examined, such as sustained improved use of medicines (RE-
AIM Maintenance). However, since each of the five RE-AIM dimensions comprise 
sub-elements, it may not be possible to examine them all within this doctoral 
research due to time and resource constraints. Therefore, any aspects of the 
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framework that were not used to examine the impact of PMHS will be noted within 
the Discussion chapter of this thesis. 
 
3.4.2 Mixed methods approach 
 
As described above, examining the impact of an intervention using the RE-
AIM evaluation framework is likely to include both quantitative and qualitative 
approaches. Thus, a mixed methods approach was chosen for this doctoral 
research. Mixed methods research refers to “research in which the investigator 
collects and analyses data, integrates the findings, and draws inferences using both 
qualitative and quantitative approaches or methods in a single study or a program of 
study” (Pg4, (13); see also Johnson, Onwuegbuzie & Turner, (14)). To date, the use 
of mixed methods research in pharmacy practice has been relatively limited (15). 
Because the investigation of MI services is a relatively new area of research for 
pharmacy practice, mixed methods research would be useful to provide both 
breadth and depth for exploring this topic. Additionally, a main initial aim was to 
explore service users’ experiences of using PMHS, for which qualitative methods 
are appropriate. However, another aim was to generate background data such as 
establishing how many NHS Trusts provide a PMHS, and whether the extant 
helplines meet national standards for PMHS provision (16), for which quantitative 
methods are appropriate. Both are important knowledge gaps, as detailed in 
Chapter 2. Therefore, employing a mixed methods approach was considered 
appropriate. What follows is an overview of mixed methods research. 
 
During the last two decades there have been increasing calls for mixing the 
contrasting paradigms of quantitative and qualitative research, rather than choosing 
one or the other methodological approach (17-20). This is because both quantitative 
and qualitative approaches have strengths and limitations, and neither one is 
considered a best overall method (14, 19, 21). Quantitative research produces data 
that are numerical, enabling comparisons to be made between participants and 
across studies, and the ability to test causal hypotheses using experimental designs 
(the hypothetico-deductive method). Qualitative approaches produce in-depth, 
textured data, whereby the personal meanings and lived-experiences of individuals 
are prioritised. Qualitative research is also useful for the generation of 
hypotheses/theory. Compared to quantitative research, which takes a nomothetic 
approach (i.e., relating to the discovery of general rules/laws), the idiographic 
approach of qualitative research places greater importance upon context, and 
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individuals’ insights, understandings, and meanings of their lived experiences (22). 
The combination of quantitative and qualitative methods is likely to result in what 
Turner and colleagues describe as complementary strengths and non-overlapping 
weaknesses, with the product being superior to that of single method studies or 
projects (19, 23). Thus, mixed methods research has been established as a third 
methodological paradigm (14, 18, 19, 24). 
 
When both qualitative and quantitative data are collected within a study or 
series of related studies, results may be enriched in ways that one form of data 
alone would not enable. For example, with mixed methods research it becomes 
possible to generalise results from a sample to a population, and to also gain a 
deeper understanding of individuals’ motives, assumptions, beliefs, and other 
relevant cognitions regarding a phenomenon of interest (25). As well as potentially 
providing more detailed answers to research questions, mixed methods research 
can identify new research questions, suggest changes to future research designs, 
and enhance theory development and practice (19, 26). 
 
The mixed methods approach has become increasingly popular within 
healthcare research. For example, the incidence of mixed methods studies 
commissioned by the Department of Health Research & Development programme 
between 1994 to 2004 increased from 17% to 30% (27). This increased use of 
mixed methods research in health services research may be motivated by 
recognition of the complex factors that influence health, illness, and healthcare, 
alongside a move towards a more patient-centred approach within both healthcare 
and research (28). Quantitative methods are useful within healthcare because of 
their generalisability of findings, such as conducting clinical trials that examine the 
efficacy of healthcare interventions and to establish whether an intervention works 
for a particular health condition or for a particular population (9). However, 
qualitative research can elucidate why some types of intervention work, and also 
why it may not work for everybody, by asking patients themselves about their 
experiences. Thus, qualitative research can be important in understanding why 







3.5 Ontology and epistemology  
 
3.5.1 Ontology and epistemology of this doctoral research 
 
Although mixed methods research has become popular, particularly within 
applied fields such as healthcare and health services research, its corresponding 
philosophical paradigm has often been ignored (31). However, recently, pragmatism 
has been identified as an appropriate philosophical paradigm for conducting mixed 
methods research (15, 18-20, 24, 26, 28, 32-34). With its focus upon the 
consequences and usefulness of research findings, pragmatism was considered an 
appropriate approach to explore the impact of PMHS, in order to develop 
recommendations for service improvement for the benefit of users and providers of 
PMHS. Additionally, the use of the RE-AIM framework, with its emphasis upon the 
importance of translating research findings into practice, also accords with the 
principles of pragmatism (18, 19, 24, 35). Thus, the epistemological position of 
pragmatism was adopted for this doctoral research. What follows is an overview of 
different ontological and epistemological approaches, including pragmatism and its 
application within health services research. 
 
3.5.2 Positivist/empiricist versus interpretivist/constructivist approaches 
 
Quantitative research is typically driven by realist ontology (i.e., reality is 
independent of human minds), with positivist and empiricist epistemologies (i.e., 
reality is what can be scientifically verified, and knowledge is based on experiences 
derived from the senses, respectively). This paradigm posits that there is a stable 
reality independent of the individual, and that this reality is capable of being studied 
and known. Additionally, according to this paradigm, emotional, subjective, or 
political perspectives should not influence empirical scientific enquiry. Quantitative 
research therefore takes an objective, value-free stance towards a phenomenon 
being studied, using methods and measures that are fully independent from the 
researcher. Qualitative research, on the other hand, is typically driven by relativist 
ontology (i.e., reality is a subjective experience dependent upon human minds), with 
constructivist and interpretivist epistemologies (i.e., knowledge is constructed based 
upon our understanding of the world, and that scientific investigations are shaped by 
the interpretations of the investigators, respectively). Here, reality is regarded as a 
construction within each individual’s mind, whereby multiple realities may exist 
simultaneously. Each person’s construction cannot be verified, since there is no 
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reality against which to verify them. Qualitative research takes the position that an 
objective account therefore cannot be achieved; there is only subjectivity, since 
each individual holds existing assumptions, beliefs, and attitudes about a 
phenomenon of interest (36). For qualitative researchers, the development of 
knowledge is seen as contextual, embedded in values and cultures, including the 
research process itself (37). The aim of qualitative research is to explore and 
understand a phenomenon of interest, rather than testing theoretically-driven 




Pragmatism largely abandons the debate over positivist versus 
interpretivist/constructivist approaches to inquiry. This is because ultimately the two 
approaches share the same goal of seeking to generate knowledge that 
corresponds with reality, irrespective of whether reality is singular or multiple (19, 
35, 38). Instead, pragmatism orients itself toward choosing appropriate methods for 
solving practical problems with an emphasis upon the consequences and 
usefulness of research, i.e. research leading to action, such as the translation of 
findings into recommendations for practice that are then implemented (18, 19, 24, 
35). Pragmatism therefore does not abandon the epistemological differences 
between qualitative and quantitative approaches but acknowledges that both are 
important for producing different types of knowledge (19, 24). Thus, approaching 
research from either a quantitative or a qualitative approach would likely be limited 
for answering all types of research questions. In this sense, the dichotomy between 
quantitative and qualitative research is unnecessary, since answering research 
questions usefully and thoroughly may require both methodologies in order to 
provide a more complete picture (19, 24). 
 
Philosophically, pragmatism accepts that there are both singular and 
multiple realities that are open to empirical enquiry (24). For example, reality could 
be seen as layered, whereby there may be a single real world, and yet all 
individuals have their own interpretations of it (18). With pragmatism, there is a 
commitment to uncertainty – that knowledge produced is relative and not absolute 
(32). Pragmatism is considered by many mixed methods researchers to be 
preferable to other potential philosophical approaches to mixed methods research, 
such as critical realism (39, 40). Critical realism is a post-positivist philosophy of 
science. Ontologically, as with pragmatism, critical realism posits that there is an 
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absolute reality which is independent of human action, but that it cannot be 
observed objectively. Reality is conceived of as stratified, comprising what we 
actually experience, what we can experience but do not, and underlying causal 
mechanisms which can be hypothesised and are only indirectly observable through 
their effects. The aim of knowledge generation is to understand these causal 
mechanisms. Critical realism recognises that each person’s perceptions of a 
phenomenon are unique, since they are based upon individual and shared 
experiences and are governed by context (e.g., social structures). In this sense, 
critical realism accords with epistemological relativism since the generation of 
knowledge is viewed as historically emergent and fallible (41). Therefore, there are 
several similarities between pragmatism and critical realism (i.e., that objectivity and 
subjectivity can co-exist, that knowledge generation is context-dependent and 
fallible, and that research should be value-oriented). However, pragmatism places 
less emphasis upon ontological and epistemological assumptions for conducting 
research compared to critical realism, thereby being less restrictive in terms of how 
research can be conducted (26, 42, 43). 
 
With pragmatism, the research question is of primary importance, rather 
than the method or the philosophical paradigm underlying the method (18, 19, 44). 
Pragmatists hold that research should therefore not aim to accurately represent or 
‘mirror’ reality, but to produce findings that have utility (35). For Morgan, the 
pragmatic approach abandons the top-down privileging of ontological assumptions, 
whereby ontology influences epistemology, which in turn influences methodology 
and the methods used within research endeavours. Instead, for Morgan, 
methodology should be the primary focus of research, and it should be the 
methodology that connects epistemology to the actual methods used, rather than 
the methods being dictated by the epistemology (18). This focus upon methodology 
helps to ensure that research is conducted thoughtfully and to a high standard (18). 
Therefore, within pragmatism, methodology is chosen based upon its usefulness for 
answering the research question, rather than based upon a pre-existing 
commitment to the philosophical underpinnings of a particular paradigm. However, 
for pragmatists, not all research questions are important, just as not all research 
methods are appropriate (18). With pragmatism, there is an emphasis upon 
producing knowledge in the pursuit of desired ends, and often, those ends involve 
ethical and moral issues (19). The focus of pragmatism regarding the usefulness 
and consequences of research accords with health research which aims to produce 
findings that are of benefit to service users in order to alleviate suffering and 
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improve quality of life (24, 33, 45). Pragmatism therefore accords with the aim of 
this doctoral research, which is to explore the impact of PMHS upon service users 
and healthcare organisations, and if relevant, suggest recommendations for the 
improvement of this service in order to enhance its impact. 
 
3.6 Chapter 3 summary 
 
Chapter 3 has presented the theoretical framework underpinning this 
doctoral research. The epistemological position of pragmatism has been adopted for 
this research, which comprises mixed methods. This chapter also described how 
and why the RE-AIM framework will be used throughout this doctoral research. RE-
AIM comprises five dimensions considered necessary to examine the impact of 
interventions and services, and was chosen since all five dimensions are particularly 
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Chapter 4: Operating a patient medicines 
helpline. A survey study exploring current 
practice in England using the RE-AIM 
evaluation framework 
 
4.1 Overview of Chapter 4 
 
This chapter presents the first study of this doctoral research. Previous 
findings show that PMHS are not provided by all NHS Trusts (1, 2), and that the way 
PMHS are operated is variable, particularly pertaining to hours/days of availability 
and promotional methods (3, 4). However, these findings are likely to be out-of-date. 
Although a study by Bramley et al. examined the provision of PMHS in a study that 
was published in 2014, the year of data collection was not reported (4). Additionally, 
they examined the percentage of medicines information centres that provide a 
PMHS, rather than the percentage of NHS Trusts that provide this service. The 
most recent studies to examine the percentage of NHS Trusts that provide a PMHS 
were published in 2007 and conducted by the Healthcare Commission (1, 2). It was 
therefore unknown how many NHS Trusts currently provide a PMHS, and there was 
a gap in the literature for establishing this. Knowing the prevalence of PMHS in the 
UK is useful to gauge the uptake of this service by pharmacy teams from the time 
that the first helpline was set up approximately 28 years ago. Relatedly, although 
the most recent study to examine the way that PMHS are operated was published in 
2014 (again, by Bramley et al., where the year of data collection was not reported 
(4)), a more thorough examination was published in 2000. Therefore, it was also 
unknown how PMHS are currently being operated.  
 
The aim of this cross-sectional survey study was to provide a foundation for 
further work on this topic, by establishing some key background information 
pertaining to PMHS. Namely, the number of PMHS being operated within England 
and the percentage of NHS Trusts that currently provide one (aspects of RE-AIM 
Adoption), and the ways that this service is being operated (aspects of RE-AIM 
Implementation). The other three aspects of the framework were also useful to 
explore, in order to provide background data pertaining to the use of PMHS (an 




effectiveness (an aspect of RE-AIM Effectiveness), and the length of time PMHS 
have been in operation (an aspect of RE-AIM Maintenance). 
 
A further aim of this study was to locate sites that were interested in taking 
part in further studies pertaining to PMHS. This enabled potential recruitment sites 
to be established for subsequent PhD studies (i.e., Studies 4 and 5). 
 
This study forms part of a sequential mixed methods design, along with 
Study 4 (Pharmacy professionals’ experiences and perceptions of providing NHS 
patient medicines helpline services: A qualitative study, described below). However, 
Study 1 alone is an example of a quantitatively-driven mixed methods design (5). 
Although the primary aim was to derive numerical data pertaining to the current 
provision and operation of PMHS in England, some qualitative data were also 
collected. For NHS Trusts that did not provide a PMHS, and for NHS Trusts that 
provided a PMHS in the past that subsequently closed, participants were able to 
write their perceived reason/s for this.  
 
This study was published in BMC Health services Research in 2018. 
Therefore, the published article is presented. Following the article is a brief 
summary of the study’s findings, and a description of how the study fits within the 
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Background: Patient medicines helplines provide a means of accessing medicines-related support following hospital
discharge. However, it is unknown how many National Health Service (NHS) Trusts currently provide a helpline, nor
how they are operated. Using the RE-AIM evaluation framework (Reach, Effectiveness, Adoption, Implementation, and
Maintenance), we sought to obtain key data concerning the provision and use of patient medicines helplines in NHS
Trusts in England. This included the extent to which the delivery of helplines meet with national standards that are
endorsed by the Royal Pharmaceutical Society (standards pertaining to helpline access, availability, and promotion).
Methods: An online survey was sent to Medicines Information Pharmacists and Chief Pharmacists at all 226 acute,
mental health, specialist, and community NHS Trusts in England in 2017.
Results: Adoption: Fifty-two percent of Trusts reported providing a patient medicines helpline (acute: 67%;
specialist: 41%; mental health: 29%; community: 18%). Reach: Helplines were predominantly available for
discharged inpatients, outpatients, and carers (98%, 95% and 93% of Trusts, respectively), and to a lesser extent,
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helpline promotion, these percentages were 3% and 40%. One Trust reported complying with all standards.
Maintenance: The median number of years that helplines had been operating was six. Effectiveness: main perceived
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of mental health and community Trusts that operate a helpline is less than half of that of the acute Trusts, and there are
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Background
Patients often experience changes to their medicines regi-
men while they are in hospital, and it is healthcare policy in
the United Kingdom (UK) to ensure that patients’ medi-
cines are managed optimally after discharge from secondary
care [1, 2]. However, UK and international research suggest
that a substantial proportion of patients who have been dis-
charged from hospital subsequently experience medicines-
related problems [3–7]. For example, Lee et al. [3]
conducted a study which involved interviewing ninety-six
patients after being discharged from one of six acute hos-
pitals in the North-West of England. They found that 36%
of patients experienced problems with their medication
following discharge, particularly around side effects (63%),
and that 26% had actually sought or been given help fol-
lowing discharge, mainly from their general practitioner.
Relatedly, UK and international research also show that
patients often lack knowledge of their medications follow-
ing discharge from hospital, particularly around side ef-
fects [8–13], and that many patients report not receiving
important medicines-related information [14–16]. Results
from the 2017 UK National Health Service (NHS) Adult
Inpatient Survey found that 30% of 46,795 patients re-
ported that they were not provided with completely clear
written or printed information about their medicines, and
43% of 43,719 patients did not recall receiving any infor-
mation from staff about side effects to look out for when
they returned home [17]. Another evident problem which
patients may also experience following hospital discharge
are medicines-related errors, such as prescribing errors
and incorrect or missing information on discharge sum-
mary documents [18–20]. In sum, discharge from hospital
presents a potentially confusing and/or risky time for the
many patients who have recently experienced changes to
their medicines.
In many countries, medicines information (MI) services
have been established to support patients and the public
with questions about their medication [21–25]. In the UK,
patient medicines helplines have become available from a
number of hospital pharmacies to provide medicines-re-
lated support for patients who have received care within
secondary healthcare [26, 27]. Patient medicines helplines
are typically operated by pharmacy professionals (pharma-
cists and pharmacy technicians registered with the General
Pharmaceutical Council) who specialise in the provision of
MI services (from here on, referred to as MI pharmacy pro-
fessionals) [28]. The first patient medicines helpline in the
UK was established in 1992, with the aim of improving
patients’ knowledge and use of their medicines [29]. In
2007, the Healthcare Commission in the UK reported that,
of the 173 acute and specialist NHS Trusts1 in England,
64% operated a patient medicines helpline, and of 42 men-
tal health Trusts in England and Wales, 31% operated this
service [27, 30]. However, over ten years later, it is unknown
how many NHS Trusts currently provide a patient medi-
cines helpline.
Recently, several service evaluation studies have been
published that provide descriptive information about
patient medicines helplines, typically reporting the types
of calls received and user satisfaction ratings. Such studies
suggest that enquiries predominantly concern issues such
as adverse effects, administration and dosage, and interac-
tions [26, 28, 31–33]. Enquiries can also result in patients
avoiding harm, such as by highlighting medicines-related
errors so that they can be corrected [26, 31, 34]. Evaluations
of patients’ and carers’ experiences of using medicines help-
lines using self-report surveys suggest that services are
thorough and that they found the advice useful, that they
felt confident with the information they received, and felt
reassured as a result [32–34]. Consequently, patient medi-
cines helplines offer a means of providing medicines-related
support following discharge from secondary care, which
users find satisfactory [34]. Moving beyond the individual,
an additional proposed benefit of patient medicines help-
lines is that they may reduce the burden on primary care
and emergency services [35]. Evaluation studies suggest
that, if patient medicines helplines did not exist, enquirers
would typically contact their general practitioner to resolve
their medicines-related queries [34]. Providing access to a
medicines helpline accords with healthcare policy regarding
the importance of patients having access to information
about their care, and being involved in care-related deci-
sions [36–39]. Additionally, a priority of UK healthcare pol-
icy is to improve patients’ transitions of care so they are
able to manage their own health, and know how to access
healthcare support [37–40].
Although service evaluation studies have been conducted
to examine patient medicines helplines, to date, no health-
care evaluation frameworks have been applied for the
evaluation of this service. Evaluation frameworks are con-
sidered to be beneficial, since they provide a structured and
guided approach to evaluating an overall program or inter-
vention, and are typically evidence-based [41]. A widely
used framework is RE-AIM, which was first published in
1999 [42, 43] and is recommended in Medical Research
Council guidance [44]. Whereas most studies focus upon
the effectiveness of an intervention, RE-AIM comprises five
dimensions that are considered important for evaluating
the public health impact of interventions. These are:
 Reach (proportion and representativeness of the
population receiving the intervention);
 Effectiveness (assessment of the positive and
negative consequences of an intervention);
 Adoption (proportion and representativeness of
settings that adopt an intervention);
 Implementation (extent to which an intervention is
delivered as intended);
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 Maintenance (extent to which an intervention
becomes a relatively stable, enduring part of the
behavioural repertoire of an individual/organisation).
The ‘RE’ dimensions are primarily concerned with
the impact on the individual (e.g., whether an inter-
vention is beneficial for the people receiving it, and
how many individuals who could benefit from it are
receiving it). The ‘AIM’ dimensions are primarily con-
cerned with the impact of an intervention at the level
of the intervention setting (e.g., whether sites that
could offer the intervention, offer it; whether the
intervention is being offered as intended in sites that
offer the intervention, and whether this is stable over
time). Glasgow and colleagues argued that whilst the
‘AIM’ dimensions are less often studied, they are
equally important factors in determining the impact
of an intervention [45].
The main aim of this study was to obtain key data
concerning the provision and usage of patient medicines
helplines in NHS Trusts in England. The RE-AIM
framework was considered particularly useful to achieve
this, since patient medicines helpline services could po-
tentially be adopted by all NHS Trusts with the aim of
being available for all of a Trust’s patients (Adoption and
Reach). Additionally, national standards for setting up
and operating a patient medicines helpline in the UK
have recently been developed, and are endorsed by the
Royal Pharmaceutical Society [46]. This provides the
opportunity to evaluate the extent that current practice
in the provision of patient medicines helplines meets
these standards (Implementation).
Using the RE-AIM framework, the following five
study objectives were developed (re-ordered so that
‘AIM’ precedes ‘RE’, since the existence and delivery
of an intervention precedes its use and perceived
effectiveness):
1) Establish the percentage of NHS Trusts in
England that provide a patient medicines helpline,
including the percentages by region, and explore
the reasons why some Trusts do not provide this
service (Adoption).
2) Examine how patient medicines helplines are
operated in England, by comparing how current
practice meets with national standards for operating
patient medicines helplines (Implementation).
3) Establish the average number of years that Trusts
have operated patient medicines helplines, and the
reasons why some Trusts stopped operating a
helpline (Maintenance).
4) Establish for whom patient medicines helpline
services are available, and the average number of
enquiries received per week (Reach).
5) Establish pharmacy professionals’ perceptions as to
the benefits that their patient medicines helpline
can have (a proxy measure for Effectiveness).
Method
Design
This study involved the use of cross-sectional surveys to
establish the provision, usage, and current practice in
the operation of patient medicines helplines in NHS
Trusts in England.
Participants
Inclusion criteria required participants to be either an
MI pharmacy professional at an acute, mental health,
specialist or community NHS Trust within England
whose role involved operating a patient medicines help-
line service at their NHS Trust, or a Chief Pharmacist at
an acute, mental health, specialist or community NHS
Trust within England that operates a patient medicines
helpline service. These two professional groups were
chosen because MI pharmacy professionals see first-hand
the benefits of medicines helplines for patients, and Chief
Pharmacists may be better placed to provide a perspective
as to how medicines helplines are beneficial within the
wider organisation. Additionally, both groups were con-
sidered to have insight regarding the operation of their pa-
tient medicines helpline service.
At the time of data collection (February–May 2017)
226 NHS Trusts were eligible to be included in the survey.
Regional Medicines Information (MI) centres were not in-
vited to participate, since they were contacted prior to
data collection and none provided a regional patient medi-
cines helpline that is separate from an NHS Trust.
Materials and procedure
Developing the data collection tools
Two online surveys were developed using SurveyMonkey
[47]. SurveyMonkey is a platform for creating online sur-
veys that is compliant with UK data protection laws, and
has been used in other pharmacy practice survey research
[48, 49]. Best practice guidance for developing and con-
ducting online surveys was sought and adopted during the
design and data collection phases of this study [50, 51].
This included writing survey questions and answer op-
tions, and considering ethical issues such as providing
participants with information about the study and obtain-
ing consent.
Survey 1 was developed to be completed by a lead MI
pharmacy professional at each NHS Trusts (or delegated
deputy). This was because Survey 1 was tailored to ask
questions about the actual operation of the helpline (e.g.,
the average number of calls per week, and what the
advertised hours are), and MI pharmacy professionals
typically perform this role. However, if no-one from the
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MI team decided to participate, or if the Trust did not
have an MI team, Survey 1 was instead sent to the
Trust’s Chief Pharmacist to complete.
Firstly, Survey 1 sought to establish whether each NHS
Trust provides a patient medicines helpline service (RE-
AIM Adoption). For those Trusts that did not provide a
helpline, subsequent questions within Survey 1 focussed
on exploring this in more detail (e.g., whether they ever
provided a helpline, and if so, the reason/s why the help-
line stopped; and the reason/s why their Trust does not
currently provide a helpline service). For NHS Trusts that
did provide a helpline service, subsequent questions
within Survey 1 explored the operation and usage of the
service, structured by the remaining RE-AIM dimensions.
To measure RE-AIM Implementation, the sections of
the national standards for operating patient medicines
helplines [46] pertaining to access, availability, and pro-
motion of patient medicines helplines were developed in
to questions for inclusion in the survey. The standards
for helpline access, availability, and promotion were used,
since these sections are most likely to impact helpline
service users (other sections pertain to use of standard op-
erating procedures, use of information and professional
support, and quality and risk). The standards are separated
in to ‘satisfactory’ and ‘commendable’ aspects of helpline
operation, and both types were included in the survey.
For RE-AIM Maintenance, participants were asked to
report the year that their helpline service was set up, so
that this information could be used to establish the aver-
age length of time that helplines have been running.
For RE-AIM Reach, participants were asked to report
who could use the helpline service, and the number of
enquiries received to the helpline service per week.
For RE-AIM Effectiveness, MI Pharmacy professionals’
and Chief Pharmacists’ perceptions as to the benefits of
patient medicines helpline services were sought. A list of
potential benefits of patient medicines helplines has been
developed by the same small working group of proponents
of the service that developed the national standards, and
have also been endorsed by the Royal Pharmaceutical Soci-
ety [35]. These proposed benefits were included in Survey
1, and were the primary feature of Survey 2. Participants’
options were to rate each item as having ‘major benefit’ or
‘minor benefit’/‘no benefit’. Participants were also given the
option to report any additional perceived benefits that were
not included in the list.
Survey 2 was developed to be completed by Chief
Pharmacists (or delegated deputy) at Trusts that operate
a medicines helpline, where Survey 1 had already been
completed by an MI pharmacy professional. The aim of
Survey 2 was to explore Chief Pharmacists’ perspectives
as to how patient medicines helplines are beneficial,
since Chief Pharmacists may be more likely to take a
wider organisational view than those involved in the
day-to-day operation of the helpline service. The pri-
mary feature of Survey 2 was therefore the RE-AIM
Effectiveness section of Survey 1.
Overall, survey questions primarily consisted of either
yes/no or multiple-choice answers, although some ques-
tions also provided free-text boxes. The questions and
response options for Survey 1 and Survey 2 are provided
in Additional file 1.
Pre-test and pilot
Following recommended methods [52], a pre-test of the
survey was conducted, with three pharmacists with
expertise in the area of patient medicines helplines. The
aim of the pre-test was to assess the content, length and
format, and to identify problems that may interfere with
respondents completing the survey consistently and
accurately. Amendments were made based upon the
feedback of the pre-test.
Additionally, prior to study commencement, a pilot
study was conducted. The pilot involved collecting survey
data using a randomly selected 10% of the main study
sample, ensuring that Trust type and geographical cover-
age of England were represented. The results of the pilot
suggested that no changes were necessary, so data from
the pilot were included in the final results.
Data collection
Figure 1 shows the procedure for collecting data using
the two surveys.
Data were collected between February–May 2017. Sur-
vey 1 was sent to MI pharmacy professionals at all acute,
mental health, specialist, and community NHS Trusts in
England, via email. If Survey 1 was not completed by an
MI pharmacy professional, it was sent to the Chief
Pharmacist of the NHS Trust, via email. If Survey 1 was
completed by an MI pharmacy professional, and if the
Trust reported providing a patient medicines helpline,
the Chief Pharmacist of the Trust received Survey 2. For
all participants, three reminder emails were sent if there
was no response, within two weekly intervals. Non-re-
sponders were contacted to establish whether or not
their Trust provided a helpline. Participants were in-
formed that by completing the survey, they would have
the option of being included in a prize draw to win a
£25 gift voucher.
Data analysis
Data were analysed using SPSS version 23, to primarily
produce descriptive statistics (e.g., percentages of NHS
Trusts complying with the standards). Chi square tests
of independence were used to examine the relationships
between Chief Pharmacists’ and MI pharmacy profes-
sionals’ ratings of the benefits of patient medicines help-
lines. To establish the percentage of NHS Trusts which
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provide a patient medicines helpline by region of England,
an official list of NHS Trusts within ten regions of
England was used [53].
Results
Response rates
Out of 226 NHS Trusts, 202 completed Survey 1 (89%).
Of these, 127 (63%) were completed by an MI pharmacy
professional, and sixty-two (31%) were completed by a
Chief Pharmacist (thirteen did not disclose their job title;
6%). The remaining 11% of Trusts were contacted to es-
tablish whether they operated a patient medicines help-
line, with all such trusts providing a response to this
item. Of the survey non-responders, eleven were from
mental health Trusts (46%; 20% of all mental health
Trusts), seven were from acute Trusts (29%; 5% of all
acute Trusts), five were from community Trusts (21%;
29% of all community Trusts) and one was from a spe-
cialist Trust (4%; 6% of all specialist Trusts).
Additionally, fifty-two Chief pharmacists also com-
pleted Survey 2 comprising the questions about the ben-
efits of providing a helpline service.
RE-AIM ‘adoption’
Table 1 shows the percentage of NHS Trusts in England
that provide access to a patient medicines helpline, by
Trust type and region. Combined, 52% of NHS Trusts
provide this service (acute, 67%; specialist, 41%; mental
health, 29%; and community, 18%).
Out of the 117 Trusts that provided a patient medi-
cines helpline, 110 answered whether they operated the
service directly or via another Trust. Three out of 110
Trusts reported providing the helpline service via another
Trust (3%). Of the 107 Trusts which operated their own
helpline, 103 Trusts operated one helpline (96%), three
Trusts operated two helplines (3%) and one Trust oper-
ated three helplines (1%). Table 2 reports the percentages
of where patient medicines helpline services are located
within NHS Trusts, showing that helplines are predomin-
antly located within MI centres (87%).
Fig. 1 Data collection procedure
Table 1 NHS Trusts in England providing access to a patient
medicines helpline service
Type of NHS Trust/region
of England
Percentage of NHS Trusts
providing access to a helplinea
Acute Trust 67% (91/136)
Specialist Trust 41% (7/17)
Mental health Trust 29% (16/56)
Community Trust 18% (3/17)
Total NHS Trusts 52% (117/226)
East of England 72% (18/25)
South Central 69% (9/13)
South East 69% (11/16)
London 60% (21/35)
North East 60% (6/10)
Yorkshire & Humber 52% (11/21)
South West 46% (11/24)
North West 41% (16/39)
East Midlands 33% (5/15)
West Midlands 32% (9/28)
aNumbers in parentheses show the actual numbers of NHS Trusts that
reported providing access to a helpline, out of the total number of Trusts, for
the type of Trust or the region of England
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Of the 109 non-helpline Trusts, seventy-six provided
comments as to why they do not offer the service. For
fifty-four of the seventy-six, the reason was a lack of re-
sources (staff time and/or funding; 71%). For sixteen of
the seventy-six, the reason was not having a MI service
(21%). Three Trusts answered that they do not have a
helpline because they do not know what the demand
would be (4%). Six per cent reported that their Trust has
plans to provide a patient medicines helpline in the fu-
ture, whereas 56% reported that this was a possibility,
and 38% reported that their Trust did not have any plan
to provide this service in the future.
Of the non-helpline Trusts, 90% reported that, if they
did receive a call from a discharged patient about their
medicines, they would answer the query.
RE-AIM ‘implementation’
Tables 3, 4 and 5 shows the percentages of NHS Trusts
which were found to comply with the national standards
for helpline access, availability and promotion.
Of the 107 NHS Trusts that answered all questions
pertaining to the helpline access standards, sixteen NHS
Trusts were fully compliant with all access standards
(15%; 54% were compliant with all ‘satisfactory’ standards,
and 26% were compliant with all ‘commendable’ stan-
dards). Of the 107 NHS Trusts that answered all questions
pertaining to the helpline availability standards, five NHS
Trusts were fully compliant with all availability standards
(5%; 86% were compliant with all ‘satisfactory’ standards,
and 5% were compliant with all ‘commendable’ standards).
Of the ninety-nine NHS Trusts that answered all questions
pertaining to the helpline promotion standards, two NHS
Trusts were fully compliant with all promotion standards
(2%; 3% were compliant with all ‘satisfactory’ standards, and
40% were compliant with all ‘commendable’ standards).
Out of the ninety-nine Trusts that answered all ques-
tions pertaining to the ‘satisfactory’ national standards,
one NHS Trust was fully compliant with all ‘satisfactory’
standards (1%). Out of the 106 Trusts that answered all
questions pertaining to the ‘commendable’ national stan-
dards, two NHS Trusts were fully compliant with all ‘com-
mendable’ standards (2%). From a total of ninety-nine
Trusts that answered all questions pertaining to both ‘sat-
isfactory’ and ‘commendable’ national standards, one Trust
was fully compliant with all standards (1%). Figure 2
shows the percentages of NHS Trusts that were found to
comply with all of the national standards for helpline ac-
cess, availability and promotion.
Table 2 Location of patient medicines helpline services within
NHS Trusts in England
Location of the helpline service within
the NHS Trust
Percentage of NHS Trusts
providing their helpline
from the specified locationa
Medicines Information Centre 87% (97/112)
General clinical pharmacy services 13% (15/112)
Dispensary 4% (5/112)
Specialist clinical pharmacy services 4% (4/112)
Note. Nine Trusts reported that their helpline service was provided by more
than one location within the NHS Trust (8%), which is why the total
exceeds 100%
aNumbers in parentheses show the actual numbers of NHS Trusts that
reported providing their helpline from the specified location, out of the total
number of NHS Trusts which reported providing access to a helpline and
answered this survey question
Table 3 Compliance with national standards for ‘satisfactory’ and ‘commendable’ levels of patient medicines helpline access
National standards: Helpline access Percentage of NHS Trusts
meeting each standarda
‘Satisfactory’ standards Calls charged at local rate or Freephone (not a premium number). 99% (108/109)
The phone line allows direct dialling from outside. 97% (106/109)
An answerphone allows a message to be left outside of advertised hours. 81% (88/108)
Contact with a pharmacy professional is always available during advertised hours. 71% (77/108)
Total compliance with access ‘satisfactory’ standards. 54% (58/108)
‘Commendable’ standards The helpline has a dedicated phone number. 60% (65/109)
There is access to the service by means other than telephone, such as email,
webform, personal visitb.
39% (42/109)
Total compliance with access ‘commendable’ standards. 26% (28/107)
Total compliance with both ‘satisfactory’ and ‘commendable’ access standards 15% (16/107)
Note. Although 117 of 226 acute, mental health, specialist, and community NHS Trusts reported providing a patient medicines helpline, not all NHS Trusts
answered every survey question
aNumbers in parentheses show the actual numbers of NHS Trusts that met the standard, out of the total number of Trusts which answered the survey question
pertaining to the standard
bThirty-four Trusts reported advertising their service as being accessible via one other method besides the telephone (31%), and eight Trusts reported advertising
their service as being accessible via two other methods besides the telephone (7%). At thirty-four Trusts, their service was advertised as being accessible via email
(31%). At eight Trusts, their service was advertised as being accessible via online web form (7%). At seven Trusts, their service was advertised as being accessible
face-to-face (6%). At one Trust, their service was advertised as being accessible via social media (Twitter; 1%)
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RE-AIM ‘maintenance’
The median time that an NHS Trust had been operating
a patient medicines helpline in England was six years
(range 1–24 years).
Out of the 109 NHS Trusts which reported that they
do not currently provide a patient medicines helpline,
eighty-eight Trusts answered whether or not they pro-
vided a helpline in the past. Nine responded that they
operated a helpline in the past (10%), citing main rea-
sons for discontinuing the service as a lack of resources
(lack of staff and/or funding; five of nine; 56%), and in-
sufficient use (two of nine; 22%).
RE-AIM ‘reach’
Results showed that out of the 117 NHS Trusts that pro-
vided a patient medicines helpline, 112 Trusts answered
who could access the helpline. Figure 3 shows the provision
of access to medicines helplines for different groups
of individuals. Medicines helplines are primarily avail-
able for discharged inpatients (98% of NHS Trusts),
outpatients (95% of NHS Trusts), and patients’ carers
(93% of NHS Trusts).
One hundred and seven participants reported the
number of enquiries typically received to their patient
medicines helpline service per week. For all Trust types
combined, the median number of enquiries received
per week was five (range 0–50). For acute Trusts, the
median was five enquiries. For mental health Trusts,
the median was three enquiries. For specialist Trusts,
the median was seven enquiries. The median number
of enquiries for community Trusts could not be ro-
bustly calculated due to the low number of community
Trusts which operated a helpline and which answered
this question.
Table 4 Compliance with national standards for ‘satisfactory’ and ‘commendable’ levels of patient medicines helpline availability
National standards: Helpline availability Percentage of NHS Trusts
meeting each standarda
‘Satisfactory’ Standards The helpline is available five days per week. 96% (103/107)
The helpline is accessible to patients/carers for minimum of four hours per day. 86% (92/107)
Total compliance with availability ‘satisfactory’ standards. 86% (92/107)
‘Commendable’ Standards The helpline is available for eight hours or more per day. 57% (61/107)
The helpline is available for extended hours (i.e., evenings, weekendsb). 7% (7/107)
Total compliance with availability ‘commendable’ standards. 5% (5/107)
Total compliance with both ‘satisfactory’ and ‘commendable’ availability standards 5% (5/107)
Note. Although 117 of 226 acute, mental health, specialist, and community NHS Trusts reported providing a patient medicines helpline, not all NHS Trusts
answered every survey question
aNumbers in parentheses show the actual numbers of NHS Trusts that met the standard, out of the total number of Trusts which answered the survey question
pertaining to the standard
bThree of 107 (3%) helpline services were reported as being available in the evenings; five of 107 (5%) helpline services were reported as being available at
weekends (and operate seven days per week)
Table 5 Compliance with national standards for ‘satisfactory’ and ‘commendable’ levels of patient medicines helpline promotion
National standards: Helpline promotion Percentage of NHS Trusts
meeting each standarda
‘Satisfactory’ Standards The helpline is promoted at all of the healthcare organisation’s sites. 59% (64/109)
Promotional materials identify access times and types of enquiries patients/carers can make. 40% (44/109)
The helpline is promoted to discharged inpatients by methods agreed with patients locally. 6% (6/100)
Total compliance with promotion ‘satisfactory’ standards. 3% (3/100)
‘Commendable’ Standards The helpline is also promoted to outpatients. 84% (91/108)
Additional promotional methods are used, such as patient leaflets and the NHS Trust websiteb. 42% (46/109)
Total compliance with promotion ‘commendable’ standards. 40% (43/108)
Total compliance with both ‘satisfactory’ and ‘commendable’ promotion standards 2% (2/99)
Note. Although 117 of 226 acute, mental health, specialist, and community NHS Trusts reported providing a patient medicines helpline, not all NHS Trusts
answered every survey question
aNumbers in parentheses show the actual numbers of NHS Trusts that met the standard, out of the total number of Trusts which answered the survey question
pertaining to the standard
bEighty-two Trusts reported that their helpline was promoted using leaflets or business cards that are given to patients (75%). Forty-two Trusts reported that their
helpline was advertised on the Trust website (38%). Forty Trusts reported that their helpline was promoted on medicines labels or on medicines bag labels (37%).
Thirty-six Trusts reported that their helpline was promoted on the patient’s discharge summary (33%). Thirty Trusts reported that their helpline was promoted
using posters in clinical areas (27%). Twenty-two Trusts reported that staff routinely tell patients about the helpline (20%). The median number of promotional
methods used was two. The maximum number of promotional methods used by a single Trust was seven
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RE-AIM ‘effectiveness’
Table 6 provides an overview of pharmacy professionals’
perceptions regarding the major benefits of their helpline
service. The top five perceived benefits were: avoiding harm
to patients (88%), improving patient medication adherence
(85%), providing assurance that patients can access profes-
sional help from home (83%), improving the patient experi-
ence (e.g., patient satisfaction; 80%), and supporting patient
discharge (76%). Chi square tests showed that there was
a significant association between professional role and
benefit rating for two of the perceived benefits: avoiding
harm to patients (χ2(1) = 5.65, p = .017), and identifying
errors (χ2(1) = 9.39, p = .002). For both, MI pharmacy
professionals were more likely to rate the benefits as being
major benefits compared to Chief Pharmacists.
Exploratory analyses
The median number of five helpline calls per week per
NHS Trust was considered by our research team to be
low. Exploratory analyses were conducted to explore
potential ways to increase helpline use, pertaining to the
areas of helpline access, availability and promotion. In
order to normalise the data so that parametric tests
could be conducted, the data were transformed using a
log transformation. Pearson’s partial correlation coeffi-
cients were calculated to establish the relationships be-
tween the number of hours that helplines were available
per week and the number of enquiries received per
week, and between the number of promotional methods
used and the number of enquiries received per week.
The size of NHS Trusts was controlled using Hospital
Episode Statistics ‘Finished Admission Episodes’ for 2015–
2016 [54]. Significant positive correlations were found
between the two sets of variables (r (95) = .31, p = .002 and
r (98) = .23, p = .02, respectively). Additionally, an analysis
of covariance was calculated to establish whether there was
a statistically significant difference between the number of
enquiries per week for Trusts that only provide access to
their service via the telephone (mean number of enquiries
per week = 7.0, SD = 8.8) versus Trusts that also provide ac-
cess via at least one other method of communication (mean
number of enquiries per week = 9.9, SD = 9.7). There
was a significant effect of number of communication
methods on the number of calls after controlling for
Trust size, F(1, 99) = 8.89, p = .004, η2 = .073.
Discussion
This study used the RE-AIM healthcare interventions
evaluation framework to establish the provision, usage,
and current practice in the operation of patient
Fig. 2 Total compliance with national standards for patient
medicines helpline access, availability, and promotion. Note.
Numbers in parentheses show the actual numbers of NHS Trusts
that met the standards, out of the total number of Trusts that
answered the survey questions pertaining to the standards
Fig. 3 Provision of access to medicines helplines for different groups of individuals (n = 112)
Williams et al. BMC Health Services Research          (2018) 18:868 Page 8 of 13
medicines helplines in NHS Trusts in England, and
pharmacy professionals’ perceptions of the main benefits
of their service.
Regarding the adoption of patient medicines helplines,
this study shows that there is disparity of access to the
service within England. Just over half of acute, mental
health, specialist and community Trusts in England op-
erate a patient medicines helpline service, although this
varies according to type of Trust and region. Only 29%
of mental health Trusts and 18% of community Trusts
currently provide their patients with access to this ser-
vice. The percentage of acute Trusts which provide a pa-
tient medicines helpline is over double that of mental
health and community Trusts. This implies that the ben-
efits of patient medicines helplines (i.e., reduced patient
harm, and error correction) [26, 31, 34] are currently not
experienced to the same extent for patients of mental
health and community services, compared to patients of
acute and specialist services. Additionally, the proportions
of Trusts in the North and Midlands of England which
provide the service is typically lower than the proportions
of Trusts in the southern regions of England. We also
found that nine Trusts reported previously operating a
helpline that had been discontinued. The main reason for
closure was a lack of resources/funding. Lack of re-
sources/funding was also the main reason why 48% of
Trusts did not currently provide a helpline, suggesting
that this is an important barrier to providing this service.
However, regarding the maintenance aspect of patient
medicines helplines, our findings suggest that, once
adopted, helplines are likely to become a relatively stable
service for NHS Trusts. On average, NHS Trusts had been
operating for six years, with the longest running for
twenty-four years.
Our findings suggest that the reach of patient medicines
helpline services could be improved. In the UK, up to 44%
of patients who have been discharged from hospital may
subsequently experience medicines-related problems [3, 4].
Given that there is an identified need for medicines infor-
mation and a high number of hospital patients [54], the
number of patients who use medicines helplines per week
should be substantial. However, we identified that the
median number of enquiries per Trust was five per week.
This finding, along with similar results from previous
studies, suggest that patient medicines helplines are an un-
derused service [26–28].
Patient medicines helplines are considered to be benefi-
cial because they have the potential to reduce the burden
upon other services, including GP and A&E visits, and also
to potentially reduce the number of medicines-related hos-
pital readmissions [35]. This is topical, given that the aver-
age waiting time from booking a standard appointment to
seeing a GP in England in 2016 and 2017 was estimated to
be approximately two weeks [55]. Also, in the UK, the
Department of Health recognises that urgent care services
are struggling to cope with rising demands [40, 56]. In
January 2017, and again in December 2017, the proportion
of patients waiting longer than four hours in A&E reached
Table 6 Pharmacy professionals’ perceptions of the benefits of patient medicines helpline services







Avoiding harm to patients (e.g., adverse effects, interactions). 93%b 80%b 88%
Improving patient medication adherence. 89% 80% 85%
Providing assurance to patients that they can access professional help from home. 84% 80% 83%
Improving the patient experience (e.g., patient satisfaction). 84% 76% 80%
Supporting patient discharge. 78% 71% 76%
Optimising medicines. 76% 73% 75%
Identifying errors. 85%c 64%c 75%
Reducing medicines-related readmissions. 67% 62% 65%
Learning from adverse patient experiences. 55% 56% 55%
Reducing visits to other healthcare services (e.g., GPs, A&E). 52% 53% 51%
Helping the organisation avoid complaints and possible litigation. 44% 42% 43%
Adhering to the NHS constitution (e.g., patients have a right to receive information). 40% 30% 37%
Improvement in Trust targets and in national surveys. 22% 26% 23%
Note. Although 117 of 226 acute, mental health, specialist, and community NHS Trusts reported providing a patient medicines helpline, not all NHS Trusts
answered every survey question. Respondents were also provided a free-text box to record other perceived benefits. However, these suggestions were not
included in the results since they were either a rewording of an item already in the list, or not also suggested by any other respondents
aNot all respondents provided their job title, which is why the total is greater than the number of MI pharmacy professionals and Chief Pharmacists combined
bA Chi square test of independence showed that there was a significant association between professional role and rating, at p < .05
cA Chi square test of independence showed that there was a significant association between professional role and rating, at p < .005
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its highest level since the collection of A&E performance
data began [57]. There is also recognition that a proportion
of A&E visits could be managed more appropriately else-
where. For example, 38% of people who attend A&E receive
guidance or advice only [58]. The 2014 NHS Five Year
Forward View, which provides an outline for improving
and modernising the NHS, emphasises that reducing the
workload in A&E is a priority [40, 56]. It would therefore
be beneficial to examine why patient medicines information
helplines are underused, and to consider how it might be
possible to encourage their use.
Our findings regarding the implementation of patient
medicines helplines, whereby we compared current prac-
tice to recommended national standards for operating
patient medicines helplines, may indicate why this service
is underused. The access, availability, and promotion of
helplines are all likely to influence their use, and we found
that adherence to the national standards could be im-
proved in all three areas. However, the greatest discrep-
ancy between current practice and the national standards
concerns the promotion of helplines. For example, pro-
motional material containing information relating to
medicine helpline access times and the types of enquiries
that patients/carers can make were used in only 40% of
Trusts. Not providing this information may cause frustra-
tion for callers who call outside of operating hours, and
may cause confusion as to what the service provides and
whether it can cater to their needs. The main reason why
overall adherence to the ‘promotion’ national standards
was particularly low, was because very few Trusts sought
the advice of patients regarding the promotional methods
to use. Including patients and carers in the development
of healthcare services is increasingly recognised as being
beneficial for understanding what works and why, in order
to improve services [59]. Involving service users may
therefore be beneficial for improving not only helpline
promotion, but all aspects of this service. Our findings
also suggest that increasing the number of promotional
methods may increase the use of patient medicines help-
lines, since the number of methods was significantly cor-
related with number of enquiries. Additionally, helplines
are typically not promoted at all hospital sites, and so this
may be another potential explanation for their lack of use.
Regarding helpline access and availability, 43% of med-
icines helplines are available for less than eight hours a
day, and at 29% of sites, a pharmacist is not always avail-
able. Therefore, service users may not be able to imme-
diately speak to a pharmacist, and it is unknown what
effect this has upon enquirers. For example, do enquirers
try accessing the helpline again later or do they perhaps
seek support elsewhere? We also found that approxi-
mately only 7% of Trusts that operate a helpline currently
provide the service out of hours (e.g., evenings and/or
weekends). For comparison, a recent survey study found
that 87% of hospitals at acute and mental health Trusts in
England provide an out-of-hours pharmacy advice service
for healthcare professionals [60]. Our findings also show
that approximately only 5% of Trusts that operate a help-
line currently provide the service seven days per week.
Since the number of hours per week that a helpline is
open correlates with the number of enquiries received per
week, another way to increase the use of patient medicines
helplines may be to increase the number of hours per
week that the service is available.
Our results suggest that approximately only 39% of NHS
Trusts that operate a patient medicines helpline advertise
the service as being accessible via at least one other method
of communication besides the telephone, with the main al-
ternative method being email. Providing access via at least
one other means of communication besides the telephone
was found to significantly increase the number of calls per
week, albeit slightly, suggesting that this could be another
way of increasing helpline use. Only one NHS Trust re-
ported advertising their service as being accessible via social
media. Service evaluation studies that have examined the
types of people who call patient medicines helplines suggest
that the majority are elderly [26]. In order to better engage
with younger people, MI services may benefit from also
providing more current methods of communication. Re-
search carried out internationally has begun to examine al-
ternative methods of providing MI to patients and
members of the public, including online ‘Ask the Pharma-
cist’ services [61], and a Facebook ‘Pharmacist Hour’ [62].
Regarding the effectiveness of patient medicines help-
lines, we found their main perceived major benefits to
be avoiding harm to patients, improving patient medication
adherence, and providing assurance that patients can access
professional help from home. Service evaluation studies
have been conducted which provide evidence that enquiries
to patient medicines helplines can result in patients avoid-
ing harm [31], and that between 95 and 97% of enquirers
subsequently report following the advice given [32, 34]. The
only significant differences found between Chief Pharma-
cists’ and MI pharmacy professionals’ endorsements of the
major benefits were for avoiding harm to patients, and
identifying errors. This could be because MI pharmacy pro-
fessionals have first-hand experience of interacting with
helpline callers to know the types of enquiries being made
and the impact they can have. Interestingly, reducing visits
to other healthcare services (e.g., GPs, A&E) was consid-
ered a major benefit by only 51% of respondents. However,
this could be because the number of enquiries per week per
Trust was found to be relatively low, and so the reduction
of visits to other services would likely be minimal (several
respondents reported this as the reason for their response,
in the ‘other comments’ section of the survey). Increasing
the use of patient medicines helplines may shift pharma-
cists’ perceptions in this respect.
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The list of benefits was originally developed by a
small working group of proponents of patient medi-
cines helplines [35]. This study provides stronger evi-
dence as to the major benefits of patient medicines
helplines, as perceived by a sample of 156 pharmacy
professionals with expertise in patient medicines help-
line provision.
Recommendations
In order to increase the impact of patient medicines
helplines, we encourage helpline providers to consider
ways to increase their use. Our findings suggest that this
may be achievable by improving the access, availability,
and promotion of helplines. For example:
 Providing access to the service by other means in
addition to the telephone, such as email, webform
via the Trust website, online chat, and Skype.
 Extending the hours of availability, such as providing
access to the service beyond typical 9–5 working
hours (e.g., evenings and weekends).
 Increasing the number of promotional methods,
and/or conducting local improvement projects to
establish the types of promotional methods that
patients and carers recommend, and would most
likely see and remember.
 Promoting the service at all sites within the
organisation, and ensuring that promotional
methods identify access times and types of
enquiries that can be made.
Limitations and future research
A limitation of our study is that we were not able to
obtain a full dataset, since some respondents chose not to
fully complete all survey questions. Although missing data
was minimal, the percentages presented in this study can
only be considered to be approximately representative of
the total number of NHS Trusts. Another limitation is
that, in order to minimise respondent burden, we chose to
only include questions that represented the sections of the
national standards pertaining to helpline access, availabil-
ity, and promotion. However, it would be advantageous
for a future study to audit the remaining standards, since
this may highlight additional ways that helpline providers
may improve the delivery of their service. Subsequent re-
search could also audit how helplines are operated in the
other three UK countries, and collect additional data to
explore some of the RE-AIM dimensions in greater depth.
For example, a more thorough approach for understand-
ing the reach of patient medicines helplines would be to
follow up a cohort of discharged patients from Trusts that
provide a medicines helpline, in order to explore those
patients who subsequently require medicines information,
and to compare the percentages and characteristics of
helpline users with patients who choose alternative
sources of support. This study design could also pro-
vide an opportunity to explore patients’ reasons for not
seeking medicines information via the medicines help-
line service.
Future research could also seek to establish whether
and in what ways the variability in the operation of pa-
tient medicines helplines has an effect upon service
users, and qualitative methods would be appropriate for
exploring patients’ and carers’ experiences of using this
service. Exploring the experiences that service users have
regarding their medicines following their use of a patient
medicines helpline could also provide further evidence
as to the effectiveness of this service. Our measure of
the effectiveness of helplines was limited, since it relied
upon the perceptions of service providers and may be
biased if participants were apprehensive about reporting
any negative or poor aspects of their service. Addition-
ally, our survey did not include a question to specifically
ask pharmacy professionals to also provide their percep-
tions as to how patient medicines helpline services could
be improved. However, our findings regarding the bene-
fits of helplines provide a useful starting point to identify
potential areas for future research. For example, studies
could be designed to empirically test whether the per-
ceived benefits of helplines are indeed benefits.
Although we have provided recommendations for
increasing the use of patient medicines helplines, we
acknowledge that increasing their use will likely require
additional resources, and we found that a lack of staffing/
funding was the main reason for NHS Trusts not provid-
ing a helpline, and for ceasing previously existing help-
lines. Future research could seek to establish whether a
more cost-effective yet acceptable approach might be to
operate a network of regional patient medicines helplines,
or a national service, with collaboration from NHS Trusts
for enquiries requiring local resources. However, a recent
study by Badiani et al. [34] found that, out of 200 en-
quiries to their patient medicines helpline service, 75% re-
quired access to local knowledge. The most commonly
used local source was the patients’ electronic medical re-
cords (73%), followed by contacting a healthcare profes-
sional involved in the patient’s care (34%). Badiani et al.
conclude that their findings support the value of having a
network of local PMHS, rather than a small number of
centralised services. Further research is needed to estab-
lish the generalisability of this finding.
Conclusion
This study demonstrates that patient medicines helplines
continue to be provided by over half of NHS Trusts in
England, with a similar percentage as reported by the
Healthcare Commission in 2007. Also, the percentages
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of mental health and community Trusts that operate a
helpline were found to be less than half of the percentage
of acute Trusts that operate a helpline. Combined, these
findings show that not all patients are able to experience
the benefits that patient medicines helplines provide, due
to a lack of adoption of this service. Adherence to the na-
tional standards could generally be improved, although
the lowest adherence was regarding helpline promotion.
Since patient medicines helplines appear to be an under-
used service, improving helpline access, availability and
promotion may help to increase their use. However, the
most cited reason for the lack of a helpline in 48% of NHS
Trusts in England is lack of resources. This is also the
main reason why some NHS Trusts stopped operating a
helpline. Without adequate resources, it may therefore be
that helpline providers do not currently have the capacity
to increase the use of their service. One option could be
to pool resources within regions, although this may not be
possible given that many enquiry answers require local
knowledge from the hospital where the patient received
care. Further research is needed to explore the best way to
support all patients who need help with their medicines
following hospital discharge, which is cost-effective with-
out diminishing quality.
Endnotes
1The English National Health Service (NHS) is organised
in to NHS Trusts, which are organisations that provide
goods and services for the purposes of health care (e.g.,
hospital and community services), and each Trust primarily
serves a geographical area within England.
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4.4 Data access statement 
 
As specified in the article, the datasets generated and analysed for this 
study are not publicly available, for data privacy and ethical considerations. This is 
because the participant consent form did not ask participants to agree to share their 
anonymised data for future research. 
 
4.5 Chapter 4 summary 
 
 This study has been a useful foundation for the PhD, in order to provide key 
background information pertaining to the provision, implementation, use, longevity, 
and perceived effectiveness of PMHS. At the time of data collection in 2017, 
approximately half of NHS Trusts provided this service, and there was variability in 
the way that PMHS were provided. Additionally, the promotion, availability, and 
access of PMHS were not meeting national standards regarding PMHS 
implementation. This may have affected their use, considering that PMHS only 
received an average of five calls per week. However, PMHS were perceived to have 
a number of benefits, by pharmacy professionals who provided them (e.g., patients 
can avoid medicines-related harm, medication errors can be corrected and learnt 
from, and patients’ medication adherence can be improved). Once established, 
PMHS tended to become a stable service for NHS Trusts, with Trusts providing the 
service for six years on average. 
 
 For transparency, the qualitative aspects of the study (i.e., participants 
providing written comments as to why their Trust does not provide a PMHS, and 
participants providing comments as to why their PMHS ceased to exist) were 
analysed using content analysis (6). This involved coding all comments and using 
the coded data to establish the proportion of participants who’s comments were in 
agreement regarding a particular code (e.g., 71% of participants commented that 
the reason why their Trust did not provide a PMHS was due to a lack of resources; 
16% of participants commented that the reason why their Trust did not provide a 
PMHS was because their Trust does not have a medicines information department). 
 
 A strength of this study was the high response rate of the survey. In order to 
increase the response rate, a Cochrane review by Edwards et al. was used, which 
describes evidence-based methods for increasing responses to online surveys (7). 
Based upon this review, the strategies I used were: offering incentives (participants 
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had the opportunity to win one of two £25 gift vouchers), sending the survey out 2-3 
times (I sent the survey out 3 times to non-responders), personalising the invite (I 
sent the email invites to participants personally, using their names, as established 
via the UKMi online directory (8)), not making the survey lengthy (I tested the survey 
beforehand to ensure it was considered an appropriate length), having a survey that 
is of interest to the potential participants (the survey pertained to the provision of 
PMHS, and was being sent to providers of PMHS), using textual presentation of 
response categories instead of visual presentation of response categories (I always 
used the former type), including a statement that others had responded (I sought to 
increase the response rate of non-acute Trusts by mentioning the low response rate 
from non-acute Trusts in their second and third email invites), and not using the 
word ‘Survey’ in the subject line of the email (I used the term ‘online study’ instead). 
Strategies that the Cochrane review found were beneficial yet were not used in my 
study were: sending a picture in the invite email (I thought this may look 
unprofessional), and having a female researcher send the email invite compared to 
a male researcher (I was the lead researcher, and male). 
 
The study presented in this chapter found that 52% of Trusts provide a 
PMHS, and 48% of Trusts do not. A stepped-wedge randomised trial design may be 
used to evaluate healthcare services that are already being provided but where the 
evidence for the effectiveness of the service is limited (9). A stepped-wedge design 
could therefore be suitable for evaluating the effectiveness of PMHS. Additionally, it 
may be possible to compare Trusts that provide a PMHS to Trusts that do not, for 
example, on medicines-related 30-day hospital readmissions. However, the study 
presented in this chapter also found that, on average, NHS Trusts receive just five 
enquiries to their PMHS per week. The low usage of PMHS suggests that the above 
study designs would be unlikely to detect an effect, if any exist. 
 
 Part of the study involved exploring how PMHS are being delivered, 
including whether current practice met national standards for PMHS provision. 
However, a limitation of this aspect of the study is that the standards were 
developed by a small group of MI pharmacists based primarily at one NHS Trust 
that provide a PMHS. Therefore, the national standards may not be free from bias 
(e.g., the standards may reflect what is considered good practice in relation to the 
PMHS provided by the developers of the standards, which may not be endorsed by 
the wider MI community). Relatedly, the document containing the national standards 
does not provide any information regarding their development to ascertain whether 
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they are evidence-based. For example, one of the standards proposes that 
alternative methods of accessing the service should be provided, such as email or 
webform. Yet, the decision to include email and webform options within this 
standard is not reported as being based upon prior evidence, and therefore their 
implementation in order to meet this standard may be a waste of time and 
resources. 
 
Another limitation of this study is that the effectiveness of PMHS was 
measured by examining pharmacy professionals’ perceptions of the major benefits 
of PMHS. Since this is an exploration of the perceptions of effectiveness, rather 
than hard outcomes (e.g., readmissions, reduced symptoms, improved health), the 
findings may be biased (i.e., response bias). For example, it could be argued that 
pharmacy professionals have a vested interest in making PMHS appear beneficial, 
since their livelihood may be dependent (to some extent) upon the continued 
provision of this service. They may therefore have reported benefits as being ‘major’ 
even if they do not typically perceive them that way. Relatedly, ‘major benefit’ was 
chosen as the term used for participants to rate the effectiveness of their service. 
However, the word ‘major’ as a quantifier could be interpreted differently by different 
participants, since it is subjective.  
 
A limitation of survey methods for examining PMHS, however, is that 
participants do not have the opportunity to describe in depth their experiences of 
providing this service. For example, it would be useful to explore further the reasons 
why NHS Trusts provide their PMHS with limited promotion and availability. It would 
also be useful to explore pharmacy professionals’ perceptions as to why the use of 
PMHS may be inadequate, and for them to describe their perceptions pertaining to 
the effectiveness of PMHS in their own words, rather than selecting from a pre-
specified list (as was the case in this survey study). Qualitative methods would 
therefore be useful to achieve this. However, it is unknown whether any qualitative 
work has been conducted on this topic. Additionally, further work could be 
conducted to provide a foundation for this PhD topic by systematically reviewing the 
available literature pertaining to PMHS. This would establish whether any qualitative 
work had been conducted, and would also highlight other gaps in the evidence-base 
for future research regarding PMHS. Systematically reviewing the available 
literature could also provide further insight into the effectiveness of this service. 
Therefore, what follows next is a systematic review examining the evidence 
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Chapter 5: A systematic review examining the 
effectiveness of medicines information 
services for patients and the general public. 
 
5.1 Overview of Chapter 5 
 
This chapter presents the second study of this doctoral research. As with 
Study 1, this second study also provides the foundations for future research 
examining PMHS. Studies that have examined PMHS have typically been service 
evaluations of individual sites to describe the characteristics of enquirers and their 
enquiries, and to report the effectiveness of PMHS using enquirer satisfaction 
surveys (e.g., (1, 2)).  Until now, a review of the literature had not been conducted to 
bring together the available evidence as to the effectiveness of PMHS, nor has the 
quality of this evidence been examined.  
 
In many countries, MI services are provided for the general public, rather 
than primarily for patients of a specific hospital (from here, medicines information 
services for the general public will be referred to as MISGP). Therefore, MISGP are 
available for patients and also the wider community, and their aim is typically to 
provide information and support for any medication. Their remit differs to that of 
PMHS, which specifically function to provide information and support regarding 
medication pertaining to a recent period of hospital care. Although this doctoral 
research focuses upon PMHS, MISGP were also included in this systematic review 
for two main reasons. First, in the UK there is currently a move towards optimising 
resources whereby healthcare services within regions aim for increased 
collaboration and coordination of services in order to improve efficiency (3, 4). 
Additionally, Study 1 found that the most cited reason for the lack of a PMHS in 48% 
of NHS Trusts in England is lack of resources. Study 1 concludes that further 
research is needed to explore the best way to support all patients who need help 
with their medicines following hospital discharge, which is cost-effective without 
diminishing quality. One option could be to adopt the model of MI provision for the 
general public (including patients) that is used in many countries outside of England 
(i.e., MISGP). Therefore, including the evidence pertaining to the effectiveness of 
both types of service would be useful for ascertaining whether the provision of MI 




all NHS Trusts. Second, since most MISGP are provided by countries outside of the 
UK, the inclusion of this literature would likely appeal to an international readership. 
 
The aim of this study was to systematically review the literature pertaining to 
the effectiveness of medicines information services for patients (i.e., PMHS) and for 
the public (i.e., MISGP). In order to achieve this, the following research question 
was to be addressed: What is the available evidence regarding the effectiveness of 
patient medicines helpline services and medicines information services for the 
general public?  
 
This systematic review focussed solely upon the ‘effectiveness’ aspect of the 
RE-AIM framework. Including all five dimensions of the RE-AIM framework within 
this systematic review was unnecessary, because the most recent findings 
pertaining to the adoption, reach, implementation, and maintenance of PMHS were 
reported in Study 1. Additionally, covering all aspects of RE-AIM within one 
systematic review was considered too broad, and with so much extant evidence 
pertaining to the effectiveness of MI services, this topic alone felt to be of sufficient 
scope.  
 
To accord with the mixed methods approach of this doctoral research, any 
type of study design was included in this systematic review (e.g., qualitative, 
quantitative, or mixed), as long as the study met our eligibility criteria. 
 
This study was published in the International Journal of Pharmacy Practice 
in 2019. Therefore, the published article is presented. Following the article is a brief 
summary of the study’s findings, and a description of how the study fits within the 
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Objectives Hospital-based patient medicines helpline services (PMHS) and
medicines information services for the general public (MISGP) are available
in many countries to support people with their medicines. Our aim was to
examine the available evidence regarding the effectiveness of PMHS and
MISGP.
Methods Searches were conducted using Medline, EMBASE, CINAHL, Scopus
and Web of Science, on 11 August 2018. Forward and backward citation
searches were conducted, grey literature was searched, and study quality/risk of
bias was assessed. Findings were synthesised in a narrative synthesis. Where
appropriate, weighted means were calculated.
Key findings Thirty-two studies were identified for inclusion (17 published
articles, 15 conference abstracts). Eighteen studies were conducted within the
United Kingdom. Mean quality assessment was moderate (51%), and risk of
bias was high (63%). PMHS and MISGP are both typically perceived as positive
(e.g. 94% and 91% of participants were satisfied with using a PMHS and
MISGP, respectively). For PMHS, the advice received is reported to be usually
followed (94%, and 66% for MISGP). For both services, users report several
positive outcomes (e.g. problems resolved/avoided, feeling reassured and
improved health). PMHS may also be effective for correcting medicines-related
errors (up to 39% of calls may concern such errors) and for potentially avoid-
ing medicines-related harm (48% of enquiries concerned situations that were
judged to have the potential to harm patients).
Conclusions Findings suggest that both PMHS and MISGP may be beneficial
sources of medicines-related support. However, the moderate quality and high
risk of bias of studies highlight that more high-quality research is needed.
Introduction
Prescription and over-the-counter medications are both
fundamental and commonplace components of healthcare
worldwide. For example, approximately half of people in
both the United Kingdom and the United States of America
take at least one prescribed medication on a regular
basis.[1,2] Additionally, the use of medications is increasing.
In the UK, there was a 65% increase in the annual number
of prescriptions dispensed between 1999 and 2009, from
approximately 653 million to 1074 million.[3,4]
A growing number of studies suggest that patients
have a need for information and support regarding their
medicines. Approximately 40% of patients who have
been discharged from hospital may subsequently experi-
ence medicines-related problems, including medicines-re-
lated errors.[5–13] Findings indicate that patients often
lack knowledge about their medications following hospi-
tal discharge[14–18] and that many patients report not
receiving important medicines-related information.[19–21]
World Health Organisation policy states that offering
information on medicines via Medicines Information
Centres, and providing public education about medici-
nes, are two of 12 essential interventions to promote the
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rational use of medicines.[22] Therefore, medicines infor-
mation (MI) services have been established in many
countries to support patients and the general public with
their medicines.
Patient medicines helpline services
In the UK, patient medicines helpline services (PMHS)
are available for patients who have received care within
some secondary healthcare settings.[23] The primary func-
tion of a PMHS is to enable discharged patients to com-
municate with a pharmacy professional from the
healthcare setting where they recently received care.
PMHS are therefore means of providing medicines-related
support following hospital discharge. The first PMHS was
established in the UK in 1992,[24] and a survey conducted
in 2017 found that 52% of NHS Trusts1 in England pro-
vide a PMHS.[23]
Although PMHS were initially set up to improve
patients’ knowledge and use of their medicines, recent
guidelines for their implementation have suggested other
benefits, for both service users and healthcare organisa-
tions.[25] Additional benefits include reducing harm to
patients, highlighting and correcting medicine-related
errors, reducing unnecessary use of other healthcare ser-
vices, and improving the patient experience of healthcare
services. While useful, the list of proposed benefits is not
currently evidence-based, which is likely to limit their
impact.
Medicines information services for the
general public
In many countries, MI services are provided for the
general public, rather than primarily for patients of a
specific hospital (from here, MI services for the general
public will be referred to as MISGP). Therefore, MISGP
are available for patients and also the wider commu-
nity, and their aim is typically to provide information
and support for any medication. Their remit therefore
differs to that of PMHS, which specifically function to
provide information and support regarding medication
pertaining to a recent period of hospital care. MISGP
are often provided from Drug Information (DI) Centres
or Drug and Poison Information Centres that are often
regional or national in scope rather than local to speci-
fic hospitals.[26–32] Additionally, the general public in
some non-UK countries such as the United States may
also have the option of acquiring MI from services that
provide alternative communication methods to tele-
phone helplines, such as online ‘Ask-the-Pharmacist’
services.[33–35]
Aim
To date, a review of the literature has not been conducted
which brings together the available evidence as to the
effectiveness of either PMHS or MISGP, nor the quality
of the evidence. The aim of this systematic review was to
answer the following research question: What is the avail-
able evidence regarding the effectiveness of PMHS and
MISGP?
Methods
The Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA)[36] was used in the planning,
conducting and reporting of this systematic review. The
PRISMA statement protocol counterpart (PRISMA-P)[37]
was used to develop the protocol for this review. The proto-
col was registered with the International Prospective Regis-
ter of Systematic Reviews (PROSPERO) on 10 October
2017 (registration number CRD42017075165).[38]
Eligibility criteria
Studies were included in this systematic review if they
used any design in order to examine any outcomes for
service users, service providers, and/or healthcare organi-
sations, pertaining to the effectiveness of PMHS and/or
MISGP. Service users’ perceptions of the value of MI ser-
vices were included as a type of effectiveness, since UK
policies emphasise the importance of the patient experi-
ence, that the NHS is committed to patient involvement
in healthcare, and that services should be shaped around
patients’ needs.[39–41]
For the purpose of this systematic review, PMHS and
MISGP were considered to have the following characteris-
tics:
(1) A service involving any type of distance communica-
tion between the service user and service provider,
instigated by the service user.
(2) A service primarily providing MI, and not general
clinical information and advice. The service could
cater for enquiries about prescribed medicines and/or
over-the-counter medicines. However, services that
function to predominantly answer enquiries about the
following were excluded: complementary and alterna-
tive medicines, illicit drugs, and poisonings. Addition-
ally, telepharmacy and e-pharmacy services typically
provide a general pharmacy service rather than an MI
service, albeit remotely.[42] Therefore, we excluded
studies that examined telepharmacy services and/or e-
pharmacy services. Services that provide MI for both
healthcare professionals and patients/public were also
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considered. However, studies were only included if
relevant findings for patients/public were separately
reported to the findings for healthcare professionals.
(3) A service that operated from any setting, within any
country.
(4) A service available over a sustained period of time.
Therefore, we excluded studies that examined services
that were available for a limited time only (e.g. a
medicine phone-in day).
(5) For PMHS: a service for patients and/or carers of
patients who received care from the healthcare organ-
isation that provides the helpline. For MISGP: a ser-
vice for the general public of a region or nation.
We included published studies (including published
theses), unpublished studies, abstracts and conference
proceedings that were written in English. Abstracts and
conference proceedings were only included if there was
sufficient reporting of method and results to meet our
study objectives. We included articles written in non-Eng-
lish languages where the abstract was reported in the
English language, if the abstract alone provided informa-
tion to support our research objectives. We excluded
studies if the data were presented in a subsequently pub-
lished format (e.g. we excluded a study in a conference
proceeding if it was subsequently published as a full-text
article). No restriction was made regarding year of publi-
cation.
Search strategy
Searches were conducted using Medline, EMBASE,
CINAHL, Scopus and Web of Science (Science Citation
Index Expanded, Social Science Citation Index, Confer-
ence Proceedings Citation Index – Science, Conference
Proceedings Citation Index – Social Science & Humani-
ties, Emerging Sources Citation Index). Where possible,
searches were conducted using both free-text and sub-
ject headings. Search terms and the search strategy were
determined for EMBASE and subsequently adapted to
the syntax and subject headings of the other databases
(see Appendix S1 for the EMBASE search strategy).
Searches were conducted on 1 August 2017 and
updated on 11 August 2018. Forward and backward
citation searches were conducted for all included stud-
ies. Forward citation searches were conducted on 11
August 2018, using Scopus, Web of Science and Google
Scholar.
The following grey literature sources were searched:
grey literature databases (OpenGrey, and ProQuest data-
base for dissertations and theses), Google and Google
Scholar, conference proceedings, and consultation with
experts (see Appendix S2 for further details).
Screening and selection of studies
Literature search results for all databases were exported to
Covidence,[43] duplicates were removed, and studies were
screened and selected. Two researchers independently
screened all titles and abstracts for relevance, and dis-
agreements were resolved by discussion. Articles that met
the inclusion criteria, or where there was any uncertainty,
were obtained in complete form. Full-text reports were
then independently examined against the inclusion criteria
by one researcher, who examined them all, and two post-
graduate researchers from the University of Bath, who
each examined 50%. Any remaining disagreements were
resolved by discussion between two researchers.
Data extraction
Data extraction was conducted by one researcher using a
data extraction form, with 20% verified by another
researcher (see Appendix S3 for the data extraction form).
No discrepancies were found. Details from all data extrac-
tion forms were subsequently entered into an Excel
spreadsheet in preparation for analysis. Raw data were
not analysed for this systematic review. However, where
there was the potential to obtain data in a more relevant
format, authors of studies were contacted.
Quality assessment of included studies
The AXIS tool[44] was chosen to assess both risk of bias
and quality, for the purpose of information and synthesis,
and not to exclude studies from this systematic review.
The AXIS tool comprises 20 items, most of which were
relevant for the descriptive cross-sectional studies likely to
comprise the majority of studies in this systematic review.
Different study designs have the potential for different
biases, and the three main potential biases in cross-sec-
tional and descriptive studies pertain to the proper selec-
tion of the sample (selection bias), the soundness of
outcome measurement (measurement bias), and the selec-
tive reporting of findings (reporting bias).[45–48] The AXIS
tool comprises subscales for separately measuring risk of
bias, quality of reporting, and quality of study design.
The risk of bias items allow for the measurement of selec-
tion bias, measurement bias, and reporting bias.
Each included study, for which there was a full report
of the study that was written in English, was indepen-
dently appraised for quality by two researchers. Only full
reports were appraised, since they contained enough
information to adequately assess the risk of bias and the
quality of reporting. Disagreements were resolved through
discussion between two researchers.
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Narrative synthesis
Findings were synthesised in a narrative synthesis around
the study objectives. The narrative synthesis was under-
taken based upon the guidelines of Popay et al.[49] Due to
heterogeneity in the services evaluated and the research
methodologies employed, meta-analysis was not consid-
ered appropriate. However, where relevant, weighted aver-
ages were calculated across studies to account for the
potential impact of varying sample sizes.
Results
Study selection
A total of 32 studies were identified for inclusion in this
review. Figure 1 shows a flow diagram of the study selec-
tion process.
Study characteristics
All of the included studies are summarised in Table 1. Of
the 32 included studies, 17 studies contained data that
examined a MISGP (53%) and 15 studies contained data
that examined a PMHS (47%). Seventeen were published
studies in peer-reviewed journals (53%), and 15 were
conference abstracts (47%).
Of the 32 studies, 18 were evaluating services in the
UK (56%), six were evaluating services in North America
(19%), five were evaluating services in other countries
within Europe (16%), and three were evaluating services
in other areas of the world (9%).
Four study designs have been used to examine the
effectiveness of PMHS and MISGP: cross-sectional surveys
of service users (27 studies; 84%), retrospective reviews of
enquiries (seven studies; 22%), retrospective reviews of
answers using expert panels (four studies; 13%) and
cross-sectional surveys of service providers (one study;
3%). Six studies had more than one design (19%).
Quality assessment and risk of bias within
studies
Sixteen studies met our criteria for quality and risk of
bias assessment (i.e. a full report, written in English).
Fleiss Kappa was conducted, showing that there was sub-
stantial agreement between raters[50], K = 0.63 (95% CI,
0.53 to 0.73), P = 0.000.
The mean percentage for overall quality for the 16
assessed studies was 51% (range = 25–95%). For the Risk
Figure 1 Flow diagram of the study
selection process.
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of Bias subscale, the mean percentage for risk of bias
across the studies was 63% (range = 17–100%). For the
Quality of Reporting subscale, the mean percentage across
the studies was 59% (range = 14–100%). For the Quality
of Study Design subscale, the mean percentage across the
studies was 55% (range = 29–100%) (See Appendix S4
for the overall scores and percentages of quality and risk
of bias for all 16 studies).
Effectiveness of PMHS and MISGP
Service users’ perceptions of using a PMHS or
MISGP
Twenty-two studies examined services users’ perceptions
of using PMHS and MISGP, using self-report survey
methods. Twelve studies examined a MISGP and 10
examined a PMHS. Nineteen outcomes were reported,
and are presented in Table 2. More outcomes were
reported for PMHS than for MISGP (14 and 11, respec-
tively). Most outcomes were reported by a high percent-
age of enquirers (typically, 90% and above).
Two studies reported negative feedback from survey
respondents.[59,60] Bramley and Hollamby[59] surveyed 97
patients who used one of several PMHS in London
between 2011 and 2013. Negative feedback reported by
service users were as follows: being provided with insuffi-
cient information; feeling that they did not gain anything
from calling the helpline, since they were referred to their
GP; being told to contact another person, which pro-
longed the process; and being advised with unclear lan-
guage. However, the authors did not report actual
Table 1 Studies meeting the eligibility criteria for the systematic review examining medicines information services for patients and the general
public
First author, year Publication status Study design/s Service type Country Sample size
Alomi, 2015 [51] CA RRE MISGP Saudi Arabia NR
Ansani, 2006 [52] PS-PR SSU MISGP USA 6 respondents
Badiani, 2017 [53] PS-PR RRE; SSU PMHS England 637 enquiries; 100 respondents
Barker, 2016 [54] CA SSU PMHS England 9 respondents
Blom, 1991 [55] PS-PR SSU MISGP Netherlands 200 respondents
Bramley, 2012 [56] CA SSU PMHS England 73 respondents
Bramley, 2014 [57] PS-PR RRE PMHS England 312 enquiries
Bramley, 2014 [58] CA SSU PMHS England 17 respondents
Bramley, 2015 [59] CA SSU PMHS England 97 respondents
Bramley, 2018 [60] PS-PR RRA-EP; SSU PMHS England 67 respondents
Conner, 1980 [61] PS-PR SSU MISGP USA 73 respondents
Conner, 1982 [62] PS-PR SSU MISGP USA 793 respondents
Cuthbert, 2013 [63] CA RRE; RRA-EP; SSU PMHS Scotland 18 enquiries; 17 respondents
Goltz, 2009 [64] CA SSU MISGP Germany 151 respondents
Goltz, 2011 [65] CA SSU MISGP Germany 496 respondents
Heaton, 2018 [66] CA SSU PMHS England 20 respondents
Jones, 2014 [67] CA RRE; SSU PMHS England 234 enquiries; 68 respondents
Joseph, 2004 [68] PS-PR SSU PMHS England 58 respondents
Law, 2015 [69] CA RRE PMHS England 109 enquiries
Markovits, 2011 [70] CA SSU MISGP Israel 30 respondents
Marvin, 2011 [71] PS-PR RRE PMHS England 500 enquiries
Maywald, 2004 [72] PS-PR SSU MISGP Germany 920 respondents
McCartan, 2016 [73] CA SSU PMHS Northern Ireland 14 respondents
Melnyk, 2000 [74] PS-PR SSU MISGP Canada 99 respondents
Melnyk, 2000 [75] PS-PR RRA-EP; SSU MISGP Canada 68 enquiries; 64 respondents
Muhammad, 1998 [76] PS-PR SSU MISGP England 57 respondents
Olofinjana, 2009 [77] PS-PR SSU MISGP UK 123 respondents
Raccah, 2011 [78] CA SSU MISGP Israel 268 respondents
Rhodes, 2017 [79] CA RRA-EP; SSU MISGP France 200 enquiries; 149 respondents
Rutter, 2012 [80] PS-PR SSU MISGP UK 77 respondents
Smith, 1985 [81] PS-PR SSU MISGP USA 154 respondents
Williams, 2018 [23] PS-PR SSP PMHS England 156 respondents
All studies evaluated services that were accessed via telephone, except the service evaluated by Ansani et al., which was accessed online.
General abbreviations: MISGP, medicines information service for the general public; NR, not reported; PMHS, patient medicines helpline service.
’Publication status’ abbreviations: CA, conference abstract; PS-PR, published study in a peer-reviewed journal. ’Study design’ abbreviations: RRE,
retrospective review of enquiries; RRA-EP, retrospective review of answers by expert panel; SSP, cross-sectional survey of service providers; SSU,
cross-sectional survey of service users.
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6 Effectiveness of medicines information services
percentages of participants who were affected by each of
these issues.
Out of 67 service users surveyed by Bramley et al.,[60]
15% (n = 10) disclosed issues with the PMHS they used.
Three patients reported that the helpline advisor could
not answer their question, three patients were referred to
somebody who could not help them, two patients said
that they were not counselled on potential side effects,
one patient felt confused by the advice, and one patient
reported being given irrelevant advice.
Impact of using a PMHS or MISGP for service
users
Service users’ perceptions of the impact of using a
PMHS or MISGP
Twenty-one studies examined service users’ perceptions of
the positive impact of using a PMHS or MISGP, using
self-report survey methods. Eleven studies examined a
MISGP, and 10 examined a PMHS. Sixteen outcomes
were reported, and the findings are presented in Table 3.
More outcomes were reported for PMHS than for MISGP
(16 and eight, respectively).
Four studies reported whether there were negative out-
comes for the patient/enquirer’s health, well-being or
symptoms that could be directly attributed to using the
MI service. For PMHS, one study found that there were
no reported negative effects.[73] Another study found that,
out of 58 respondents, 6% reported some negative impact
on social well-being and physical well-being, and 4%
reported some negative impact on emotional well-be-
ing from using a PMHS.[68] Additionally, a quarter of
their sample felt more anxious after using a PMHS (exact
percentage not reported).[68] For MISGP, one study found
that, out of 920 respondents, 1% reported poorer
health,[72] and another study found that, out of 123
respondents, 5% reported that their condition was
worse.[77]
Use of expert panels to examine the impact of
PMHS and MISGP
Two studies included a design whereby an expert panel
reviewed enquiries and answers provided by a
PMHS.[60,63] In one of the studies, the expert panel com-
prised three independent experts in medicine, pharmacol-
ogy and patient safety methodology,[63] and in the other
study, the expert panel comprised 12 MI pharmacists.[60]
For the two studies, the panels agreed that there was a
potential positive impact on patient care or outcome in
74% and 89% of cases (n = 46/62 and n = 16/18, respec-
tively) and that there was a potential positive impact on
medication safety in 71% and 78% of cases (n = 44/62
and n = 14/18, respectively).
Two studies included a design whereby an expert
panel reviewed enquiries and answers provided by a
MISGP.[75,79] Melnyk et al.[75] used an expert panel (two
clinical pharmacists and two physicians experienced in
general medicine) to classify the potential impact on
patient outcome of responses to 68 enquiries to a
MISGP in Canada. None of the responses were consid-
ered to result in a negative outcome. There were 25
potential positive patient outcomes (37%). Of the
queries that potentially resulted in a positive patient out-
come, medication administration may have been opti-
mised in 44% of cases, there may have been a
reduction/elimination of symptoms in 44% of cases, and
there may have been a prevention of disease/symptoms
in 12% of cases.
Rhodes et al.[79] used an expert panel (membership not
reported) to evaluate the perceived impact of 200 enqui-
ries to a MISGP in France. They found that 81% of
responses to enquiries were evaluated as potentially hav-
ing a significant, very significant or vital impact (n = 162/
200). The remaining 19% were evaluated as having no
significant impact (n = 38/200).
Preventing harm from medicines
One study examined the potential for harm pertaining to
the enquiries received by a PMHS.[71] This was achieved
by coding 500 calls as to whether or not they pertained to
harm (harm was defined as temporary or permanent
impairment of the physical, emotional or psychological
function or structure of the body and/or pain resulting
therefrom, requiring intervention). Findings identified
that 48% of enquiries (n = 241) were regarding situa-
tions judged to have the potential for harm from the
medicine/s in question. Of these, 1.7% were then cate-
gorised as Harm Index Category F (requiring intervention
and referral), 19.9% were categorised as Harm Index Cat-
egory E (temporary harm not requiring follow-up), and
78.4% were categorised as Harm Index Categories B–D
(an error occurred, but did not cause harm). This sug-
gests that PMHS have the potential to prevent medicines-
related harm to patients. However, a limitation of this
study is that only one researcher (expertise not reported)
coded the enquiries.
Correcting medicines-related errors
Six studies reported data from retrospective reviews of
enquiries to PMHS, to establish the percentage that were
regarding medication errors.[53,57,63,67,69,71] Combined, the
studies found that between 8% and 39% of calls to PMHS
International Journal of Pharmacy Practice 2019, , pp. – © 2019 Royal Pharmaceutical Society
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8 Effectiveness of medicines information services
concerned errors (mean = 26%; weighted mean = 28%).
This suggests that correcting errors is an important func-
tion of PMHS. However, it is unknown whether different
definitions of an error were used across the studies, which
may have influenced the results. Additionally, one study
reported that only one researcher coded the enquiries,[71]
and the remaining five studies did not report the number
of coders used.
Reducing the burden upon other healthcare
services
Six studies reported the percentages of service users
who would use alternative healthcare professionals/ser-
vices had the MI service not been available; two exam-
ining PMHS[67,73] and four examining MISGP.[55,76,77,81]
The findings are presented in Table 4. Additionally, out
of 920 respondents, Maywald et al.[72] found that 18%
of callers to a MISGP in Germany (n = 168) believed
that the advice they received prevented a visit to their
physician.
Economic impact
Two studies explored the economic impact of MISGP.
Both studies were available as conference abstracts only,
therefore their descriptions were limited.
Alomi et al.[51] sought to establish the cost-efficiency of
a national MISGP in Saudi Arabia. They analysed all
calls received to the service during 2014 and predicted the
cost for each situation pertaining to the enquiries, had
the service not been available. They estimated that the
cost avoidance of answering public enquiries for one year
was $80 806. However, they did not provide details as to
how this was assessed.
Rhodes et al.[79] conducted an analysis of 200 calls
received in 2016 to a national MISGP in France. Using an
expert panel, they concluded that 25% of calls to the ser-
vice had an economic impact, although they do not
report what impact, nor the monetary value of the
impact.
Service providers’ opinions as to the effectiveness
of their service
Williams et al.[23] surveyed pharmacy professionals (MI
Pharmacists and Chief Pharmacists) in 2017 for their per-
ceptions regarding the major benefits of their PMHS. The
top 10 perceived benefits were as follows: avoiding harm
to patients (88%; n = 137/156), improving patient medi-
cation adherence (85%; n = 133/156), providing assur-
ance to patients that they can access professional help




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































International Journal of Pharmacy Practice 2019, , pp. – © 2019 Royal Pharmaceutical Society
Matt Williams et al. 9
experience (80%; n = 125/156), supporting patient dis-
charge (76%; n = 119/156), optimising medicines (75%;
n = 117/156), identifying errors (75%; n = 117/156),
reducing medicines-related readmissions (65%; n = 101/
156), learning from adverse patient experiences (55%;
n = 86/156) and reducing visits to other healthcare ser-
vices (51%; n = 80/156). However, a limitation of this
study as a measure of effectiveness is that it relied upon
the perceptions of service providers rather than a direct
measure. Results also may be biased if participants were
apprehensive about reporting any negative or poor aspects
of their service.
DISCUSSION
This systematic review examined the available evidence
regarding the effectiveness of MI services for patients and
the general public. The evidence suggests that both PMHS
and MISGP may help to increase service users’ knowl-
edge, understanding and use of their medicines, and that
advice is typically reported as being followed. Both PMHS
and MISGP are typically perceived as positive by service
users (e.g. satisfaction ratings are typically very high), and
service users may report several positive outcomes attrib-
uted to using them, such as problems being resolved or
avoided, and experiencing improvements to their health.
Studies also suggest that both PMHS and MISGP may
have an impact upon other healthcare services, such as
reducing the burden upon primary care (i.e. if the help-
line did not exist, respondents report that they would
likely contact their GP instead; weighted mean for
PMHS = 41%; weighted mean for MISGP = 38%). This
is topical, given that the average waiting time from book-
ing a standard appointment to see a GP in England in
2016 and 2017 was estimated to be approximately
2 weeks.[82] This suggests that, by increasing patients’ and
carers’ awareness of MI services that are available to them,
patients can receive support much sooner than if they
book an appointment to see their GP, and GP time will
be less taken up with answering MI queries that may be
more appropriately dealt with via MI pharmacists.
Although a larger number of studies have been con-
ducted to examine a MISGP compared with a PMHS,
more outcomes have been reported for PMHS than for
MISGP. Of those outcomes reported for both service
types, some outcomes are superior for PMHS whereas
other outcomes are superior for MISGP. However, it is
not legitimate to draw comparisons between the effective-
ness of the two service types based upon the available evi-
dence in this review, since no evidence was found that
compared the two service types within the same study.
Additionally, a comparison between the two service types
may be inappropriate, since their functions are not exactly
the same. A recent study by Badiani et al.[53] found that,
out of 200 enquiries to their PMHS, 75% required access
to hospital-based resources (e.g. patients’ electronic medi-
cal records, and contacting a healthcare professional
involved in the patient’s care). Badiani et al. conclude
that their findings support the value of hospitals provid-
ing a PMHS for their own patients, rather than having a
smaller number of centralised MI services for all individu-
als within a region. It may be that MISGP are suitable for
more general enquiries that do not require access to a
patients’ record (e.g. enquiries pertaining to over-the-
counter medicines), whereas PMHS may be more suitable
for more complex enquiries pertaining to medicines
specifically prescribed from the hospital where the
enquirer recently received care. Future research could aim
to establish this by examining the types of enquiries made
to the two different services. Due to their different func-
tions, it may be that providing patients and the general
public with both PMHS and MISGP is useful for support-
ing them regarding all types of medicines-related queries.
A potential strength of the available evidence is that
several different study designs have been used to examine
the effectiveness of MI services, including retrospective
reviews of enquiries, use of expert panels, and cross-sec-
tional surveys with service users and service providers.
However, the use of a variety of study designs can only
be considered a strength if the studies themselves are
methodologically robust and of a high quality. We found
that the overall quality of the evidence was moderate (on
average, 51%), and there was a high risk of bias (on aver-
age, 63%). Most of the included studies were service eval-
uations whereby study authors had evaluated their own
service. Additionally, evidence was primarily based upon
self-report methods, and such findings may be subject to
bias since service users’ perceptions of impact may not be
the same as actual impact. A small number of studies
have also been conducted using expert panels, and these
also report PMHS and MISGP to have a positive impact
on patient outcomes. However, expert panels require
expertise in judging both the nature of the enquiry and
the appropriateness of the response in the context in
which it is made, and such details were not always explic-
itly reported in the included studies. This review high-
lights the need for more high-quality research to
adequately evaluate the impact of these services.
Recommendations
Practice
The evidence from this review shows that PMHS and
MISGP may have a number of benefits for service users
and healthcare organisations. Healthcare organisations
© 2019 Royal Pharmaceutical Society International Journal of Pharmacy Practice 2019, , pp. –
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that currently do not provide an MI service to patients
and/or the public should consider whether the evidence is
sufficient to merit developing their own.
We encourage MI service providers to evaluate the
types of enquiries they receive by using standardised cate-
gories and coding instructions/training (e.g. those that
were developed by the UK Medicines Information net-
work; UKMi). This will enable the types of enquiries to
be more appropriately compared across sites and regions
within a country and across countries. Relatedly, the wide
variety in error rates found across studies in this review
(i.e. 8–39%) may reflect the use of different definitions as
to what constitutes a medicines-related error, since the
definition of an error has been found to have an effect
upon rates.[83,84] We therefore also recommend that sites
use a standardised definition of ‘medicines-related error’,
including a standardised categorisation/coding scheme for
collecting and analysing enquiry data.
Future research
Further research is needed to examine the effectiveness of
both PMHS and MISGP (both in the UK and interna-
tionally), and we encourage researchers to use the findings
from this review to design and conduct high-quality stud-
ies that fill gaps in the evidence base for both types of ser-
vice.
In the UK, the UKMi provide an example survey to
collect feedback regarding service users’ experiences of
using PMHS.[25] This tool was used in several of the stud-
ies included in this review. However, the psychometric
properties of the tool have not been evaluated, and its
reliance upon checkboxes may produce misleading results.
It would therefore be beneficial for a psychometrically
robust survey tool to be developed in order to more ade-
quately examine service users’ perspectives regarding the
effectiveness of PMHS and MISGP.
The evidence in this review is compiled predominantly
from studies conducted by sites that have examined their
own service, which may not be generalizable and are at a
high risk of bias. For both types of services, independently
conducted, larger and higher-quality multi-centre studies
are needed to examine their effectiveness. Relatedly, the
average response rate for cross-sectional surveys com-
pleted by service users in this review was 55%, and
reported response rates were often calculated based upon
the number of responses received out of the total number
of callers who were asked and who agreed to participate.
Therefore, it is questionable as to whether the positive
findings regarding the effectiveness of PMHS and MISGP
are generalizable if, for example, those who had a negative
experience chose not to respond or were not asked to
participate in the first place. Future research could seek to
improve the generalizability of survey studies by inviting
all callers during the recruitment phase of the study.
Examples of ways to improve response rates include offer-
ing an incentive, providing respondents with different
modes of completing the survey (i.e. postal and online)
and by resending the survey to non-responders.[85]
Only six of the 32 studies that examined the effective-
ness of PMHS and MISGP provided data regarding per-
ceived negative opinions/outcomes of the service. One
study found that a quarter of service users felt more anx-
ious after using a PMHS, although the study authors did
not explore reasons for these findings.[68] Therefore, fur-
ther research could seek to examine both positive and
negative aspects of service users’ experiences. For example,
qualitative interviews with service users could be benefi-
cial for exploring in greater depth the experiences of
patients and the general public regarding their use of a
PMHS or a MISGP. This could help to understand why
some callers report feeling more anxious after using a
PMHS, and potentially detect other adverse effects that
may not be captured in surveys. Qualitative methods
would also be useful for establishing what patients and
the general public want from an MI service, and whether
there are specific ways that PMHS and MISGP could be
improved to better suit their needs.
Future research could also examine whether PMHS and
MISGP have the potential to reduce hospital readmission
rates, and the extent that the reduced burden upon other
healthcare services (e.g. emergency departments and pri-
mary care services) translates into cost savings. Two stud-
ies sought to examine the cost-efficiency of MISGP.
However, the available evidence was limited, since the
studies were conference abstracts. Such findings could
help support sustainable funding models, thus improving
the adoption and maintenance of MI services for patients
and the general public.[86]
Strengths and limitations
This is the first systematic review that has examined the
effectiveness of MI services for patients and the general
public. We have identified, synthesised and appraised a
large body of evidence regarding MI services for both
patients and the general public from countries worldwide.
This has resulted in our development of recommenda-
tions to improve current practice in the operation of MI
services, and for areas for future research.
One limitation of this systematic review is that the tool
selected to assess the quality and risk of bias of studies
was new, and consequently, its psychometric properties
had not been evaluated.[44] This may have affected the
inter-rater agreement that was conducted for this review.
However, we found that our inter-rater agreement was
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satisfactory.[87] Additionally, the issue of lack of psycho-
metric evaluation was common to all of the tools we con-
sidered for use in this study to assess quality and risk of
bias. Systematic reviews of tools for assessing quality and
risk of bias have concluded that there is no single obvious
candidate tool for assessing the risk of bias or quality in
cross-sectional studies.[88–90]
Relatedly, only 16 of the 32 studies in this review met
our eligibility criteria for the assessment of quality and
risk of bias, since most studies were from conference
abstracts. Of the 16 studies, on average, their quality was
found to be moderate (51%; range = 25–95%) and their
risk of bias was found to be high (63%; range = 17–
100%). Therefore, the findings may be limited due to the
lack of high-quality studies currently available.
Another limitation of this review is that we only
included articles written in non-English languages where
the abstract was reported in the English language, if the
abstract alone provided information to support our
research objectives. Therefore, it may be that some rele-
vant articles were excluded from this review. However,
the maximum number of articles that this could have
applied to was six (out of 8676). Additionally, the search
for studies for this review was conducted in August 2018.
It is possible that other studies may have subsequently
been published which could affect the overall findings.
Finally, this systematic review combined the results for
MISGP across countries (e.g. USA, Canada, Germany,
France, Netherlands, Israel, Saudi Arabia). It is possible
that differences may exist regarding the provision of
MISGP by each of these countries, which may have
affected the pooled findings in our review. However, the
aim of our review was to provide an overview of the
effectiveness of MISGP as a starting point for future
research to build upon.
Conclusions
This systematic review provides evidence to suggest that
PMHS and MISGP may be beneficial sources of support
for recently discharged hospital patients and the general
public, respectively. Overall, the quality of the
included studies was found to be moderate, and there
was a high risk of bias in the studies. Most studies were
service evaluations conducted by the providers of their
own service. Therefore, more high-quality research is
needed to build the evidence base regarding the effective-
ness of both types of services, ideally by researchers who
are independent of the services being studied. This will
enable healthcare commissioners and providers to be bet-
ter informed to make decisions regarding robust MI ser-
vice design and delivery.
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Note
1 The National Health Service (NHS) in England is
organised into NHS Trusts, which are organisations that
provide goods and services for the purposes of health care
(e.g. hospital and community services), and each Trust
primarily serves a geographical area within England.
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5.5 Data access statement 
 
As specified in the published article, no data are available, since no primary 
data were collected for this research. 
 
5.6 Gaps in the evidence-base 
 
In 2015, a small group of medicines information pharmacists compiled and 
published a list of proposed benefits of providing a PMHS (5). Table 5.5 presents 
these proposed benefits, whether the systematic review found any relevant 
evidence for each of the benefits, and if so, the type of data used to collect the 
evidence and the quality of the evidence.  
 
This table highlights that there are gaps in the evidence-base regarding 
PMHS. For example, all conducted studies have collected quantitative data. No 
studies have been conducted to evidence whether PMHS reduce hospital 
readmissions. Additionally, all of the evidence in the systematic review was 
assessed as being of moderate quality, with a high risk of bias (the AXIS tool 
measured selection bias, measurement bias, and non-response bias). Therefore, 
the studies that have been conducted could be replicated to a higher standard in 














































































































































































































































































































































































































































































































































































































































































































































































































































































































5.7 Chapter 5 summary 
 
 This chapter reported the findings of a systematic review examining the 
effectiveness of medicines information services for patients and the general public. 
Based upon the evidence found, both types of services appear to be valued by 
service users (satisfaction ratings are excellent, and most respondents would use 
the services again), and service users report several benefits (e.g., improved 
knowledge of medicines, improved adherence, feeling reassured, avoiding harm 
from medicines). However, most of the findings from this systematic review come 
from studies that collected data using service user surveys, with other data coming 
from studies examining the types of enquires received to the service. Therefore, 
most of the data pertaining to the effectiveness of PMHS have used quantitative 
methods to examine perceived benefits. No studies were found that explored 
service users’ and service providers’ views regarding the effectiveness of PMHS 
using qualitative methods. Therefore, this is a notable gap in the literature.  
 
Whilst conducting this systematic review, it became apparent that there were 
several additional studies that explored the characteristics of individuals who use 
PMHS, and the types of enquiries made to PMHS. This information could be useful 
for exploring the reach of PMHS, since the developers of the RE-AIM framework 
consider exploring the types of individuals who use an intervention as an aspect of 
Reach (6). The combined findings of these service evaluation studies may be more 
generalisable than the individual studies alone. Therefore, what is presented next is 
a systematic review examining the characteristics of individuals who use PMHS, 
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Chapter 6: A systematic review examining the 
characteristics of users of NHS patient 
medicines helpline services, and the types of 
enquiries they make 
 
6.1 Overview of Chapter 6 
 
As described in the previous chapter for the systematic review examining the 
effectiveness of PMHS, studies that have examined PMHS have typically been 
service evaluations of individual sites to describe the characteristics of enquirers 
and their enquiries, and to report the effectiveness of PMHS using enquirer 
satisfaction surveys (e.g., (1, 2)).  Until now, a review of the literature had not been 
conducted to bring together the available evidence regarding the characteristics of 
enquirers to PMHS, nor the enquiries they make. The findings of such a review 
would be more generalisable to PMHS throughout the UK than individual service 
evaluations. Study 1 found that NHS Trusts receive on average five calls per week 
to their PMHS, which suggests that these services could be used more. However, it 
is difficult to establish exactly how many patients are eligible to use this service, 
since Hospital Episode Statistics (HES) data do not exist as to the proportion of 
patients who experience changes to their medicines following hospital discharge (3). 
A study by Mackridge et al. followed up 99 patients two weeks after being 
discharged from one of six hospitals in England, and they found that 31 patients 
(31%) felt they needed support with their medicines (4). Had HES data existed as to 
the proportion of patients experiencing changes to their medicines following hospital 
discharge, it may be possible to use the findings by Mackridge et al. to estimate the 
proportion of patients on average per NHS Trust who require medicines-related 
support following hospital discharge.  
 
This systematic review could be useful for establishing whether PMHS are 
under-used by any specific types of patients, and for understanding patients’ needs, 
which could highlight areas for service improvement. The aim of this systematic 
review was to address the following research questions, in order to develop 
recommendations for improving PMHS, and potentially, hospital pharmacy services 




helpline services? What are the characteristics of enquiries made to patient 
medicines helpline services? 
 
This systematic review focussed upon aspects of the ‘reach’ dimension of the 
RE-AIM framework. The developers of RE-AIM define Reach as the absolute 
number, proportion, and representativeness of individuals who are willing to 
participate in a given initiative, intervention, or program, and reasons why or why not 
(5). In order to examine the representativeness of individuals who use PMHS, 
where possible, outcomes from the evidence included in this systematic review 
were compared with Hospital Episode Statistics (HES) admitted patient care and 
outpatient data for England. 
 
To accord with the mixed methods approach of this doctoral research, any 
type of study design was included in this systematic review (e.g., qualitative, 
quantitative, or mixed), as long as the study met our eligibility criteria. 
 
This study was published in the European Journal of Hospital Pharmacy in 
2019. However, the journal has requested that the submitted manuscript is 
presented, rather than the published article. Following the submitted manuscript is a 
brief summary of the study’s findings, and a description of how the study fits within 
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A systematic review examining the characteristics of users of NHS patient 




Background and objective: Patient medicines helpline services (PMHS) are 
available from some National Health Service Trusts in the United Kingdom to 
support patients following discharge. The aim of this systematic review was to 
examine the available evidence regarding the characteristics of enquirers and 
enquiries to PMHS, in order to develop recommendations for service improvement. 
 
Methods: Searches were conducted using Medline, EMBASE, CINAHL, Scopus, 
and Web of Science, on 4th June 2019. Forward and backward citation searches 
were conducted, and grey literature was searched. Studies were included if they 
reported any characteristics of enquirers who use PMHS, and/or enquiries received. 
Study quality was assessed using the AXIS tool. A narrative synthesis was 
conducted, and where appropriate, weighted means (WM) were calculated. Where 
possible, outcomes were compared to Hospital Episode Statistics (HES) data for 
England, to establish whether the profile of helpline users may differ to that of 
hospital patients.  
 
Results: Nineteen studies were included (~ 4423 enquiries). Risk of bias from 
assessed studies was 71%. Enquirers were predominantly female (WM = 53%; 
HES mean = 57%), elderly (WM = 69 years; HES mean = 53 years), and enquired 
regarding themselves (WM = 72%). Out of inpatient and outpatient enquirers, 50% 
were inpatients and 50% were outpatients (WM). Six of fourteen studies reported 
adverse effects as the main enquiry reason. Two of four studies reported 
antimicrobial drugs as the main enquiry drug class. From two studies, the main 
clinical origin of enquiries were general surgery and cardiology. Across six studies, 
27% (WM) of enquiries concerned medicines-related errors. 
 
Conclusions: Our findings show that PMHS are often used by elderly patients, 
which is important since this group may be particularly vulnerable to experiencing 
medicines-related issues following hospital discharge. Over a quarter of enquiries to 
PMHS may concern medicines-related errors, suggesting that addressing such 
errors is an important function of this service. However, our study findings may be 




a more detailed profile of helpline users (e.g., ethnicity, average number of 
medicines consumed), and we encourage helpline providers to use their enquiry 
data to conduct local projects to improve hospital services (e.g., reducing errors). 
 
Registration: PROSPERO CRD42018116276.  
 
Keywords: systematic review, patient medicines helplines, National Health Service, 








Approximately 40% of patients who have been discharged from hospital may 
experience medicines-related problems (6, 7). Additionally, patients often lack 
knowledge about their medications following hospital discharge (8, 9), and many 
patients report not receiving important medicines-related information (10, 11). 
Patients may also experience medicines-related errors following hospital discharge, 
such as dispensing errors and incorrect or missing information on discharge 
documents (12, 13). Hospital discharge may therefore be a confusing and/or risky 
period for patients who have recently experienced changes to their medicines.  
 
Consequently, in the UK, hospital-based patient medicines helpline services 
(PMHS) have become available from some NHS Trusts.  The first PMHS was 
established in the UK in 1992 (14), and a survey study conducted in 2017 found that 
52% of NHS Trusts provided a PMHS (15). The function of a PMHS is to enable 
discharged patients to seek medicines-related support from pharmacy professionals 
from the healthcare setting where they recently received care. This accords with 
World Health Organisation (WHO) policy, which states that offering information on 
medicines via Medicines Information (MI) centres, and providing public education 
about medicines, are two of twelve essential interventions to promote the rational 
use of medicines (16). 
 
Studies that have examined PMHS have typically been service evaluations 
of individual sites to describe the characteristics of enquirers and their enquiries, 
and to report the effectiveness of PMHS using enquirer satisfaction surveys (e.g., 
(1, 2)). A recent systematic review examined the evidence regarding the 
effectiveness of PMHS, concluding that they are typically perceived as positive, 
advice is usually followed, and users report several positive outcomes (e.g., 
problems resolved/avoided, and improved health) (17). However, to date, a review 
of the literature has not been conducted which brings together the available 
evidence regarding the characteristics of enquirers to PMHS, nor the enquiries they 
make. The findings of such a review would be more generalisable to PMHS 
throughout the UK than individual service evaluations. Such information could be 
useful for establishing whether PMHS are under-used by any types of patients, and 








The aim of this systematic review was to address the following research 
questions, in order to develop recommendations for improving PMHS, and 
potentially, hospital pharmacy services more widely: What are the characteristics of 




The Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
were used in the planning, conducting, and reporting of this review. The protocol 
was registered with the International Prospective Register of Systematic Reviews on 




Studies were included if they reported any characteristics of enquirers who 
use PMHS, and/or enquiries received. PMHS were defined as: (1) a service for 
patients and/or carers of patients who received care from the NHS Trust within the 
UK that provides the PMHS, and not for a specific subset of patients and/or their 
carers; (2) a service involving distance communication, via any means, between the 
service user and service provider, instigated by the service user; and (3) a service 
providing MI, and not general clinical information.  
 
We included published and unpublished studies, abstracts, and conference 
proceedings that were written in English. We excluded studies if the data were 
presented in a subsequently published format (e.g., a study in a conference 
proceeding if it was subsequently published as a full-text article). No restriction was 
made regarding year of publication. 
 
Studies were only included where the types of enquirers and/or enquiries 
were based upon either the total number of all enquiries received within a specified 
period (e.g., six months), or a randomly selected number of enquiries from all 
enquiries received within a specified period. Studies were excluded if they solely 
described a subset of all enquirers or enquiries (e.g., only female enquirers, or 
enquiries about adverse effects), since the focus was upon PMHS, and not upon 






Searches were conducted using Medline, EMBASE, CINAHL, Scopus, and 
Web of Science. Where possible, searches were conducted using both free-text and 
subject headings. The search strategy was determined for EMBASE, and 
subsequently adapted to the syntax and subject headings of the other databases 
(see Supplementary Information 1 for the EMBASE search strategy). Searches 
were conducted on 1st August 2017 and updated on 4th June 2019. Forward and 
backward citation searches were conducted for all included studies. Forward citation 
searches were conducted on 4th June 2019, using Scopus, Web of Science, and 
Google Scholar. 
 
The following grey literature sources were searched: grey literature 
databases, Google and Google Scholar, conferences proceedings, and consultation 
with experts (see Supplementary Information 2 for further details).  
 
Screening and selection of studies 
 
Database search results were exported to Covidence (19), duplicates were 
removed, and studies were screened and selected. Two researchers independently 
screened all titles and abstracts for relevance, and disagreements were resolved by 
discussion. Articles meeting the inclusion criteria, or where there was uncertainty, 
were obtained in complete form. Full text reports were independently examined 
against the inclusion criteria by two researchers, and disagreements were resolved 




Data extraction was conducted by one researcher using a data extraction 
form, with 20% verified by another researcher (see Supplementary Information 3 for 
the data extraction form). No discrepancies were found. Details from all data 
extraction forms were entered in to an excel spreadsheet, in preparation for 
analysis.  
 
Raw data were not analysed for this systematic review.  However, where 




were contacted (e.g., to ask if they would be willing to provide the mean age of 
enquirers from their retrospective review of enquiries). 
 
Quality assessment of included studies 
 
The AXIS tool (20) was chosen to assess risk of bias and quality within 
studies. This tool comprises 20 items for assessing cross-sectional studies, and is 
composed of three subscales. The subscales measure risk of bias (i.e., selection 
bias, measurement bias, non-response bias, and reporting bias; e.g., ‘Was the 
selection process likely to select subjects/participants that were representative of 
the target/reference population under investigation?’), quality of reporting (e.g., 
‘Were the methods (including statistical methods) sufficiently described to enable 
them to be repeated?’), and quality of study design (e.g., ‘Was the study design 
appropriate for the stated aim(s)?’). The assessment of risk of bias and quality were 
used for information, and not to exclude studies. Each included study, for which 
there was a full report, was independently appraised by two researchers. Only full 
reports were appraised, since they contained enough information to adequately 
assess risk of bias and quality of reporting compared to, for example, conference 
abstracts.  




Findings were synthesised in a narrative synthesis around the study 
objectives, following the guidelines by Popay et al. (21). Where possible, weighted 
averages were calculated across studies to account for varying sample sizes. 
Additionally, where possible, outcomes were compared to Hospital Episode 
Statistics (HES) admitted patient care and outpatient data for England, to examine 
the representativeness of PMHS enquirers. Since the years of data collection varied 
across studies, the average of HES data for the past five years were used (2013-14 














Nineteen studies were identified for inclusion in this review. Figure 1 shows 




Included studies are presented in Table 1. Eight studies contained data 
regarding the characteristics of enquirers of PMHS. Eighteen studies contained data 
regarding the types of enquiries made to PMHS. All studies were retrospective 







Table 1. Studies meeting eligibility criteria for the systematic review examining characteristics of 
enquirers and enquiries to patient medicines helpline services. 















  Outcomes 
  Enquirers Enquiries 
Adam, 2004 (22) CA RRE England 2003 (1 week) 90 
 
X X 
Badiani, 2017 (2) PS-PR RRE England 2015 (9 months) 637 
  
X 
















Cooke, 2010 (25) CA RRE England 2009-2010 (NR) 56 
  
X 
Cuthbert, 2013 (26) CA RRE Scotland NR (6 weeks) 18 
 
X X 
Dhillon, 2001 (27) PS-PR RRE England NR (3 months) 109 
 
X X 
Dugdale, 2018 (28) CA RRE England 2016-2017 (24 
months) 
538   X 





Jones, 2014 (30) CA RRE England 2012-2014 (NR) 234 
  
X 
Law, 2015 (31) CA RRE England 2015 (4 months) 109 
  
X 





Marvin, 2011 (33) PS-PR RRE England 2008 (6 months) 500 
  
X 
Price, 2011 (34) CA RRE England 2010-2011 (NR) 51 
  
X 
Raynor, 1994 (14) PS-BR RRE England NR (NR) NR 
  
X 
Sims, 1996 (35) CA RRE England NR (NR) > 1000 b 
  
X 
Teli, 2001 (36) CA RRE England 1999 (NR) NR 
 
X X 
Williams, 1994 (37) PS-PR RRE England 1993 (NR) 170 
 
X X 
Note. Abbreviations: CA = conference abstract; LE = letter to the editor; NR = not reported; PS-BR = study 
published as a brief report; PS-PR = published study in a peer reviewed journal; RRE = retrospective review of 
enquiries. 
a Of the included studies, the data collection period ranged from one week to twelve months (mean = 
approximately 31 weeks; seven studies did not report the data collection period length).   










Quality assessment and risk of bias within studies 
 
Five studies met our criteria for quality and risk of bias assessment. The 
overall score and percentage of quality and risk of bias for these studies are 
presented in Table 2. Fleiss Kappa was conducted, showing that there was 




Table 2. Quality assessment and risk of bias in full reports of studies meeting eligibility criteria for the 
systematic review. 
First author, Year published Total a RoB b QoR QoSD 
Badiani, 2017 (2) 50% (10/20) 50% (3/6) 57% (4/7) 43% (3/7) 
Bramley, 2014 (1) 63% (12/19) 40% (2/5) 71% (5/7) 57% (4/7) 
Dhillon, 2001 (27) 29% (5/17) 100% (3/3) 14% (1/7) 57% (4/7) 
Marvin, 2011 (33) 65% (11/17) 67% (2/3) 71% (5/7) 71% (5/7) 
Williams, 1994 (37) 35% (6/17) 100% (3/3) 43% (3/7) 43% (3/7) 
     
Average (mean) percentage 48% 71% 51% 54% 
Note. Abbreviations: QoR = quality of reporting score (out of a maximum score of 7); QoSD = quality of 
study design score (out of a maximum score of 7); RoB = risk of bias score (out of a maximum score of 
6). 
a Quality assessment was measured using the AXIS tool, developed by Downes et al. (2016). Depending 
on the study design, not all RoB items were relevant (i.e., three RoB items pertain to non-response bias, 
and three of the studies did not recruit study participants since their aim was to only assess PMHS 
enquiries. Additionally, the study by Bramley (2014) recruited study participants with no non-responders, 
thus rendering one item obsolete). This accounts for the different maximum Total scores and RoB scores 
across studies. 
b The Risk of Bias items were reversed, so that the reported percentages reflect the amount of potential 
bias in each study. However, the AXIS total score was calculated without reversing the Risk of Bias items, 
to ensure that the reported total score percentages reflect the amount of positively coded items in the tool. 











Characteristics of enquirers 
 
Table 3 presents eight studies that reported data regarding the 
characteristics of enquirers. Enquirers are predominantly female, elderly, and 






Table 3. Characteristics of enquirers who use patient medicines helpline services 


















Adam, 2004 (22) 90 ― 62% ― ― ― ― 
Bramley, 2014 (1) 312 ― 50% 70% ― ― ― 
Burgess, 2009 
(24) 






61% 56% ― ― ― 
Dhillon, 2011 (27) 109 ― 63% 64% 15% ― ― 
Martin, 2014 (32) 262 69 
(SD = 
NK) 
50% 79% ― 51% d 49% d 
Teli, 2001 (36) NR ― ― ― ― 72% 18% 
Williams, 1994 (37) 170 ― ― ― 4% ― ― 
        
Average (mean) 
 




69 53% 72% 8% 50% e 50% e 
HES data, where 
available 
 
53 a 57% b ― ― 18% 82% 
Note. Abbreviations: HES = Hospital episode Statistics; NK = not known; NR = not reported. Part of 
the data for the studies by Cuthbert et al. and Martin et al. was obtained from the authors via 
personal communication.  
a Range of mean ages over five years of HES data = 52 years to 54 years. Only HES admitted 
patient care data were used, since mean age was not reported in HES outpatient datasets. 
b Range of percentages over five years of HES data = 57% to 58% 
c In the study by Burgess, 2009, two service users were members of the public. Therefore, in order 
to only use the data regarding inpatients and outpatients, we calculated the percentages of 
discharged inpatients and outpatients using only the total number of callers who were discharged 
inpatients or outpatients (n = 15).  
d In the study by Martin, 2014, 21% of service users were reported as being from ophthalmological 
surgery or clinics, and 22% were not reported. Therefore, in order to only use the data regarding 
inpatients and outpatients, we calculated the percentages of discharged inpatients and outpatients 
using only the total number of callers who were discharged inpatients or outpatients (n = 149).  
e The weighted averages for percentages of discharged inpatients and percentages of discharged 
outpatients are based upon two of three studies, since the sample size was not reported in the study 











Table 4 presents the findings from fifteen studies that reported reasons for 
contacting a PMHS. Adverse effects was the category reported as the primary 
reason for enquiries from six of the fifteen studies, with a weighted mean of 37% of 






Table 4. Reason for enquiries reported in studies examining patient medicines helpline services. 
Enquiry category 
Numbers and percentages of studies reporting the specified category 
as the primary reason for enquiries 
Total (N = 15) 
Range of reported 
percentages of enquiries 
(mean; WM) 
Sample size 
range (Total n) 
    
Adverse effects 
6 (14, 22, 25, 29, 
36, 37) 
21% - 46% (33%; 37%) 
56 - 209 (at least 
525a) 
Administration or dosage 
5 (23, 28, 31, 32, 
34) 
21% - 52% (37%; 34%) 49 - 538 (1058) 
Interactions 1 (33) 22% 500 
Appropriateness or safety of 
medicines 
1 (2) 50% 637 
Indications, efficacy or 
mechanisms of action 
1 (35) 34% At least 1000 b 
Insufficient information on 
hospital discharge letter 
1 (1) 24% 413 
        
Note. Abbreviations: WM = weighted mean (weighted by sample size). Enquiry categories are listed 
according to the number of studies within each category. There may be overlap between some enquiry 
categories, since study authors did not use exactly the same categories.  
a Two of the six studies did not report their sample size. 







Clinical origin of enquiry 
 
Two studies reported the clinical origin of enquiries to their PMHS. For Price 
et al., (34) the top three clinical origin of enquiries were Surgery (59%), General 
Medicine (13%), and Paediatrics (6%). For Bramley et al., (1) the top three clinical 
origin of enquiries were Cardiology (20%), General Medicine (8%), and Ear, Nose 




Four studies reported the percentage of enquiries by drug class. The largest 
drug class was reported to be antimicrobial drugs by two studies (19% and 21% of 
all enquiries) (27, 33) and cardiovascular drugs in a third study (27% of all 
enquiries) (37). The fourth study, which took place at a mental health Trust, reported 
atypical antipsychotics as the main drug class (38% of all enquiries) (29).  
 
Enquiries regarding medicines-related errors 
 
Table 5 presents six studies that reported the percentage of enquiries that 
were regarding medication errors (1, 2, 26, 30, 31, 33). Combined, the studies 
suggest that between 8% and 39% of enquiries concern errors (mean = 31%; 








Table 5. Studies examining the number of enquiries received by patient medicines 
helpline services that were regarding medicines-related errors. 
Author, Year published N 
Total percentage of 
enquiries regarding 
errors 
Primary error type 
Bramley, 2014 (1) 312 8% Missing medicines (38%) 
Badiani, 2017 (2) 637 39% Transfer of care errors (69%)  
Cuthbert, 2013 (26) 18 33% NR 
Jones, 2014 (30) NR 19% NR 
Law, 2015 (31) 109 20% NR 
Marvin, 2011 (33) 500 34% 
Wrong/insufficient information 
supplied with medicine (49%) 
Note. NR = not reported. There may be overlap between some error type categories, 







This systematic review synthesised the current evidence regarding the 
characteristics of enquirers to PMHS, and the types of enquiries they make. 
Included studies were all service evaluations where authors evaluated their own 
service, and we found the average risk of bias in study articles to be 71%, which we 
perceive to be high.  
 
Characteristics of enquirers 
 
Our findings suggest that users of PMHS are broadly representative of 
hospital patients regarding gender, but not age. The average age of helpline 
enquirers was 69 years, compared to an average age of 53 years for hospital 
patients. This could reflect that older people tend to seek health information from 
healthcare professionals directly, compared to younger people who may be more 
inclined to seek information online (39, 40).  
The age difference may also suggest that PMHS are particularly valued as a 




there is an association between age and polypharmacy (41). Research suggests 
that polypharmacy increases the risk of prescribing errors (42), adverse drug 
reactions (43), drug-drug interactions (41), suboptimal adherence (44), emergency 
department visits (45), unplanned hospital admissions (46), and readmissions (47). 
Polypharmacy also increases the likelihood that patients will lack knowledge or 
understanding of their medicines (48). Although no data were found as to the 
average number of prescribed medicines consumed at the time of contacting a 
PMHS, approximately 22% of enquiries to PMHS in the UK are regarding 
interactions, suggesting that a number of enquirers are consuming more than one 
medicine.  
 
Population projections produced by the Office for National Statistics 
suggests that there will be a significant increase in the population of older people in 
the next two decades (49). This may indicate an increased need for MI services in 
the future, in order to provide support to this growing population.  
 
Our findings, in the context of previous evidence, suggest that there are a 
number of individuals who may be denied access to some PMHS. We found that 
28% of users contacted the service on behalf of a patient, and that 50% of enquiries 
to PMHS may be from outpatients compared to discharged inpatients. A recently 
conducted survey of PMHS in England reported that 7% of PMHS (eight NHS 
Trusts) do not provide advice to carers, and that 5% of PMHS do not provide the 
service to outpatients (15). This suggests that a proportion of individuals in need of 
medicines-related support are not able to access it from these particular PMHS. 
This is important, since one study found that approximately 48% of 500 answered 
enquiries to a PMHS were considered to have the potential to prevent harm from 
medicines (33). This highlights the need to advertise this service, and make it 
available, to all patients who may benefit from using it.  
 
Our systematic review found no studies that reported the ethnicity nor 
educational level/socioeconomic status of enquirers, nor the average number of 
medicines consumed. Additionally, of the eight studies that reported data regarding 
the characteristics of enquirers, none of the data were collected within the past five 







Types of enquiries 
 
Our findings suggest that there is wide variation in the percentages of types 
of enquiries received to different PMHS, since six different categories were reported 
as being the primary reason for enquiries. This highlights the importance of 
conducting locally tailored improvement projects whereby PMHS data for an NHS 
Trust are used to produce recommendations to improve their own services.  
However, this variation may also be a consequence of sites coding their enquiries 
using unstandardised enquiry category options, and/or possible confusion regarding 
how to code certain enquiries (e.g., those that may fit more than one category).  
 
In six of fifteen studies that reported reasons for contacting a PMHS, the 
largest category of enquiries to PMHS concerned adverse effects. These findings 
are congruent with the results from the UK National Health Service (NHS) annual 
Adult Inpatient Survey found that, between 2013-2017, 42-44% of patients (n range 
= 38384-52554) did not recall receiving any information from staff about side effects 
(11). Consequently, by improving medicines-related counselling to patients at 
hospital discharge, particularly around side effects, patients may be less likely to 
need support following discharge (50). However, there is always likely to be a need 
for PMHS to support patients and carers following patients’ discharge from hospital. 
Evidence suggests that some patients, particularly the elderly, may forget or 
misunderstand aspects of discharge counselling pertaining to their medicines (8, 51, 
52). Additionally, it could be that even if patients are provided with information about 
potential side effects at the time of discharge, they may still require support later on, 
at the time when side effects develop.  
 
One proposed benefit of PMHS is that they act as a safety net to identify 
errors (15).  Our synthesis suggests that up to 39% of enquiries to PMHS are 
regarding medicines-related errors, with a weighted mean of 27%. Medication errors 
can have significant health and economic consequences, such as adverse drug 
reactions, reduced medication efficacy, increased use of healthcare services, and 
death (53). Learning from medicines-related errors in order to implement methods 
for their reduction is a current NHS and worldwide healthcare priority (53). Royal 
Pharmaceutical Society-endorsed national standards for operating a PMHS are 
available (54), one of which is having a mechanism in place to feed back to the 
Trust medication problems and ‘systems errors’ identified by patients/carers in order 




medicines-related errors, if the information from such enquiries is developed into 
recommendations and implemented in order to improve practice. However, it is 
currently unknown what percentage of Trusts currently adhere to this standard, and 




Further research is needed to establish patients’ MI needs and preferences, 
including those of younger patients. Our findings indicate that enquiries to PMHS 
are often from elderly patients, and cross-sectional studies suggest that younger 
people are more likely to seek health-related information online compared to older 
people (40). However, depending on the source, online information about medicines 
may not be as reliable as seeking the advice of a pharmacy professional with 
expertise in MI. Therefore, one way to improve the reach of PMHS may be to 
establish electronic means to access them, which may be more appealing to 
younger patients. However, it would be advantageous to first establish the 
medicines-related needs of younger patients, and how best to engage with them to 
increase their awareness and use of PMHS. 
 
We recommend that PMHS sites conduct service evaluations in order to 
provide a more detailed and standardised profile of enquirers (e.g., including 
ethnicity, educational level/socioeconomic status, and the average number of 
medicines consumed by patient enquirers). This would help to establish how 
enquirers compare to the local patient population, and to enable comparisons 
across sites. Such data could be useful to explore whether certain types of patients 
are less likely to use the service. This could result in projects to understand why, 
and whether more can be done to provide a service that is equitable and available 
for all hospital patients who require support with their medicines.  
We encourage providers of PMHS to evaluate the types of enquiries they receive 
(including whether they pertain to a medicine error) by using nationally standardised 
categories and coding instructions/training materials that are endorsed by the UK 
Medicines Information network (UKMi). This will enable the types of enquiries 
received to be more appropriately compared across sites and regions within the UK. 
 
We also encourage sites to use data on types of enquiries to PMHS to 
produce recommendations for improving local hospital services. For example, six 




studies reported that enquiries were predominantly about antimicrobial drugs. 
Therefore, potential projects could involve improving patient leaflets and counselling 
regarding adverse effects and antimicrobial drugs. Another example could be for 
sites to monitor the number of enquiries regarding medication errors to establish 
whether using helpline data to improve practice within the hospital results in a 
reduced number of calls about errors over time. It would also be useful if sites were 
more easily able to share learning from their local projects, for example, having the 
capability to share brief reports via the UKMi network. 
 
Strengths and limitations 
  
This is the first systematic review that has examined the types of enquirers 
and enquiries of PMHS. This has resulted in our development of recommendations 
to improve current practice in the operation and evaluation of PMHS, and potentially 
hospital pharmacy services more widely.  
 
 However, the findings of this review may be limited by the small number of 
studies available to establish averages for certain enquirer characteristics. For 
example, our findings regarding the average age of participants, the average 
percentage of repeat enquirers, and the weighted average percentage of inpatients 
versus outpatients, are all based upon two studies each. Therefore, these findings 
should be treated with caution, and also emphasise the need for additional, larger 
studies to examine the profile of enquirers to PMHS. 
Relatedly, the findings of this review may also be limited due to the potential lack of 
high-quality studies currently available. Only five of the nineteen studies in this 
review met our eligibility criteria for the assessment of quality and risk of bias, since 
most studies were from conference abstracts and their content was considered too 
limited to perform a thorough quality assessment upon. We considered the quality of 
these five studies to be moderate (on average, 48%; range = 29%-65%) and their 
risk of bias to be high (on average, 71%; range =40%-100%). Therefore, a limitation 
of this review is that our quality assessment and risk of bias average scores are only 
based upon 26% of the studies included in this review. However, since the 
remaining 74% of studies comprised conference abstracts, brief reports, and a letter 






Another limitation of this review concerns our comparison of PMHS findings 
to HES data, since the HES data used in this study is not specifically regarding 
patients that consume medicines. Also, the HES average age percentage (53%) 
was calculated from HES admitted patient care data only, since mean age was not 
reported in HES outpatient datasets. Therefore, the HES age percentage used in 
this study may not be fully representative of the types of patients who may use a 
PMHS. Additionally, we compared the findings of this review with HES data over the 
past five years. Therefore, the data collection years for the studies included in this 
review and for the HES data did not correspond, which will likely affect the 
comparison. However, the HES data used were relatively stable over the five years.  
 
 Finally, we did not contact all sites that provide a PMHS in the UK to 
establish whether any local unpublished work could be included in this review. 
Instead, we contacted authors of included studies within the past ten years to 
establish the availability of unpublished work from their sites. Therefore, it is 
possible that other studies may have been conducted with findings that are relevant 




 This systematic review synthesised evidence regarding the users of PMHS 
and the enquiries they make. The service seems particularly appealing for patients 
who are vulnerable to experiencing medicines-related issues following hospital 
discharge, since PMHS are often used by the elderly, and elderly patients are more 
likely to experience polypharmacy. Additionally, over a quarter of enquiries to PMHS 
may concern medicines-related errors, suggesting that addressing such errors is an 
important function of this service. However, our study findings may be limited by a 
high risk of bias within included studies. Further research could provide a more 
detailed profile of helpline users (e.g., ethnicity, average number of medicines 
consumed). We recommend standardising the way that PMHS data are categorised 
and reported so that data are more easily comparable and collated across sites for 
a more generalisable picture of PMHS use. We encourage PMHS providers to use 
routinely collected data to conduct local quality improvement projects (e.g., to 
reduce medicines-related errors, and improve patient MI leaflets/counselling), and to 
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6.4 Data access statement 
 
As specified in the published article, no data are available, since no primary 
data were collected for this research. 
 
6.5 Chapter 6 summary 
 
This chapter presents the findings of a systematic review that examined the 
available evidence regarding the characteristics of users of PMHS, and the types of 
enquiries they make. Therefore, this study fits within the wider context of the PhD by 
exploring the Reach aspect of the RE-AIM framework for establishing the impact of 
interventions.  
 
The findings show that PMHS are particularly used by elderly patients, which 
is important considering that this group may be particularly vulnerable to 
experiencing medicines-related issues following hospital discharge. However, as 
with the systematic review examining the effectiveness of PMHS, the quality of 
evidence was found to be moderate, and there was a high risk of bias (the AXIS tool 
measures selection bias, measurement bias, and reporting bias).  
 
This systematic review is limited by being reliant upon retrospective reviews 
of enquiries, using already collected and coded data. There were noticeable gaps 
pertaining to the demographics of enquirers (e.g., no studies had examined the 
ethnicity of enquirers, nor established their socioeconomic status). A study by 
Peconi et al. (55) examined 400,000 enquiries to the telephone advice service NHS 
Direct wales. They found that deprivation had no consistent effect on demand for 
the service. However, callers were typically contacting the service about themselves 
(58%), more females called the service than males (62% were female), and most 
callers were of white ethnicity (98%). Aside from ethnicity, for which no data were 
available, these findings accord with the findings from the systematic review 
presented in this chapter. Similarly, a study by Cook et al. examined 1,342,245 calls 
to NHS Direct in England (56). Findings showed that all mixed ethnic groups had a 
higher than expected uptake of NHS Direct, whereas Black and Asian ethnic groups 
had lower than expected uptake. The authors conclude that barriers to uptake in 
certain ethnic groups needs to be examined, in order to recommend ways to ensure 




the importance of examining the ethnicity of enquirers to telephone helpline 
services, such as PMHS.  
 
The findings also show that, across six studies, most enquiries to PMHS are 
regarding side effects. However, further research is needed to establish exactly 
what advice is provided by PMHS staff to enquirers, and whether the advice is 
actually able to help the enquirer. It could be that, if patients and carers contact the 
service because the patient is currently experiencing a side effect, then the 
pharmacist dealing with the enquiry may not be able to help other than recommend 
that the patient seek urgent medical help, depending on the severity of the situation. 
This could mean that some enquiries to PMHS may be inappropriate and better 
dealt with elsewhere. This is currently conjecture, since data are not available to 
ascertain this. Relatedly, the findings of this review show that a sizeable number of 
enquiries concern medicines-related errors (between 8% and 39%, across six 
studies). This suggest that, had the errors not occurred in the first place, the 
enquiries would not be necessary. Therefore, using enquiry data to try to improve 
hospital services (i.e., reducing errors) will likely reduce the number of enquiries 
received to PMHS over time. Further research is needed to establish whether this is 
the case, and if so, the extent to which enquiries can be reduced over time. As 
established in Study 1 of this thesis, NHS Trusts that provide a PMHS receive five 
enquiries per week on average (15). If the number of enquiries is able to be reduced 
over time through using the content of enquiries to devise healthcare quality 
improvement projects, providers of PMHS may then have the resources to promote 
their service more thoroughly in order to reach as many patients and carers who 
may need medicines information. As also established in Study 1, the promotion of 
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Chapter 7: Pharmacy professionals’ 
experiences and perceptions of providing 




7.1 Overview of Chapter 7 
 
Study one comprised an online survey examining PMHS using the RE-AIM 
evaluation framework (i.e., how many NHS Trusts in England provide a PMHS, how 
PMHS are operated, and what pharmacists think are their benefits). However, a 
limitation of survey studies is that surveys include questions and answer options 
that are important to the researcher, rather than allowing participants to provide 
information that is important to them. Therefore, a limitation of Study 1 is that it did 
not seek to provide pharmacy professionals with the opportunity to describe in detail 
their perceptions of PMHS. For example, it did not explore pharmacy professionals’ 
perceptions as to the benefits and possible limitations of PMHS, nor perceived ways 
that PMHS could be improved. Establishing this may help to increase the availability 
and reach of PMHS. To achieve this, qualitative methods would be more 
appropriate. Therefore, this study forms part of a sequential mixed methods 
approach along with Study 1, whereby the findings from Study 1 were explored 
ideographically using qualitative research methods. This is an example of what 
Creswell and Plano Clark call an emergent mixed methods design, whereby a 
complimentary research study was subsequently designed and conducted in order 
to elucidate previous findings (1). 
 
In line with healthcare quality improvement approaches, services are likely to 
be improved by seeking to understand the perceptions of service providers (2). As 
established in the systematic reviews presented in previous chapters, no qualitative 
studies had been conducted to examine pharmacy professionals’ perceptions of 
operating a PMHS. Therefore, the aim of this novel qualitative study was to address 
this gap in the literature by exploring pharmacy professionals’ experiences and 
perceptions of providing a PMHS, their benefits, and areas for improvement. In 
particular, this study addressed the following research question: What are pharmacy 




This study was published in BMC Health services Research in 2020. 
Therefore, the published article is presented. Following the article is a brief 
summary of the study’s findings, and a description of how the study fits within the 
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Abstract
Background: Patient medicines helpline services (PMHS) have been established at some National Health Service
(NHS) Trusts in England, with the aim of providing medicines-related support to patients after they have been
discharged. Addressing an important knowledge gap, this qualitative study sought to examine pharmacy
professionals’ experiences and perceptions of their PMHS, including perceived benefits of the services, and areas for
improvement.
Methods: Invitations to participate were sent to all NHS Trusts within England that were known to provide a PMHS
(n = 117). Semi-structured interviews were conducted via telephone with 34 pharmacy professionals who provide a
PMHS (female = 76%, male = 24%; predominantly from Acute NHS Trusts, 76%). Interviews were audio-recorded and
transcribed verbatim. The RE-AIM framework for evaluating interventions (RE-AIM: Reach, Effectiveness, Adoption,
Implementation, Maintenance) informed the development of the interview schedule and the analysis of the data
using framework analysis.
Results: Two themes were generated from the analysis: Resources, and Perceived benefits. Findings illustrate how
providing a PMHS with limited resources (e.g., no specific funding, understaffed) negatively impacts the
implementation, maintenance and reach of PMHS, and the ability to evidence their effectiveness. Despite operating
with limited resources, PMHS are considered to have many benefits for patients and healthcare organisations (e.g.,
providing a ‘safety net’ to patients during the transfer of care period, providing reassurance to patients, helping to
optimise patients’ medicines, resolving medicines-related errors, reducing the burden upon other services, and
providing the potential to improve hospital services based upon the content of enquiries). However, actually
establishing the effectiveness and cost-effectiveness of PMHS is challenging due to perceived logistical difficulties of
collecting data, and the difficulty measuring hard outcomes (e.g., prevention of readmissions).
(Continued on next page)
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Conclusions: PMHS are typically perceived to be under-resourced, although they are considered by pharmacy
professionals to have several benefits for service users and NHS Trusts. For those sites that provide a PMHS, we
recommend using enquiry data to improve hospital services, and to share ideas for implementing and maintaining
a PMHS within a resource-limited context. High-quality research is needed to evidence the effectiveness and cost-
effectiveness of PMHS, which may help to secure adequate resources for this service in the future.
Keywords: Patient medicines helplines, National Health Service, Medicines information, Drug information, Hospital
pharmacy, Hospital discharge, Medication errors, Qualitative, Framework analysis, RE-AIM
Background
Patients often experience changes to their medicines
regimen while they are in hospital, and healthcare policy
in the United Kingdom (UK) requires that patients’ med-
icines are managed optimally after discharge from sec-
ondary care [1, 2]. However, a growing body of evidence
highlights that a number of patients in the UK lack
knowledge of their medications following hospital dis-
charge [3], and report not receiving important informa-
tion about their medications [4–7]. Additionally,
findings suggest that up to 40% of patients who have
been discharged from hospital may subsequently experi-
ence medicines-related problems or need support with
their medicines [8–11].
Patient medicines helpline services (PMHS) have been
set up by some National Health Service (NHS) Trusts1
in England, with the aim of providing support to re-
cently discharged patients regarding changes to their
medicines regimen as a result of their hospital care. The
first PMHS was set up in 1992, and a survey study con-
ducted in 2017 reported that 52% of NHS Trusts in Eng-
land provided a PMHS [12]. A recent systematic review
examined the evidence regarding the effectiveness of
PMHS, concluding that PMHS are typically valued by
service users (e.g., satisfaction ratings are excellent) and
that the advice provided to service users is usually
followed. Results of the review also identified that service
users report several positive outcomes of consulting a
PMHS which include resolution or avoidance of
medicines-related problems, feeling reassured, and im-
proved health [13]. This systematic review highlights
that, to date, studies examining PMHS have mainly ex-
amined the views of service users, using quantitative
methods.
PMHS are likely to be improved by seeking to under-
stand the perceptions of not only service users but also
service providers [14]. To date, the only studies to exam-
ine pharmacy professionals’ views of PMHS are survey
studies examining how PMHS are provided [12, 15, 16].
For example, the most recent was an online survey con-
ducted in 2017 that examined how PMHS are provided
by NHS Trusts in England (N = 117) [12]. Findings
showed that PMHS are under-used, under-promoted,
and not sufficiently available to patients. Since the aim
of the survey study was to provide a general overview as
to how PMHS are provided, the authors did not seek to
explore pharmacy professionals’ perceptions regarding
the underuse of PMHS, nor why the implementation of
PMHS are limited in several respects. This study also
did not directly seek pharmacy professionals’ views re-
garding the effectiveness of PMHS. Instead, participants
selected options from a list of perceived benefits that
were compiled by three medicines information (MI)
pharmacists [17], which may have biased the results.
Qualitative research can be important for understanding
perceived reasons why healthcare services are effective or
not, and how services can be improved [18, 19]. The idio-
graphic approach to studying phenomena is unique to
qualitative methods and enables greater importance to be
placed on studying individuals' insights, understandings,
and meanings of their lived experiences [20]. With the
need to adopt a more in-depth and idiographic approach
to exploring pharmacy professionals’ experiences and per-
ceptions of providing a PMHS, qualitative methods are
well suited to address this important issue.
Aims
The aim of this novel study was to use qualitative methods
to explore pharmacy professionals’ experiences and per-
ceptions of providing a PMHS, in order to develop recom-
mendations for service improvement for the benefit of
users and providers of PMHS. In particular, this study ad-
dressed the following research question: What are phar-
macy professionals’ experiences and perceptions of
providing an NHS patient medicines helpline service?
Method
Study design
A qualitative interview design was chosen to explore
pharmacy professionals’ experiences and perceptions of
providing a PMHS. The authors adopted the epistemo-
logical position of pragmatism [21].
Participants and recruitment
Participants were eligible for this study if they were ei-
ther a Chief Pharmacist at an NHS Trust within England
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that operates a PMHS, or a pharmacy professional who
operates a PMHS at their NHS Trust within England.
Chief Pharmacists were invited to participate to provide
a perspective as to how PMHS are beneficial within the
wider organisation. Pharmacy professionals who operate
a PMHS were invited to participate, since they see first-
hand the benefits and potential limitations of this ser-
vice. Eligible participants were required to be registered
with the General Pharmaceutical Council (GPhC), which
is the UK licensing body for pharmacy professionals.
Our estimated sample size was based upon that of
published qualitative studies of healthcare professionals’
(HCPs) perceptions of healthcare services, and recom-
mendations in literature [20]. We therefore aimed to
conduct between 20 and 30 interviews. Upon reaching
the thirtieth interview, we decided to invite the few
remaining NHS Trusts that provide a PMHS in England
who had not yet been contacted, to ensure that all rele-
vant sites had the opportunity to participate (n = 117
Trusts, [12]). This resulted in a total of 34 participants.
Table 1 provides an overview of participant character-
istics (see Additional file 1 for anonymised information
regarding each participant). Most participants were fe-
male, and employed within an acute Trust.
Data collection
Interviews were chosen as the data collection method in
order to enable flexibility through the use of probes and
unplanned questions. Telephone interviews were chosen
to enable pharmacy professionals throughout England to
be easily interviewed. Each participant was interviewed
once.
An interview schedule was developed for the purpose
of exploring participants experiences and perceptions of
their PMHS, and was informed by the RE-AIM frame-
work [22]. RE-AIM comprises five dimensions that are
considered important for evaluating the impact of
healthcare interventions: Reach (whether an intervention
is reaching everyone who would benefit from it; per-
ceived reasons for underuse); Effectiveness (the positive
and negative consequences of an intervention); Adoption
(whether an intervention is adopted by settings that
could provide it; perceived reasons for or against adop-
tion); Implementation (extent to which an intervention
is delivered as intended); and Maintenance (extent to
which an intervention becomes a stable, enduring part
of the behavioural repertoire of an individual/organisa-
tion). We ensured that questions pertaining to each of
the five RE-AIM dimensions were included in the sched-
ule. For example, for Adoption, participants were asked
Table 1 Participant characteristics
Characteristic Participants (n = 34)
n (%), or mean years (SD; range)
Gender Male 8 (24%)
Female 26 (76%)
Age 39 (9.50; 25 to 59)
Ethnicity White or White British 27 (79%)
Asian or Asian British 7 (21%)
Job title Senior or Lead MI Pharmacist 16 (47%)
Chief Pharmacist 4 (12%)
MI Pharmacist 4 (12%)
MI Manager 3 (9%)
Pharmacist 3 (9%)
Senior or Lead Pharmacist 2 (6%)
Junior Pharmacist 1 (3%)
Senior or Lead MI Technician 1 (3%)
Number of years employed as a pharmacy professional 16 (9.97; 3 to 35)
Number of years working on a PMHS 6 (3.71; 0.5 to 12)
NHS Trust type Acute 26 (76%)
Mental health 3 (9%)
Integrated (two or more types) 2 (6%)
Specialist 2 (6%)
Community 1 (3%)
Note. Abbreviations: MI = medicines information; PMHS = patient medicines helpline service. NHS = National Health Service
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the following: “Please could you describe why your pa-
tient medicines helpline service was developed?” (see
Additional file 2 for the interview schedule). The topics
of the interview schedule are presented in Table 2. The
interview schedule was developed by the study authors
in accordance with established conventions for semi-
structured interviewing [23–25]. The interview schedule
was not piloted. However, once drafted, the interview
schedule was reviewed by three MI Pharmacists with ex-
pertise in operating a PMHS, with refinements made
based upon their feedback.
During data collection, the interview schedule served
as a flexible guide for interviews, enabling participants to
discuss aspects of their PMHS that were important to
them. All interviews were audio-recorded.
After their interview, the following background data
were collected from each participant over the telephone:
age, gender, ethnicity, job title, number of years
employed as a pharmacy professional, and number of
years’ experience of operating or providing a PMHS.
All data were collected by a trained interviewer (MW)
between May and October 2018. Interview duration
ranged from 16 to 53 min (mean = 30min).
Data analysis
All audio-recorded interviews were transcribed verbatim
into separate Microsoft Word documents. Framework
analysis (FA) was used to analyse the transcribed data.
FA is a systematic, rigorous and transparent technique
for organising, describing, and interpreting data, which
has been used within health research [26–28]. FA was
chosen instead of other thematic methods because the
RE-AIM framework was to guide the analytic frame-
work, and also because FA was developed to help man-
age relatively large qualitative datasets [27].
Analysis involved the following stages, as outlined by
Ritchie and Spencer [29]: familiarisation with the data,
coding, developing an analytical framework, indexing,
charting, and interpretation. Being a flexible approach,
FA can be used for deductive, inductive, or combined
qualitative analysis [27]. A combined approach was used
for the present study, whereby the five aspects of the
RE-AIM framework were used as categories, and codes
were developed from the data if they pertained to one of
these five categories. However, inductive coding was also
conducted as new concepts became apparent. All inter-
view transcripts were uploaded into NVivo version 12
[30], which was used for the framework development
and indexing stages. The only deviation to the FA stages
was that Iterative Categorisation (IC) [31] was used in
place of charting. The choice to use IC was made in
order to increase transparency and rigour. IC leaves a
clear audit trail, which provides a route back to the
indexed data. With IC, each indexed code within the
framework was exported from NVivo to a Microsoft
Word document. Each document was then reviewed
line-by-line, summarizing and organising the findings it-
eratively into points that represented commonalities and
differences across participants. This ensured transpar-
ency as to which participants contributed to each point
(see Neale [31] for further details). Final themes were
generated after re-reading all of the IC documents. Study
participants did not provide feedback on the findings,
since evidence suggests that such checks may not im-
prove study findings [32].
Establishing quality in qualitative research
Yardley’s criteria for demonstrating the quality of quali-
tative research were met [33]. For sensitivity to context,
previous literature was reviewed, and a theoretical
framework (RE-AIM) was used to guide data collection
and analysis. For commitment and rigour, FA and IC
stages were followed, and a ‘paper trail’ approach was
used. Credibility checks were conducted, where each
stage of the analysis was checked by another member of
the research team to verify that the identified codes and
themes were appropriate. Additionally, the consolidated
criteria for reporting qualitative research (COREQ) were
followed [34]. For coherence and transparency, the study
results are grounded in example quotations from the
raw data. A reflective diary was used throughout the
process of data collection and analysis, to record
thoughts about each interview, contextual features that
Table 2 Main topics for interviews with pharmacy professionals
regarding their patient medicines helpline service
Topics
1. Perceived purpose of their patient medicines helpline service.
2. Why the patient medicines helpline service was set up.
3. Perceived qualities of a good patient medicines helpline service.
4. How the quality of the patient medicines helpline service is ensured.
5. Perceived benefits of operating a patient medicines helpline service.
6. Perceived challenges of operating a patient medicines helpline
service.
7. Perceptions as to whether and in what ways the patient medicines
helpline service meets service users’ needs.
8. Perceptions as to whether and in what ways the patient medicines
helpline service is cost-effective.
9. Perceptions as to whether and in what ways any aspects of the
patient medicines helpline service could be improved.
10. Perceptions as to the usage of the patient medicines helpline
service.
11. Perceptions as to whether they feel they have all the resources
needed to provide their patient medicines helpline service the way they
want to.
12. Perceptions as to procedures that are in place when an enquiry
reveals that there has been a medicines-related error, and/or there is
the potential to learn from an enquiry.
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may have influenced interviews, and/or any ways that in-
terviews could have been improved in order to enhance
subsequent interviews. For impact and importance, the
study findings were used to develop recommendations
for improving the provision of PMHS.
Results
Two themes were generated from the analysis: Resources,
and Perceived benefits. Resources identifies that PMHS
are often provided with limited resources. Perceived ben-
efits identifies that PMHS are perceived to have several
benefits, although evidencing the benefits is considered
challenging.
Resources
Participants described several resources that are consid-
ered useful for ensuring that they provide a high-quality
PMHS. These included mechanisms for documenting
enquiries, support of colleagues within the wider organ-
isation (e.g., to promote the service), support of local
and regional MI centres for conducting quality checks,
and the use of standard operating procedures and train-
ing materials for new staff. Because PMHS function to
resolve enquiries resulting from care received from sec-
ondary care services, participants expressed the need for
local, Trust-based resources to achieve this (e.g., dis-
charge summaries, blood results, drug charts, inpatient
notes, access to HCPs involved in their care). Some par-
ticipants described how their service is also available for
patients of neighbouring Trusts, and that lacking local
resources to answer enquiries may result in delayed help
for these patients.
“We offer the service to other places now… We don’t
have access to their patient records, which is not ideal for
operating a patient helpline. But we have a system in
place where, if we need to look at the records, we have a
contact to ring... And they will have a look at, say, the
patient’s discharge letter and perhaps fax that over to us
or email it to us.” (P1, Lead MI Pharmacist, Acute
Trust).
Participants perceived one of the biggest challenges for
adopting, implementing and maintaining a PMHS to be
inadequate funding and resources. Many participants de-
scribed the lack of specific funding and resources for
their service.
“We initially formed and set up the service and took it
live with no additional cost to the pharmacy department.
It was an additional role added in to the portfolio of our
medicines information department.” (P4, Chief Pharma-
cist, Acute Trust).
Some participants described the difficulty in obtaining
funding due to the low number of enquiries received to
the service. This suggests a difficult situation where the
numbers of enquiries are too small to justify additional
funding/resources, yet without additional funding/re-
sources, the number of callers is unlikely to increase.
“I think it would be difficult with the number of en-
quiries we get to say that there is, you know, a pressure.
Or to support a business case for getting additional staff.”
(P13, Senior MI Pharmacist, Acute Trust).
Although some participants considered their PMHS to
be inexpensive to run, other participants described that
funding is needed, and that not having funding has a
negative impact upon the service.
“I think it’s probably as good as it could be, given the
amount they’re investing in it, to be honest. So, what
they’re prepared to put in, they’ll get out.” (P16, Pharma-
cist, Mental Health Trust).
A consequence of limited funding/resources is that the
availability of PMHS may be inadequate. Some providers
acknowledged that they do not currently meet national
standards for satisfactory PMHS availability (i.e., avail-
able for at least 4 hours a day, 5 days a week), but that
some provision is better than none. At some sites, phar-
macy professionals described how, even when their help-
line should be manned, they may not always be available
to answer enquiries due to other commitments and
staffing issues.
“You’ve got discharges to do, new patients to see, high
risk patients, and you’ve got those that have been dis-
charged that have phoned up with queries. So, it’s kind of
going into more of a clinical pot to be prioritised and an-
swered at some point during the day.” (P20, Lead
Pharmacist, Specialist Trust).
At some sites, the enquiries are received only by voice-
mail, which means that a caller will never directly speak
to a pharmacy professional when they contact the ser-
vice for help. Providing a service with limited access and
availability, such as a voicemail service, was acknowl-
edged as having potential negative consequences. For ex-
ample, callers may feel frustrated and seek advice
elsewhere, or not seek help at all. Limited access and
availability may therefore also have an impact upon the
use of the service.
“I think being able to have someone answering the
phone more consistently throughout the day [would im-
prove its use]… I think if there’s no-one there to answer
the phone, then people don’t leave a message. So, I think
we are probably missing people because of that.” (P13,
Senior MI Pharmacist; Acute Trust).
Since the majority of enquiries to PMHS were consid-
ered to be relatively straightforward, some participants
described that a triaging system would be cheaper and
more efficient, whereby a pharmacy technician receives
and answers enquiries, and forwards more complex ones
to a pharmacist. Some sites had already implemented
such a model.
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Lack of resources was also discussed in relation to the
perceived under-promotion of PMHS. Most participants
commented that their service is not promoted enough,
and in some cases, not promoted at all. Reasons in-
cluded not having the time to monitor the advertising,
and fear of over-promoting the service and not being
able to cope with the demand.
“It was decided that we would just promote through
cards [given out with prescriptions]. We didn’t want to
sort of over-promote the service and then have me drown-
ing in enquiries. Because I’m on my own.” (P7, MI
Pharmacist, Acute Trust).
This suggests that, due to lack of time/resources, some
PMHS providers are purposefully restricting the use of
their service. However, this may mean that some pa-
tients will not learn of the existence of the service, which
may result in them being inconvenienced or suffering as
a consequence of improper use of their medicines. Par-
ticipants commented upon the link between the lack of
promotion of their service, and its perceived underuse.
“I think it could be more widely used, if we found ways
of promoting it better. So, we need to make sure that the
number is on every piece of paper that comes out of any
department. And then I think we would have more up-
take.” (P15, MI Manager, Acute Trust).
Some participants described the benefit of particular
promotional methods. For example, promoting the ser-
vice via the discharge summary is not only free advertis-
ing, but it also ensures that the service is promoted to
every discharged patient, which increases the number of
enquiries.
Despite often providing a PMHS with limited re-
sources, most participants commented that answering
enquiries to their PMHS and helping patients provides
them with job satisfaction. This could be a motivation
for continuing to run a PMHS, despite limited resources.
“We love providing the service. We really do…When
you’ve resolved something for a patient, even if it’s very
simple for us, obviously it’s concerned them enough to
give you a ring. When you’ve resolved an issue, it actually
kind of leaves you with quite a nice fuzzy feeling.” (P26,
Lead MI Pharmacist, Acute Trust).
Perceived benefits
Participants described several perceived benefits of pro-
viding a PMHS. Primarily, PMHS were perceived to be
beneficial for providing patients with personalised, ex-
pert support during the transfer of care period. PMHS
were considered necessary in order to address often in-
adequate discharge processes in which discharge coun-
selling is limited. Discharges were perceived to be
inadequate for several reasons, such as the difficulty of
patients/carers retaining a large amount of information
provided on discharge, HCPs having insufficient time to
explain everything, and discharges occurring out-of-
hours when HCPs are often unavailable.
“It’s a safety net. The pharmacists are quite time-
pressured on the wards but unfortunately counselling of
patients on discharge probably doesn’t happen as much
as we would like. So, the advice line helps sort of mop up
any missed important counselling points really, for those
proactive patients that call us.” (P2, Lead MI Pharmacist,
Acute Trust).
The above quotation also highlights that PMHS may
not reach all patients who require support, since the
onus is upon the patient or carer making contact with
the service. It is likely that there is an unknown number
of patients who require support with their medicines
after discharge but who are not proactive and do not call
the hospital’s PMHS.
Perceived benefits upon patients and carers also in-
cluded improving patients’ adherence and knowledge of
their medicines, helping patients take medicines safely
and therefore potentially avoiding harm, and improving
patients’ experiences of care. No participants described
any perceived adverse effects of providing a PMHS.
“[A benefit of the helpline is] them continuing to take
the right medicines at the right times in the right way,
meaning that they have the best outcomes and have the
most, you know, optimal use of their medicines.” (P21,
Lead MI Pharmacist, Acute Trust).
Offering a helpline also enabled pharmacists to pro-
vide reassurance to patients who have queries about
their medication. This was considered to be an import-
ant function, and may be pivotal in encouraging patients
to use medication appropriately.
“Sometimes, people just want some reassurance. We
know that patients don’t often take their medications as
they’re prescribed. And actually, often that can be due to
kind of misconceptions that they have about their medi-
cines. Or concerns. Being able to speak to someone in a
bit more of a calm environment than a ward post-
discharge, can be all patients need sometimes to consider
continuing to take their medicines.” (P33, MI Manager,
Acute Trust).
Extending the benefits of PMHS beyond the individual
level, participants described how PMHS successfully
sought to positively promote pharmacy services and the
Trust at a wider level (e.g., showing continued responsi-
bility after discharge).
“I think it [PMHS] sheds a positive light on to the
Trust. It shows that the Trust cares about their patients.
And you know, their level of responsibility doesn’t end
when the patients are physically discharged.” (P12,
Pharmacist, Mental Health Trust).
Participants also described the PMHS as being a
mechanism for catching and/or resolving medicines-
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related errors, which can provide a learning and im-
provement opportunity for the Trust.
“Sometimes queries do bring out that there has been an
error. So sometimes patients have got home and they
haven’t got something that they should’ve had, or they’ve
got somebody else’s something that they shouldn’t have.
So, it’s making sure that those errors are fed back to the
appropriate people and filling in the appropriate incident
reporting forms, as well.” (P21, Lead MI Pharmacist,
Acute Trust).
Participants also described how use of PMHS could
benefit the trust more widely though acting as a mech-
anism for fixing medication-related issues before they re-
sult in formal complaints to the Trust.
“You would hope you’d have less formal complaints.
Because it’s the first place that people come to, we can
hopefully resolve any queries that they’ve got before, you
know, they escalate in to something else whereby they
then need to make a more formal complaint.” (P14, Chief
Pharmacist, Acute Trust).
Other perceived benefits for the Trust included pre-
venting hospital readmissions, reducing the burden upon
other services, and the potential to learn from enquiries
in order to improve services (e.g., examining trends in
the types of enquiries received to improving discharge
counselling and/or patient information leaflets).
“We can collect [enquiries], and where we get a trend,
what we’ll do is we’ll go to the department and say
“We’ve had a fair number of enquiries about this. You
might want to have a rethink about your system.”” (Par-
ticipant 29, MI Pharmacist, Acute NHS Trust).
Although several perceived benefits were described,
many participants reported being unsure regarding the
actual effectiveness of their PMHS, since the effective-
ness of their service had not been evaluated. Measuring
the effectiveness of PMHS was considered to be prob-
lematic for numerous reasons including difficulties with
collecting data from PMHS users (e.g., lack of time and
resources, difficulty obtaining consent, and previous re-
sponse rates being low).
“We are supposed to send out questionnaires to pa-
tients who have used the service to find out about their
experiences… It’s very very rare that any of them re-
spond.” (P34, Senior MI Pharmacist, Acute Trust).
The following quotation also highlights how, for some
Trusts, the underuse of PMHS can hinder evidencing
the effectiveness of the service, since it may be difficult
to collect meaningful data from a small sample.
“We’ve definitely not done any sort of studies looking at
[the effectiveness of the service]. And our numbers are
probably too small for it to really be significant details.”
(P9, Chief Pharmacist, Specialist Trust).
In addition to the challenges around the logistics of
collecting data, participants also described the difficulty
of measuring effectiveness and cost-effectiveness in
order to evidence that providing their PMHS is worth-
while (e.g., the difficulty evidencing what would have
happened had the service not existed, the difficulty evi-
dencing that the service reduces readmissions and/or the
burden upon other healthcare services, and the difficulty
measuring actual outcomes for patients instead of their
perceived outcomes).
“To actually benchmark and measure better outcomes
is incredibly difficult. How do you actually show to the
Trust that Fred Bloggs… how do you actually demon-
strate that his outcomes were better because he had that
intervention? … It’s very difficult for the Trust to know
that that service is good.” (P18, Chief Pharmacist, Inte-
grated Trust).
Despite this, participants commented on the import-
ance of using enquiry data to show the value of their
PMHS. For example, performance statistics (e.g., number
of enquiries received per month, types of enquiries) can
be produced for the Trusts’ pharmacy dashboard, senior
managers, and the hospital executive team.
Discussion
This study explored the experiences and perceptions of
providing a PMHS in a sample comprising 34 pharmacy
professionals. Two themes were generated: Resources,
and Perceived benefits. The findings illustrate how pro-
viding a PMHS with limited resources (e.g., specific
funding, adequate staffing) impacts upon their imple-
mentation, maintenance, reach, and the ability to evi-
dence their effectiveness. Despite this, PMHS are
considered to have a number of benefits for patients and
healthcare organisations (e.g., providing a ‘safety net’ to
patients during the transfer of care period, providing re-
assurance, helping to optimise patients’ medicines, pre-
venting readmissions, and reducing the burden upon
other healthcare services). However, actually establishing
the effectiveness and cost-effectiveness of PMHS is chal-
lenging due to perceived logistical difficulties of collect-
ing data, and the difficulty measuring hard outcomes.
Our finding that PMHS are often provided with lim-
ited resources corresponds with a recent survey study
showing that the main reason why 48% of NHS Trusts
in England in 2017 did not provide a PMHS was also
due to lack of staffing/resources [12]. Our findings also
suggest that a particular challenge for proving a PMHS
was having pharmacy professionals being available to an-
swer calls during the working day. This accords with
findings of the same survey study, showing that, al-
though 86% of Trusts that provide a PMHS reported it
as being accessible for at least 4 hours per day, only 57%
of Trusts reported that their PMHS was accessible for
eight or more hours per day. Additionally, 29% of Trusts
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reported that contact with a pharmacy professional is
not always available during advertised hours.
The lack of access and availability of PMHS may mean
that patients choose to seek advice elsewhere, increasing
the burden upon primary care. A recently conducted
systematic review found that, if a PMHS was not avail-
able, patients and carers would most likely seek the ad-
vice of their GP instead [13]. This is topical, given that
the average waiting time from booking a standard ap-
pointment to seeing a GP in England in 2016 and 2017
was approximately 2 weeks [35]. A delay to receive ap-
propriate medicines-related support may have implica-
tions for patients regarding the optimisation of their
medicines and their ability to be adherent, which may
impact their wellbeing. Patients and carers also have
other options, such as visiting a community pharmacist
or contacting NHS 111 (a general health information
service in England). However, Badiani et al. found that,
out of 200 enquiries received to their PMHS, 74.5% re-
quired access to hospital-based resources (e.g., patient
records, and healthcare providers) [36]. Thus, commu-
nity pharmacists and NHS 111 are currently unlikely to
be able to answer the majority of enquiries.
Our findings suggest that, from the perspectives of
pharmacy professionals, PMHS have a number of bene-
fits for patients and the healthcare organisation. These
perceived benefits are consistent with the outcomes re-
ported in a recently conducted systematic review exam-
ining the effectiveness of PMHS (e.g., patients feeling
reassured, patients’ improved use of medicines) [13].
However, the outcomes in this systematic review are also
based upon perceptions, since the identified studies pri-
marily involved surveying service users, or having clini-
cians rate enquiries and answers in order to hypothesise
the impact upon patients. Therefore, to date, no studies
have examined hard outcomes from using a PMHS (e.g.,
readmissions). This accords with our finding that phar-
macy professionals view measuring hard outcomes from
PMHS as challenging.
Participants’ description of their PMHS as a ‘safety
net’ for supporting patients who had experienced a
medicines-related error is consistent with findings re-
garding error rates following hospital discharge. Ap-
proximately 40% of patients may experience medicines-
related errors after discharge from hospital [37, 38].
Learning from medicines-related errors in order to im-
plement methods for their reduction is a current NHS
and worldwide healthcare priority [39]. In relation to
PMHS, a recent systematic review examined the types of
enquiries received to PMHS and found that, on average,
27% of calls are regarding medicines-related errors [40].
Therefore, a PMHS may provide one avenue for redu-
cing medicines-related errors, if the information from
such enquiries is developed into recommendations and
implemented to improve practice.
Our findings suggest that a consequence of reducing
medicines-related errors and improving medicines-
related counselling at hospital discharge may be that
fewer patients need support with their medicines follow-
ing hospital discharge. This may result in the number of
enquiries to PMHS being reduced. Reducing the need
for patients to contact a PMHS after their discharge may
help to address one of the key issues of providing a
PMHS that was found in our study – that resources are
often insufficient. Additionally, providing better
medicines-related support to patients earlier in their care
pathways could mean that more patients avoid
medicines-related issues after discharge, and not just the
proactive patients and carers who choose to seek
support.
Recommendations for practice
Our findings suggest that recommendations to improve
the impact of PMHS must be achievable within a
resource-limited context. Therefore, we recommend the
following:
PMHS providers could examine the types of calls they
receive, and where possible, learn from them and im-
prove practice. Over time, certain enquiries (e.g., those
regarding errors, and those received as a consequence of
inadequate discharge counselling) may be reduced,
which may also reduce the burden upon PMHS
providers.
To reduce the cost of manning a PMHS, rather than
having a pharmacist answer enquiries, a triaging system
would be cheaper and more efficient whereby a phar-
macy technician answers enquiries, and forwards more
complex ones to a pharmacist.
In order to reduce the cost of promotion, and increase
the reach of PMHS to all discharged hospital patients
who may require support with their medicines, helpline
providers could promote their service for free by ensur-
ing that their helpline number is included within dis-
charge summaries that patients receive.
Relatedly, we recommend that providers of PMHS
share their ideas for implementing and maintaining a
PMHS within a resource-limited context. This could be
co-ordinated by regional MI centres, and published via
the UK medicines information network [41]. We also
recommend that outputs from all improvement projects
are made available by PMHS providers to their senior
managers and their hospitals’ executive team, in order to
show the value and efficiency of providing a PMHS.
Recommendations for future research
High-quality, multi-site research is needed to examine
whether the perceived benefits of PMHS described in
Williams et al. BMC Health Services Research          (2020) 20:364 Page 8 of 11
this study can be evidenced. Such evidence may result in
more NHS Trusts establishing their own PMHS. This is
important, since a survey study conducted in 2017 found
that only 52% of Trusts in England provided a PMHS
[12]. However, evaluation of PMHS services was a crit-
ical issue in the present study, with participants describ-
ing difficulties measuring the effectiveness and cost-
effectiveness of PMHS services. In order to share expert-
ise and resources, and increase the generalisability of
findings, we recommend that sites collaborate with one
another, for example, within a region. Such studies could
be coordinated by regional MI centres.
The views and experiences of both service users’ and
service providers’ are considered important for improv-
ing the quality of healthcare services [14]. It would
therefore also be advantageous for future research to ex-
plore patients’ and carers’ experiences of using a PMHS,
also using qualitative methods. Such an idiographic ap-
proach would enable service users themselves to provide
a detailed consideration of how and why PMHS may be
beneficial, and ways that they may be improved, in order
to develop further recommendations for their
improvement.
Strengths and limitations
This is the first study to take an idiographic approach to
exploring pharmacy professionals’ perceptions of PMHS,
thereby providing rich and contextualised accounts of
PMHS provision that have resulted in recommendations
for service improvement and future research endeavours.
Additionally, we used RE-AIM, an established evaluation
framework, to achieve this [22]. Thus, all five aspects of
the impact of interventions, as conceptualised by the de-
velopers of RE-AIM, have been incorporated into our
data collection and analysis processes. Consideration
was also made throughout the study processes to en-
hance the validity and trustworthiness of our findings.
A limitation of this study is that although we invited
pharmacy professionals from all known NHS Trusts that
provided a PMHS, pharmacy professionals were still re-
quired to opt in to participate. This may have resulted in
bias, since the perspectives of the pharmacy profes-
sionals who decided not to participate are not repre-
sented. Additionally, the sample predominantly
comprised pharmacy professionals from acute NHS
Trusts, and therefore could have be improved by the
addition of pharmacy professionals from other Trust
types (e.g., mental health, specialist, and community
Trusts).
Conclusion
This qualitative study highlights several potential bene-
fits of PMHS, for both patients and healthcare organisa-
tions. However, actually evidencing the benefits of
PMHS is perceived to be challenging, such as the diffi-
culty measuring what would have happened had the ser-
vice not existed, and not having the resources to
evidence their effectiveness. Lack of resources (e.g., no
specific funding, staffing) was also perceived to impact
the implementation, maintenance, and reach of PMHS.
We recommend that helpline providers share best prac-
tice for providing a PMHS within a resource-limited
context. High-quality research is needed to evidence the
effectiveness and cost-effectiveness of PMHS, which may
help to secure adequate resources for this service in the
future.
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7.4 Chapter 7 summary 
 
This chapter presented the findings of a qualitative study exploring 
pharmacy professionals’ experiences and perceptions of providing PMHS.  This 
study expands upon the findings of Study 1, the survey study exploring the provision 
and operation of PMHS in England. Study 1 found that the availability and 
promotion of PMHS do not meet national standards, which suggests that this could 
be a reason for the suboptimal use of this service. The qualitative data presented in 
this chapter shows that pharmacy professionals perceive the limited availability and 
promotion of PMHS to be a consequence of limited resources (i.e., being 
understaffed, and not having specific funding for the service). However, despite this, 
PMHS are perceived to have a number of benefits, and these benefits accord with 
those found using survey methods in Study 1. For example, PMHS are perceived to 
provide a ‘safety net’ to patients during the transfer of care period, provide 
reassurance to patients, help to optimise patients’ medicines, resolve medicines-
related errors, reduce the burden upon other services, and provide the potential to 
improve hospital services based upon the content of enquiries. Therefore, the 
perceived benefits of PMHS from the perspectives of pharmacy professionals who 
provide this service has now been explored using both quantitative and qualitative 
methods.  
 
The systematic reviews presented earlier in this thesis also established that 
the perceived benefits of PMHS from the perspectives of service users have only 
been explored using survey methods. Therefore, the next chapter presents a study 
using qualitative methods to explore the experiences of service users who use 
PMHS.  
 
The development of the data collection tool for this study was informed by 
the RE-AIM framework (3). RE-AIM is a detailed framework, since all five of its 
dimensions comprise sub-elements that should be explored in order to establish the 
impact of an intervention or service (4). However, in order to examine all aspects of 
the RE-AIM framework, both quantitative and qualitative methods are needed, and 
the perspectives of both service providers and service users are required (4).Thus, 
although the interview schedule used in this study was informed by the RE-AIM 
framework, certain aspects of it were excluded because they did not seem relevant 




participants about the representativeness of enquirers to PMHS more broadly, and 
the representativeness of sites that provide a PMHS). 
 
Relatedly, the RE-AIM framework was used to analyse the interview data 
using framework analysis (FA). FA involves the stages of familiarisation with the 
data, coding, developing an analytical framework, indexing, charting, and 
interpretation (5). With framework analysis, there is no rule that the framework used 
will then become the final themes that are presented (5). So, although RE-AIM was 
used deductively, during the ‘developing an analytical framework’ stage, it became 
apparent later in the analysis that it did not make sense to present the findings in 
terms of five themes that corresponded to the five dimensions of RE-AIM. For 
example, each theme had at least two sub-themes, which meant there were over 
ten sub-themes to report, had this approach been taken. This may have been 
confusing for the reader. Additionally, whilst conducting the analysis, there were 
noticeable linkages across the different elements of RE-AIM, which meant that 
organising the findings across the five RE-AIM dimensions would have ignored 
these linkages. It made more sense to abandon the RE-AIM framework at the 
interpretation stage, and to organise the findings into themes that made the most 
sense to me and my supervisors. During the write-up, where relevant, I tried to 
show where the different elements of RE-AIM influenced each other. For example, 
lack of promotion and availability (Implementation) influences the reach of the 
service, and reach influences the assessment of its effectiveness (e.g., low numbers 
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Chapter 8: Service users’ experiences of 
contacting NHS patient medicines helpline 
services: A qualitative study. 
 
 
8.1 Overview of Chapter 8 
 
As established in the systematic review examining the effectiveness of 
PMHS, to date, studies of PMHS have predominantly examined the views of service 
users using user satisfaction surveys. The aim of this novel qualitative study was to 
address a gap in the literature by idiographically exploring patients’ and carers’ 
experiences of using a PMHS, their benefits, and ways that they can be improved. 
Through learning about patients’ and carers’ experiences of PMHS, we aimed to 
make suggestions to improve how helplines are operated. In particular, this study 
addressed the following research question: What are patients’ and carers’ 
experiences of contacting an NHS PMHS? 
 
This study has been submitted for publication and is currently under review. 
Therefore, the submitted manuscript is presented. Following the manuscript is a 
brief summary of the study’s findings, and a description of how the study fits within 
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Objectives: Patient medicines helpline services (PMHS) are available from some 
National Health Service (NHS) Trusts in the UK to provide medicines information to 
hospital patients and carers. To date, studies of PMHS have examined the views of 
service users via satisfaction surveys. This study used qualitative methods to 
explore service users’ experiences of using a PMHS, including perceived benefits 
and areas for improvement.  
 
Methods: This study was conducted across seven NHS Trusts in England. Forty 
users of PMHS were individually interviewed over the telephone. Interviews were 
audio-recorded, transcribed verbatim, and analysed using Braun & Clarke’s 
inductive reflexive Thematic Analysis. Ethical approval was obtained before study 
commencement.  
 
Results: Participants predominantly called a PMHS for themselves (82%). Two main 
themes were generated. Theme 1: Timeliness: PMHS provide support during the 
uncertain transition of care period from hospital to home, when patients and carers 
often feel vulnerable because support is less available. PMHS met service users’ 
needs for timely and easily accessible support, and quick resolution of their issues. 
PMHS could be improved with staffing beyond typical work week hours, and by having 
staff available to answer calls instead of using an answerphone. Theme 2: PMHS are 
best-placed to help: PMHS were perceived as best-placed to answer enquiries that 
arose from hospital care. Service users felt reassured from speaking to pharmacy 
professionals, and PMHS were perceived as the optimal service in terms of knowledge 
and expertise regarding medicines-related questions. However, several participants 
were initially unaware that their PMHS existed.  
 
Conclusions: PMHS are perceived to be a valuable means of accessing timely 
medicines-related support when patients and carers may be feeling particularly 
vulnerable. However, their availability and promotion could be improved. We 
recommend that providers of PMHS consider whether this is achievable, in order to 





Keywords: Patients, carers, service users, medicines information, drug information 
services, patient medicines helpline services, hospital discharge, National Health 
Service, qualitative, thematic analysis.  
 
Strengths and limitations of this study 
 
• This is the first study to adopt an idiographic approach to exploring service 
users’ experiences of using patient medicines helpline service. 
• Participants were recruited from a geographically diverse range of NHS 
Trusts (n=7) across England. 
• Providers of the service acted as gatekeepers to participants, which may 
have resulted in participant selection bias. 
• The sample primarily comprised service users from acute NHS Trusts, and 
therefore could have been improved by additional service users from other 








Many patients leave hospital with gaps in their knowledge about their 
medicines,(1-6) and a sizeable number of patients subsequently experience 
medicines-related errors and require support with medicines-related problems.(7-
14) Consequently, hospital discharge may be a confusing and/or risky period for 
patients who have recently experienced changes to their medicines.  
 
Patient medicines helpline services (PMHS) have been set up at many 
National Health Service Trusts (NHS) in the United Kingdom with the aim of 
providing medicines-related support to recently discharged hospital patients and 
their carers. The first PMHS was set up in the UK in 1992, and a survey study 
conducted in 2017 reported that 52% of NHS Trusts provided a PMHS.(15) 
Providing a PMHS accords with World Health Organisation (WHO) policy, which 
states that offering information on medicines via Medicines Information (MI) centres, 
and providing public education about medicines, are essential interventions to 
promote the rational use of medicines.(16) 
 
In line with healthcare quality improvement approaches, services are likely to 
be improved by seeking to understand the experiences of service users.(17) In 
order to ascertain service users’ views and experiences of PMHS, quantitative 
satisfaction survey studies have been conducted, whereas qualitative studies have 
not.(18) The results of such survey studies suggest that service users typically 
consider PMHS to be beneficial.(18) For example, a recent systematic review found 
that satisfaction ratings are excellent, the advice received is reported to be usually 
followed, and users report several positive outcomes, such as feeling reassured, 
and improved health.(18) However, a limitation of survey studies is that surveys 
include questions that are important to the researcher, rather than allowing 
participants to provide in-depth information that is important to them. Relatedly, 
survey answer options do not permit participants to respond in-depth using their 
own words. To enable service users to provide a detailed consideration of how and 
why PMHS may be beneficial and how they could be improved, an idiographic 





Whereas the nomothetic approach is considered useful for making 
generalisations about groups of individuals in order to make assumptions about 
populations, the idiographic approach is considered useful for exploring individuals’ 
lived experiences of a phenomenon.(19) Idiography is concerned with exploring the 
in-depth experiences of particular individuals in particular contexts, and qualitative 
methods are considered appropriate for collecting rich data in order to achieve 
this.(19) Consequently, our study sought to address an important knowledge gap by 
being the first study to take an idiographic approach, and use qualitative methods, 




The aim of this novel qualitative study was to explore patients’ and carers’ 
experiences of using a PMHS, their benefits, and ways that they can be improved. 
Through learning about patients’ and carers’ experiences of PMHS, we aimed to 
suggest improvements to how PMHS are delivered. In particular, this study 
addressed the following research question: What are patients’ and carers’ 






The authors adopted the epistemological position of pragmatism, in order to 
develop recommendations for service improvement for the benefit of users of 
PMHS. Pragmatism uses appropriate methods for solving practical problems, with 
an emphasis upon the usefulness of research.(20) Pragmatism has become 
increasingly popular in health research, since its aim is to produce findings that are 
of benefit to service users.(20-22) 
 
For transparency, the study authors comprise three University academics 
with PhDs (one male, two female) and one PhD student with an MSc (male). All 
study authors have an interest in pharmacy practice, health services research, 
and/or health psychology. One author (MJ) has prior experience of managing a 





Participants and recruitment 
 
  Recruitment was conducted via seven NHS Trusts from different regions 
within England: four acute Trusts, one mental health Trust, one specialist Trust, and 
one community Trust. Initially, four Trusts were recruited, one of each type. 
Additional Trusts of all types were subsequently recruited in order to ensure that our 
sample target was met, and to enhance the diversity of experiences included in the 
analysis. However, only three additional acute Trusts agreed to take part. Pharmacy 
professionals who provided the PMHS at sites acted as gatekeepers to the 
recruitment of participants, with each site recruiting participants over a six-month 
period.  
 
 Eligible participants were required to be either a patient, or a patient’s non-
professional carer, who recently used a PMHS provided by an NHS Trust within 
England for the purpose of seeking support regarding medicines. Participants were 
also required to be aged 16 years or older, fluent in English, and available to 
participate in a telephone interview within one month of having used the PMHS. 
Participants were excluded if, in the pharmacy professional’s judgement, taking part 
would likely cause distress to the service user. Pharmacy professionals were also 
required to exclude service users who stated they were (or were considering) 
making a complaint against the Trust, and if the service user was a healthcare 
professional to the patient.  
 
 Invitations to participate in the study were sent from Trusts to all helpline 
enquirers who agreed to receive study information at the end of their call to the 
PMHS. After reading the study participant information sheet, interested individuals 
opted in by contacting the research team via telephone or email in order to 
participate. Prior to participation, interested individuals were informed as to the 
purpose of the study and what participation entailed, including key ethical issues 
(e.g., data storage and confidentiality). Interested individuals also had the 
opportunity to ask questions about the study. 
 
 Our estimated sample size was based upon that of published qualitative 
studies of service users’ experiences of healthcare services, and recommendations 




The sample size was not based upon reaching data saturation. The concept of data 
saturation has been challenged as a means of identifying the appropriate number of 
participants to include in a study.(24) For example, it has been suggested that data 
may never be truly saturated, since there could always be potential codes and 
themes to be identified.(25) 
 
 The first forty individuals who contacted the study team and met the study 
eligibility criteria were recruited into the study. Prior to data collection, verbal 
informed consent was obtained from each participant via telephone, which is 




 Semi-structured interviews were chosen as the data collection method in 
order to provide flexibility through the use of probes and unplanned questions. This 
increased the potential for producing richer data compared with other approaches 
that were considered, such as a qualitative survey.(23) Data were collected via 
telephone, enabling participants throughout England to be easily interviewed. 
Evidence suggests that telephone interviews can lead to rich data, provided that 
interviewers ensure that participants’ needs are understood and respected.(27, 28) 
Consequently, care was taken to ensure that participants were comfortable being 
interviewed over the telephone, and that they also felt able to pause the interview at 
any time and to ask clarification. Each participant was interviewed once.  
 
 During the same telephone call as the interview, but before the interview was 
conducted, the following background information was collected from participants: 
Name of NHS Trust contacted, date of PMHS contact, whether they had previously 
used a PMHS. Patients were also asked whether they were an inpatient or 
outpatient for their recent period of care, and the number of prescribed medicines 
they were prescribed at the time of the PMHS contact. Carers were also asked their 
relationship to the patient who the PMHS contact was regarding. 
 
 Separate interview schedules were developed for patients and carers (see 
Supplementary file 1 for the interview schedules). Table 1 provides a summary of 




their experience of contacting the PMHS). The interview schedules were broadly 
similar, although, for ethical reasons, the carer version did not contain questions 
that would have resulted in them providing personal information about the individual 
in their care. The aim of the interview with carers was to explore whether the PMHS 
met their needs as a carer seeking information. Both schedules comprised open-
ended questions, and were developed in accordance with established conventions 





Table 1. Topics for the interviews with service users 
Topics for interviews with service users 
1. Why the patient/carer contacted the helpline service, including what their question or 
concern was, the perceived seriousness of the issue, whether they considered any 
other sources of medicines information, and their decision-making process for choosing 
to use the helpline service.  
2. What the patient/carer found helpful and unhelpful about their experience of 
contacting the medicines helpline service. 
3. What impact the patient's/carer's use of the service has had (e.g., Was the advice 
followed? If so, what were the outcomes of this? If the advice was not followed, what 
were the reasons for this?). 
4. Whether there were any negative consequences of using the helpline service. 
5. How the patient/carer felt about the medicines now, compared to before the helpline 
contact. 
6. How the patient/carer felt about the hospital and NHS Trust now, compared to before 
the helpline contact. 
7. What the patient/carer would have done had the helpline service not been available, 
and why. 
8. Whether the patient/carer sought any other sources of medicines-related information 








 During data collection, the interview schedules served as flexible guides for 
interviews, enabling participants to discuss aspects of their experiences of using a 
PMHS that were important to them.  
 
 During the same telephone call as the interview, but after their interview had 
been conducted, the following background data were collected from each 
participant: age, gender, ethnicity, and current occupational status. 
 
 All interviews were conducted by a trained interviewer (MW), audio-




 Braun and Clarke’s inductive reflexive thematic analysis (TA) was used to 
analyse the qualitative interview data.(32, 33) TA is a systematic, rigorous and 
transparent technique for organising, describing, and interpreting data, which has 
been used within health research to explore patients’ experiences of healthcare 
services.(34-36) Braun & Clarke’s TA was chosen instead of other thematic 
methods, since it provides a straight-forward step-by-step process for conducting a 
thorough and transparent analysis. 
 
 Analysis involved the following stages, as outlined by Braun and Clarke: 
familiarisation with the data, generating initial codes, developing themes, reviewing 
themes, defining and naming themes, and writing the analysis.(23, 32) Individual 
interview transcripts were uploaded into NVivo version 12,(37) which was used for 
generating initial codes and developing and reviewing themes. The only deviation to 
the TA stages was that Iterative Categorisation (IC) was used in place of the 
defining themes stage.(38) The choice to use IC was made in order to increase 
transparency and rigour. IC is also a systematic, rigorous and transparent 
technique, which can be used to support a range of analytical techniques, including 
TA .(38) IC leaves a clear audit trail, which provides a route back to the coded data 






Patient and public involvement 
 
 The study design and documents (participant information sheet and 
interview schedules) were reviewed by six members of the public who were either 
recent hospital patients or carers. Refinements to the documents were made based 
upon their feedback. Patients/the public were not involved in the recruitment of 
participants, nor dissemination of findings. 
 
Establishing quality in qualitative research 
 
Yardley’s criteria for demonstrating the quality of qualitative research were 
met (39). For sensitivity to context, previous literature was reviewed in preparation 
for the study, and we endeavoured to recruit participants from several different NHS 
Trusts. For commitment and rigour, TA and IC stages were followed, including 
Braun & Clarke’s 15-point guidelines on conducting TA,(23) and a ‘paper trail’ 
approach was used. Also, credibility checks were conducted, where each stage of 
the analysis was checked by another member of the research team to verify that the 
identified codes and themes were appropriate. Additionally, the consolidated criteria 
for reporting qualitative research (COREQ) and the standards for reporting 
qualitative research (SRQR) were followed.(40, 41) For coherence and 
transparency, the study results are grounded in example quotations from the raw 
data. A reflective diary was used throughout the process of data collection and 
analysis, to record thoughts about each interview, contextual features that may have 
influenced interviews, and/or any ways that interviews could have been improved in 
order to enhance subsequent interviews. Additionally, the authors have disclosed 
their positions regarding the research topic. For impact and importance, the study 







Table 2 provides an overview of participant characteristics (see 
Supplementary file 2 for anonymised information regarding each participant). 




themselves, and had used a PMHS that was based at an acute Trust. Table 3 





Table 2. Participant characteristics 
Characteristic 
Participants (n = 40) 
n (%), or mean years (SD; 
range) 
   
Type of enquirer Patient, calling for self 33 (82%) 
 Carer / calling on behalf of patient 7 (18%) 
   
Type of patient a Inpatient 17 (52%) 
 Outpatient 12 (36%) 
 Member of the public 4 (12%) 
   
Type of carer b Spouse or partner of patient 5 (71%) 
 Parent of patient 1 (14%) 
 Son or daughter of patient 1 (14%) 
   
No. medicines currently prescribed a Zero to 4 11 (33%) 
 5 to 9 19 (58%) 
 10 or more 3 (9%) 
   
Gender of enquirer Male 17 (42%) 
 Female 23 (58%) 
   
Age of enquirer (years)  68 (9.87; 44 to 85) 
   
Ethnicity of enquirer White or White British 38 (95%) 
 Asian or Asian British 1 (3%) 
 Mixed race 1 (3%) 
   
Occupational status of enquirer Retired 30 (75%) 
 Employed 4 (10%) 
 Unemployed 4 (11%) 
 Carer and/or homemaker 2 (5%) 
   
Has enquirer used PMHS in the past? No 34 (85%) 
 Yes 6 (15%) 
   
NHS Trust type where PMHS was 
used 
Acute 1 23 (57.5%) 
 Acute 2 6 (15%) 
 Acute 3 6 (15%) 
 Acute 4 3 (7.5%) 
 Mental health 1 (2.5%) 
 
Specialist 1 (2.5%) 
 Community 0 (0%) 
      
Note. Abbreviations: NHS = National Health Service; PMHS = patient medicines helpline service. 
a Data collected only from participants who were patients 
b Data collected only from participants who were carers 
Table 3. Types of enquiries made by study participants (n = 40) 





Administration or dosage 10 (25%) 
Interaction 9 (23%) 
Supply 7 (18) 
Medicines-related error a 6 (15%) 
Side effects 6 (15%) 
Storage 2 (5%) 
    
a Incorrect medicine prescribed (n = 3); missing medication (n = 2); 
discharge paperwork not sent to primary care, causing a delay to 







Interview duration ranged from 12 to 66 minutes (mean = 25 minutes).   
 
Overview of themes 
 
Two main themes were generated from the analyses: Timeliness, and 
PMHS are best-placed to help. Timeliness identifies that service users often feel 
vulnerable after discharge from secondary care, and that service users want quick 
access to support when they need it, from pharmacy professionals who are 
available to help them. This is what PMHS have the potential to provide, although 
their availability could be improved. PMHS are best-placed to help reveals that 
PMHS may reduce the burden upon other healthcare services, and that PMHS are 
considered to be the best place to access medicines-related support pertaining to 
hospital care, from pharmacy professionals with expert knowledge. Pharmacy 
professionals were considered to have positive personal qualities that helped to 
reassure service users. However, although PMHS are considered best-placed to 







Theme 1: Timeliness 
 
Vulnerable after discharge 
 
Participants described feeling vulnerable after leaving hospital, and in need of 
support during this transition of care period. Reasons for feeling vulnerable after 
leaving hospital included being in recovery, feeling isolated, being house-bound, 
experiencing a medicines-related error (e.g., a missing medication), being 
discharged with multiple medicines and feeling confused, and realising that they had 
not asked important questions during discharge. The PMHS was perceived to fulfil 
this important service gap. 
 
“If you’ve been discharged from hospital, for instance, you’re given a bunch 
of medicines, it’s explained to you, and perhaps you don’t absorb it all completely… 
It probably just doesn’t quite go in until you come home… and then you think “Ah. 
Perhaps I should’ve asked this question.” In which case, if you’ve got something like 




Pertaining to feeling vulnerable after leaving hospital, participants perceived the 
situation as stressful, and spoke of the need for immediate help with regards to 
medication advice. In order to reduce this stress, it was therefore important to be 
able to access support quickly (i.e., no answerphone or additional buttons to press 
to get through), and to also have the situation resolved as soon as possible. This is 
what the PMHS typically enabled.  
 
“I was relieved, actually, to have somebody to talk to immediately that could help 
me within a short space of time.” (P5, Female, Patient) 
 
Participants spoke of the importance of the method of accessing the PMHS, and 
that the telephone was vital for accessing the service quickly, compared to 
accessing the service via email. Access methods were often described in relation to 




situations where help was not needed immediately).  
 
“I think it depends on the urgency of the situation… Because of this situation, 
[telephone access] was great. It was immediate… but if it wasn’t a vital thing, then 
yes…I could just email it through thinking “I don’t even need it today, this minute, 
but in the next couple of days would be helpful.”” (P32, Female, Carer) 
 
Relatedly, some participants commented that potential access options, such as 
online chat or a mobile phone app, would increase their stress.  
 
“I’m not that keen on technology. At a time when I felt really stressed out, I 
would’ve had an added stressor, having to work out how to do it. So, for me, it’s 
very comforting, because I’m very familiar with the telephone [laughs].” (P10, 
Female, Patient) 
 
However, participants felt that having more than one method of accessing 
support is useful, such as telephone and email. Several participants considered the 
access options of email, online chat, and mobile phone app to likely be preferable 
for younger service users.  
 
Availability of help 
 
Participants described how contacting the PMHS was likely to lead to a quicker 
resolution in comparison to other sources of support (e.g., their GP, a local 
pharmacy, NHS 111, or another hospital contact). This was another reason why 
participants typically contacted the PMHS in the first instance. 
 
“I was waiting to hear back from the surgery, because I left it with the 
receptionist at the surgery… But actually, I only got a call from the surgery this 






Although most participants described their PMHS as timely, some were 
concerned about needing the service when it was unavailable (e.g., evenings and 
weekends, to support patients who get discharged out-of-hours, and people who are 
unable to contact the service during typical work hours).  
 
“Seven days a week would improve it. If you were discharged on the Friday 
night, being in the situation I was in, I would’ve been very concerned.” (P9, Female, 
Patient) 
 
Additionally, only one participant had a negative experience of contacting a 
PMHS, when they contacted the service for a second time. Here, the helpline team 
were not available to take the call. The participant left a message on the PMHS 
answerphone and was not called back.  
 
“I’m wondering if… a vulnerable patient was calling hoping to get some kind of 
reassurance,… and left a message and they weren’t called back, they would 
mistrust this service.” (P6, Female, Patient) 
 
Theme 2: PMHS are best-placed to help 
 
Reduced burden upon other services 
 
Participants considered their PMHS to be best-placed to help for several 
reasons. Primarily, participants spoke of the importance of returning to the place 
where they recently received care, rather than seeking advice elsewhere. Many 
participants felt that they would contact the hospital anyway, had the PMHS not 
existed. 
 
 “As far as I was concerned. I’d just left the hospital, so I reckoned they 
[PMHS] would know.” (P28, Female, Patient) 
 
There was recognition that contacting the PMHS could reduce the burden upon 




participants described not wanting to burden other healthcare services. PMHS 
providers were perceived as having more time to answer queries compared to other 
HCPs, particularly hospital consultants and GPs. 
 
“Hospitals and doctors are extremely busy, and some of the queries you might 
have might be very trivial, and take up time, which is not the best use of the medical 
practitioners’ time. Some of those issues, if you can deal with a call to this helpline, 
then I think it’s in everybody’s best interest.” (P31, Male, Patient) 
 
A source of expertise 
 
Participants spoke of the PMHS having the knowledge and resources to deal 
with enquiries that other HCPs would not necessarily have (e.g., access to medical 
records; an overview of their multiple health conditions and medicines regimen). 
 
 “There’s no point ringing up the doctor. Because they aren’t specialised in all 
this treatment, you know. So that’s why we rang the [PMHS].” (P1, Female, Carer) 
 
Relatedly, participants described the benefit of speaking to a pharmacy 
professional regarding their medicines, since pharmacists are experts about 
medication and their advice can be trusted. Participants often described this as 
providing them with the reassurance needed to take their medicines as advised, 
particularly when taking multiple medicines, when the potential for mistakes is 
increased. 
 
“To make sure that whatever you’re proposing to do has at least been under the 
eye of a pharmacist, makes you feel reassured that you’re not doing anything that 
you shouldn’t.” (P21, Male, Patient) 
 
Positive personal qualities 
 
Participants also spoke of helpline staff as having positive personal qualities, 




anxious. Several participants compared the positive experience with the helpline 
staff to less positive experiences with other HCPs (e.g., their GP). Positive personal 
qualities of helpline staff included being professional, calm, compassionate, down to 
earth, having good listening and communication skills, being knowledgeable and 
confident, being thorough, going above and beyond what they wanted, not being 
dismissive, and working with the patient to devise a plan to support them.  
 
 “The person who I dealt with, she listened, she was compassionate, she 
normalised how I was feeling, and then in order to help alleviate the distress that I 
felt she made a plan that would reduce the distress that I was feeling. And it was a 
really really positive experience.” (P37, Male, Patient) 
 
Helpful but hidden 
 
 Although PMHS were considered best-placed to help, awareness of the 
service was sometimes poor. A number of participants described how they were not 
initially aware that the PMHS existed (e.g., they called the hospital and were 
transferred to the PMHS). There was recognition that PMHS should be promoted 
more, since they are considered beneficial and could help a greater number of 
patients. 
 
 “I wasn’t aware it was available… So I think the more that they can let 
people know that the service is available, the better.” (P36, Female, Carer) 
 
 Suggestions for improving promotion of PMHS included pharmacy 
professionals visiting wards to tell patients about it, putting posters up around the 
hospital and in the local area (GP surgeries, local pharmacies), and advertising 
within discharge summaries. However, one participant struggled to find the contact 
details within their discharge summary, and was initially unsure what the service 







 “Almost put a bit more higher priority… Because it was buried along in page 
three or five. I wouldn’t have known how I could use that service, or if it was a 
priority I could use them, or whether I should try other routes before I use them.” 




This study explored forty service users’ experiences of using an NHS PMHS. 
Two themes were identified during the analysis: Timeliness, and PMHS are best-
placed to help. The findings illustrate how PMHS meet patients’ and carers’ needs 
for timely and easily accessible support, and for enquiries to be quickly resolved. 
However, PMHS may not always be considered a timely source of support, since 
the service is not available all the time. PMHS could therefore be improved by being 
available during evenings and at weekends. Additionally, providing a PMHS with an 
answerphone will mean that service users will experience a delay to receive help, 
and there may be a risk that messages are missed. PMHS were perceived to be 
uniquely placed to answer medication queries that arose from hospital care, and 
were more positively viewed as approachable and valuable when compared with 
other sources, such as GPs. However, several participants were initially unaware 
that the service existed, and so, increasing the promotion of PMHS would ensure 
that more patients have access to timely help when it is needed. Relatedly, 
increasing the promotion of PMHS will only be useful if the promotional materials 
are clear as to who the service is for, and what the service provides. 
 
Our findings accord with those of a recent systematic review and a literature 
review that examined the evidence regarding the effectiveness of medicines 
information services for patients and the general public, both within the UK and 
internationally.(18, 42) Based upon survey study findings, the systematic review 
concluded that such services are typically perceived positively by service users 
(e.g., satisfaction ratings are excellent), and users report several positive outcomes 
such as feeling reassured.(18) Our qualitative study found that PMHS provide 
reassurance to service users during the transition of care period when service users 
may be feeling particularly vulnerable. Their anxieties were alleviated by having 
quick access to an expert who had the skills to address their enquiries efficiently 





Our findings also are consistent with two survey studies examining the 
provision of PMHS in the UK.(15, 43) The most recent of these was conducted in 
2017, and surveyed all NHS Trusts in England in order to examine whether Royal 
Pharmaceutical Society endorsed national standards for providing a PMHS were 
being met.(15, 44) This survey identified that both the availability and promotion of 
PMHS were below standard. For example, out of 117 Trusts that provided a PMHS, 
only 57% reported that their PMHS was available for eight or more hours per day, 
and only 7% reported that their PMHS was available out-of-hours, such as during 
evenings and weekends. Additionally, only 40% of Trusts used promotional material 
describing PMHS access times and the types of enquiries that patients/carers can 
make. Under-promotion was also identified as an issue in a recently conducted 
qualitative study exploring thirty-four pharmacy professionals’ perceptions of 
providing PMHS.(45) Under-promotion was perceived by pharmacy professionals as 
a reason why PMHS are underused. Additionally, some pharmacy professionals 
described how their PMHS is under-promoted for fear of not being able to cope with 
the demand due to lack of resources to adequately deliver the service. Promotion of 
PMHS is important because if patients do not know that the service exists, they 
cannot utilise it, thus the opportunity to resolve medicines-related issues is missed. 
This may result in harm to patients. An evaluation of 500 calls to one PMHS at an 
acute NHS Trust found that 48% of issues may have resulted in patient harm had 
professional information from the helpline not been available.(46)  
 
Recommendations for practice 
 
Study findings suggest that to better meet the needs of the service users, the 
provision of PMHS could be improved by extending their opening hours so that they 
are available during evenings and weekends. Providers should also ensure that 
helpline staff are available to answer the telephone rather than using answerphones. 
The promotion of the service could be improved to increase knowledge of the service 
among patients and carers. Such promotion could include ward pharmacists telling 
their patients and patients’ carers about the PMHS during ward rounds, and by 
advertising the PMHS clearly in patients’ copies of their discharge summaries. 
However, we appreciate that the above recommendations may be challenging since 
PMHS are often established without funding and are often provided within a resource-
limited context.(43, 45) Because our findings described in this study and in a recently 




patients,(18) budget holders/commissioners should consider whether they should fund 
new PMHS. This is important, since a survey study conducted in 2017 reported that 
only 52% of NHS Trusts provided a PMHS.(15) 
 
Recommendations for future research 
 
Future research is needed to better understand the needs of patients and 
carers when contacting a PMHS, particularly pertaining to service availability, methods 
of access, and promotion. One option could be to conduct a large, prospective, multi-
site mixed methods survey, with enquirers of all ages, in order to enhance the 
generalisability of the findings. Another option could be to conduct a discreet choice 
experiment in order to elicit potential service users’ preferences regarding the provision 
of PMHS, such as the availability, access, and promotion of the service. Further 
research is also needed to explore the experiences of patients and carers who have 
problems or queries regarding medicines following hospital discharge, yet do not 
contact their Trust’s PMHS. This may result in additional recommendations to improve 
the awareness and use of PMHS.  
 
Strengths and limitations 
 
This is the first study to take an idiographic approach to exploring service 
users’ perceptions of PMHS, thereby providing rich and contextualised accounts of 
PMHS use that have resulted in recommendations for service improvement and future 
research endeavours. Service users were recruited from seven NHS Trusts from 
different regions within England in order to include a broad range of experiences of 
PMHS use. Additionally, consideration was made throughout the study to enhance the 
validity and trustworthiness of the findings. However, providers of the service acted as 
gatekeepers to participants, which may have resulted in selection bias. Furthermore, 
the sample predominantly comprised service users from acute NHS Trusts, and 
therefore could have been improved by the addition of service users from other Trust 
types (e.g., mental health, specialist, and community Trusts). Finally, the sample may 
also be limited since participants had already chosen to contact a PMHS and may 








PMHS are seen as a valuable means of easily accessing timely medicines-
related support during a transfer of care period, when patients and carers may be 
feeling particularly vulnerable. PMHS were perceived as best-placed to answer 
enquiries that arose from hospital care. PMHS were also perceived as the optimal 
service in terms of knowledge and expertise with regard to answering questions about 
medications. However, the availability and promotion of PMHS could be improved. We 
recommend that providers of PMHS consider whether this is achievable, in order to 
better meet the needs of service users.  
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8.4 Chapter 8 summary 
 
 This chapter presented the findings of the final study of this doctoral 
research. This was a qualitative study exploring service users’ experiences of 
contacting PMHS. The two themes generated from the analysis show that service 
users value having timely access to pharmacy professionals who they consider are 
best-placed to help them at a time when they may be feeling particularly vulnerable 
and anxious regarding their medicines. However, the findings also suggest that the 
availability and promotion of PMHS could be improved. This accords with previous 
findings from studies comprising this doctoral research. For example, Study 1 used 
survey methods to establish that the promotion and availability of PMHS in England 
are not meeting national standards for operating a PMHS. Additionally, the 
qualitative study of pharmacy professionals’ perceptions of PMHS showed that 
pharmacy professionals perceived the promotion and availability of their PMHS to 
be suboptimal, and attributed this to not having sufficient resources to provide the 
service.  
 
The development of the data collection tool for this study was, to some 
extent, informed by the RE-AIM framework (48). RE-AIM comprises five dimensions 
(Reach, Effectiveness, Adoption, Implementation, and Maintenance), and all five of 
its dimensions comprise sub-elements that should all ideally be explored in order to 
establish the impact of an intervention or service (49). However, depending on the 
study being conducted, it may not be appropriate to examine all aspects of RE-AIM. 
For example, in order to examine all aspects of the RE-AIM framework, both 
quantitative and qualitative methods are needed, and the perspectives of both 
service providers and service users are required (49). Service users will only be 
able to comment upon those aspects of the intervention or service that they 
experienced as a user. Therefore, they may be well-placed to comment upon the 
use of the service in order for recommendations to be made to improve its 
implementation. They will also be able to describe their experiences of the 
effectiveness of the service. However, they are not well placed to answer questions 
pertaining to the adoption and reach of the service, since these aspects have 
nothing to do with their experience of using one PMHS on one occasion. They 
could, however, describe the longer-term effect (if any) that the service had upon 
them. This is a sub-element of the Maintenance aspect of the framework. However, 




using the helpline service, it was not possible to ask questions about the longer-
term effect that the advice may have had upon them. Therefore, the focus of this 
study in terms of the RE-AIM framework was on the Effectiveness and 
Implementation aspects only. Relatedly, the Implementation aspect primarily 
focused upon the national standards for providing a PMHS, namely the access, 
availability, and promotion of the service. However, participants were given the 
opportunity to describe their experiences of using the helpline service beyond these 
three aspects, so that a broader understanding of their use of PMHS could be 
established. 
 
A limitation of this study is that helpline providers acted as gatekeepers to 
study participants. This likely resulted in selection bias. Helpline providers had the 
opportunity to not invite enquirers if they felt that inviting them would be 
inappropriate (e.g., if the enquirer was upset, or angry). However, interviewing such 
individuals about their experiences of the helpline services could have resulted in 
novel data, and may have resulted in additional recommendations for improving 
these services. Ideally, all individuals who contacted the seven PMHS during the 
six-month recruitment period would have been invited to participate in this study. 
Prior to starting this study, discussion with potential research sites made it clear that 
they would not participate in the study without this exclusion criteria. Therefore, our 
research question could only be investigated by allowing helpline providers to 
choose who to invite.  
 
The theme ‘PMHS are best-placed to help’ shows that participants perceived 
the helpline services to be the most appropriate place to receive help for the 
enquiries that they had. This was often in comparison to other options, such as their 
GP, a consultant at the hospital, or the ward where they stayed during their 
admission. Participants felt that calling the PMHS resulted in them having more time 
to discuss their issue (compared to, for example, contacting their GP), and that the 
helpline pharmacists based at the hospital were best-placed to answer questions 
about medicines that were changed or started as a result of a hospital stay. They 
were seen as a source of expertise. Additionally, participants were very 
complimentary about the care they received during the helpline call. All participants 
described the person who helped them positively, using words such as 




skilled. However, it is unknown as to whether helpline providers are typically like 
this, or whether participating in the study modified their behaviour to increase the 
likelihood that participants in the study would be complimentary of the service and 
the helpline provider.   
 
 Since this was the final study of the doctoral research, the next and final 
chapter of this thesis provides a general discussion of the five studies, and their 
contribution to the wider literature around PMHS. 
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Chapter 9: General Discussion 
 
9.1 Overview of chapter 
 
This chapter provides a general discussion of the research conducted for 
this doctorate, which examines the impact of NHS patient medicines helpline 
services (PMHS) upon service users and healthcare organisations using the RE-
AIM evaluation framework. The chapter begins with a summary of the main findings, 
in order to answer the research question. Next, the main study findings are 
discussed in relation to relevant literature pertaining to medicines information 
services, and pharmacy services research more broadly. This section ends with a 
discussion of the potential future direction of MI services for patients and carers. 
Following this, the strengths and limitations of the research are discussed, along 
with potential avenues for future research. Finally, the chapter ends with 
recommendations for clinical practice, and concluding thoughts. 
 
9.2. Summary of findings from this doctoral research 
 
The aim of this research was to address the following question: What is the 
impact of National Health Service patient medicines helpline services upon service 
users and healthcare organisations? To examine the impact of PMHS, the RE-AIM 
evaluation framework was used throughout this research (1). The RE-AIM 
framework conceptualises the impact of an intervention as the product of its reach, 
effectiveness, adoption, implementation, and maintenance.  
 
The findings across all five studies suggest that PMHS have the potential to 
provide timely medicines-related support to patients and carers following discharge 
from hospital. A systematic review of the literature regarding enquiries to PMHS 
show that this service provides information pertaining to medicines such as adverse 
effects, administration and dosage, interactions, and efficacy. PMHS also support 
patients and carers by correcting medication errors (e.g., providing supplies of 
medications missing from discharge prescriptions). PMHS are perceived as 
effective and valued from the perspectives of pharmacy professionals who provide 
them, and patients and carers who use them. However, the evidence generated 
from this research regarding the effectiveness of PMHS is limited by primarily 




data) rather than hard outcomes (e.g., readmission rates, symptoms and disease 
recurrence). The findings from this research also show that, despite their perceived 
benefits, the insufficient adoption, implementation, and reach of PMHS hinders their 
overall impact. The insufficient adoption, implementation and reach of PMHS are 
perceived to be consequences of limited resources and staffing. For example, 
limited resources and staffing are barriers to providing a PMHS, and also negatively 
affect the availability and promotion of extant PMHS. This means that PMHS may 
not be able to help all of the people who want to seek support regarding their 
medicines following hospital discharge. However, despite limited resources and 
staffing, the findings from this research suggest that once adopted, PMHS are likely 
to become a relatively stable service for NHS Trusts. This may be a consequence of 
PMHS being perceived by their providers as being beneficial and valued, and 
providing job satisfaction.  
 
Based upon the findings from this research, which primarily comprise survey 
and qualitative data, it cannot be concluded that PMHS are effective in terms of 
hard outcomes. Nor does the research show that good implementation (i.e., strict 
adherence to the national standards) result in improved outcomes. Thus, the 
findings from this research are unlikely to result in all NHS Trusts providing a 
PMHS, nor helpline providers strictly adhering to all of the national standards for 
operating a PMHS. However, the findings do suggest that PMHS provide value to 
patients and carers at a time when they are feeling particularly vulnerable. 
Additionally, the findings also highlight that, currently, the NHS does not provide an 
adequate nor efficient support system for patients and carers who wish to seek 
information regarding their medicines during the transition from secondary to 
primary care. 
 
9.3 Findings in relation to the wider research context 
 
The following sections briefly describe how each of the five elements of RE-
AIM were examined throughout the five studies comprising this research, 
summarises the findings that were generated, and compares the findings to relevant 
literature. The five elements of RE-AIM have been re-ordered here so that ‘AIM’ 
precedes ‘RE’, since the existence and delivery of an intervention precedes its 








The adoption of PMHS was examined in Studies 1 and 4 only, because 
these two studies explored the provision of PMHS from the perspectives of 
pharmacy professionals, who are ideally placed to have an opinion on why their 
PMHS was adopted, or why they have not adopted a PMHS.  
 
A common theme across Studies 1 and 4 is that one of the biggest 
challenges to adopting a PMHS is inadequate funding and resources. Lack of 
resources/ funding was the main reason why almost half of NHS Trusts did not 
provide a PMHS, suggesting that this is an important barrier to providing this 
service. Resources was also one of two themes that were generated from the 
analysis from interviews with pharmacy professionals regarding their PMHS. In line 
with the findings from Study 1, many participants described the lack of specific 
funding and resources for their PMHS, and how their service was set up as an 
additional role for the hospital pharmacy team regardless. Lack of resources and 
staffing have also been found to be reasons for limited adoption of other pharmacy 
services, such as optional ‘enhanced’ services within community pharmacies (2-7). 
 
The survey study (Study 1) also found that there was disparity of adoption of 
PMHS within England, since this varied according to type of Trust and region. This 
shows that there is inequity in the provision of medicines-related support following 
hospital discharge, with patients of mental health and community services being at a 
disadvantage compared to patients of acute and specialist services. This accords 
with a growing body of research showing that there are inequalities in healthcare 
provision for individuals with mental illness (8, 9). Additionally, the proportions of 
Trusts in the North and Midlands of England that provided a PMHS was typically 
lower than the proportions of Trusts in the southern regions of England. These 
findings also highlight how the lack of adoption of this service affects its reach (i.e., 
it is not reaching those patients and carers who may need help, from the Trust types 




The implementation of PMHS was examined in Studies 1, 4 and 5, primarily 
focusing upon the access, availability, and promotion of PMHS. In the survey study 




PMHS was examined by comparing how current practice meets with national 
standards for operating PMHS. Adherence to the standards could be improved 
regarding all three aspects of providing a PMHS (compliance with all standards 
pertaining to PMHS availability, access, and promotion, was 5%, 15%, and 2%, 
respectively). In the qualitative studies of pharmacy professionals’ experiences and 
perceptions of providing a PMHS, and service users’ experiences of contacting a 
PMHS (Studies 4 and 5, respectively), participants in both studies perceived that the 
availability, access, and promotion of PMHS could be improved. The findings from 
Studies 4 and 5 therefore correspond with the findings from Study 1. 
 
9.3.2.1 Availability of patient medicines helpline services 
 
Studies 1 and 4 show that the availability of PMHS could be improved, since 
only about half of PMHS are available throughout the day during typical working 
hours, and very few Trusts provide their PMHS out-of-hours (i.e., evenings and 
weekends). Pharmacy professionals also described how a consequence of limited 
funding/resources is that the availability of PMHS may be inadequate. In Study 5, 
service users expressed how PMHS could be improved with staffing beyond typical 
working week hours, with some feeling concerned about needing the service when it 
was unavailable. This highlights that PMHS may not always be considered a timely 
source of support, since the service is not available all the time. 
 
Little research has explored service users’ preferences regarding the 
availability of pharmacy services. However, the research that has been conducted 
accords with the findings from this doctoral research. For example, two studies have 
examined the importance of availability of community pharmacy services (10). The 
first was a survey study  by Krska et al., published in 2010, which examined the 
views of three hundred members of the general public on the role of community 
pharmacies in public health (11). One of the main facilitators to using community 
pharmacies was their long opening hours. However, a limitation of this study is that 
respondents were recruited from one city within one region of England, and so the 
findings may not be representative of the general population. Similarly, only one 
mode of data collection was used (face-to-face, with questions asked verbally), 
which may have resulted in biased responses. The second study was a large survey 
conducted by Saramunee et al., and published in 2016 (n = 2,661) (12). 
Overcoming the limitations of the study by Krska et al., data were collected using 




telephone, or by post), and recruitment was conducted within fifteen regions of 
England. Saramunee et al. found that the majority of respondents reported 
preferring community pharmacies to be open on a Saturday (approximately 65%), 
with about half of respondents wanting community pharmacies to be open on a 
Sunday (approximately 46%). Additionally, over half of respondents endorsed 
community pharmacies being available in the evening, particularly amongst those 
working full-time. A limitation of this study is that response rates for the three modes 
of data collection were low (approximately 20%), which may have resulted in biased 
responses (response rate for the study by Krska et al. was not reported). 
 
As with PMHS, studies of enhanced community services show that the 
numbers performed are dependent upon pharmacists’ availability (e.g., the working 
hours available to conduct reviews; available time away from core responsibilities) 
(4, 6). Studies also suggest that, once adopted, the implementation of healthcare 
services within the NHS more widely, not just within pharmacy services, can be 
limited due to inadequate staffing and resources (13-16). The NHS has struggled to 
meet the rising demand of the health and care needs of the population within the 
constraints of available resources, particularly during  the period of austerity, which 
has seen a reduction in the average annual NHS budget increase (1.1% per year 
between 2009/10 and 2020/21, compared to the typical average of 3.7% per year 
since the NHS was established) (17). Efficiency is therefore an important value in 
healthcare provision, where limited resources need to be used carefully and 
thoughtfully in order to maximise positive outcomes with what is available.  
 
9.3.2.2 Access of patient medicines helpline services 
 
The findings of Study 5, which explored service users’ experiences of using 
PMHS, show that patients and carers value easy access to medicines information, 
and that contacting a PMHS results in quicker access to help than contacting a GP. 
Ease of access to pharmacy services has been found in other studies. For example, 
in a systematic review by Hindi et al., (10) community pharmacists were perceived 
to be more accessible for situations that were considered by service users as not 
serious enough or worthy enough of GP’s time. Additionally, participants in such 
studies often mentioned easier access in relation to not having to book an 





Findings from this PhD also suggest one potential way to improve access to 
PMHS is to provide additional access methods other than the telephone. Options 
may include email, online chat, or video consulting (VC) (e.g., via Skype or Zoom). 
The 2019 NHS long-term plan mandates that patients and carers will have access 
to healthcare services online via VC within the next five years (18). Additionally, the 
covid-19 pandemic is accelerating the expanded use of VC for providing healthcare 
services that do not require attending a healthcare setting (19). For this doctoral 
research, the survey study examining the operation of PMHS in England found that, 
in 2017, no NHS Trusts were providing their PMHS via VC. Similarly, a recent study 
that surveyed GP practices in five areas of the UK found that none were providing 
VC as an access method for patients (20). However, some VC services are now 
available (21, 22), and studies suggest that there is a demand for VC from patients 
(23, 24). For example, a recent qualitative interview study by Donaghy et al. 
explored the acceptability, benefits, and challenges of VC in primary care, between 
patients and clinicians (24). They found that patients and clinicians considered VC 
as superior to telephone consultations regarding reassurance, building rapport, and 
communication, as a result of having visual cues. VC was also considered 
potentially useful as time-saving alternatives to face-to-face consultations. However, 
technical issues were common, and the technical infrastructure required to allow VC 
to become routine was considered a significant barrier. The latter may no longer be 
an issue, though, because the covid-19 pandemic is accelerating the expanded use 
of VC for providing healthcare services that do not require attending a healthcare 
setting (19). 
 
Relatedly, Hammersley et al. conducted a non-randomised, quasi-
experimental study to compare the content, quality, and experience of VC, 
telephone, face-to-face consultations with NHS GPs (25). The study found that both 
VC and telephone consultations were comparable in terms of content and quality. 
This suggests that VC may also be a useful access method for PMHS. Participants 
chose the access method they preferred, with younger patients typically opting for 
VC. Similarly, a study by Johnston et al. found that, out of a survey of 270 patients 
in Scotland, patients under 60 years of age were over two-times more likely to use 
VC, if it were available (23). These findings are important regarding the use of 
PMHS. The qualitative study of service users’ experiences of PMHS (Study 5) 
suggested that enquirers would prefer to access the service via telephone, but that 
other options (e.g., email, apps, and VC) might be more appealing to younger 




of participants in this study was 68 years, and that all participants in this study were 
chosen to be participants because they opted to contact a PMHS (i.e., a telephone 
helpline). Therefore, it may be possible that the sample selection process filtered 
out individuals who would prefer to contact the service via other methods. 
 
To date, no high quality studies, such as randomised controlled trials, have 
been conducted that examine patients use of, and preferences for, accessing NHS 
advice services by telephone versus online. This is surprising, since NHS 111 is 
now available online (26), and two NHS apps have been developed; one for patients 
to book appointments to see a GP (27), and another for patients to access a virtual 
assistant to check minor symptoms and to offer basic advice (28). However, a study 
by Eminovic et al., published in 2004, examined 25 patients’ experiences and views 
of using a pilot web chat for NHS Direct (29). They found that web chat sessions 
lasted on average 30 minutes, which was twice as long as the average telephone 
call to NHS Direct. Additionally, participants provided their views regarding the use 
of the web chat version, suggesting that it was beneficial to be have information 
written down so that it could be re-read, and that access to NHS Direct via web chat 
is easier than by telephone.  
  
9.3.2.3 Promotion of patient medicines helpline services 
 
Across studies 1, 4 and 5, the promotion of PMHS was found to be minimal. 
For example, PMHS are typically not promoted at all of a Trust’s hospital sites, and 
pharmacy professionals described that their service is not sufficiently promoted, 
often as a result of lack of time and resources. Service users also reported that 
PMHS could be improved by increasing patients’ and carers’ awareness of the 
service via improved promotion. Pharmacy professionals also commented upon the 
link between the lack of promotion of their service, and its perceived underuse. 
Promotion of PMHS is important because if patients do not know that the service 
exists, they cannot use it, thus the opportunity to resolve medicines-related issues is 
missed. This may result in harm to patients (30). This highlights the link between the 
implementation of PMHS, and their reach. These findings accord with related 
literature, which suggest that there has been low public awareness, promotion, and 
uptake of extended community pharmacy services in the UK, such as Medicines 
Use Reviews (a review of a patients’ medicines following hospital discharge; (31)), 
New Medicines Services (support to help patients be adherent to new medicines for 




10, 33-45). Studies also show that community pharmacists who provide enhanced 
pharmacy services are aware that patients lack awareness of such services, and 
that they are under-promoted (5, 46-48).  
 
Despite a large body of research showing low levels of public awareness of 
services that community pharmacies offer, very little research has been conducted 
to explore the best promotional techniques for increasing the uptake of pharmacy 
services. A large survey study conducted by Saramunee et al., and published in 
2016, identified the promotional methods for pharmacy public health services that 
the general public consider as likely to influence them (12). From 2,661 responses, 
89.4% of participants endorsed promotion of pharmacy services via personal 
recommendation from a health professional. Other highly endorsed preferences 
were posters in GP surgeries (76.7%) or in pharmacies (71.0%). The findings by 
Saramunee et al. accords with the findings from this doctoral research. Service 
users also expressed a preference for being told by healthcare professionals about 
the availability of the Trust’s PMHS. However, this research also found that one of 
the least used promotional methods by pharmacy teams to promote their PMHS 
was having staff routinely tell patients about their PMHS. The most widely used 
promotional method was providing patients with leaflets or business cards about the 
service. However, business cards and leaflets may not be seen, which will affect the 




The maintenance of PMHS was examined in Studies 1 and 4. The findings 
suggested that, once adopted, PMHS are likely to become a relatively stable service 
for NHS Trusts. At the time of data collection in 2017, on average NHS Trusts had 
been operating for six years, with the longest service running for twenty-four years. 
Interviews with pharmacy professionals provided insight as to why PMHS are 
maintained. Findings highlighted the importance of ensuring that PMHS are 
embedded within NHS Trusts. For example, it is important that other staff know 
about the helpline and see its benefits, so that they value it as a source of support 
(e.g., it frees up their time by directing patients to it). This accords with literature 
pertaining to UK pharmacy services, which acknowledge the importance of other 
healthcare professionals knowing what pharmacists and their services can offer (5, 
6, 49-52). Additionally, in this doctoral research, pharmacy professionals reported 




which may also be another reason for maintaining it. Studies suggest that providing 
a helping and/or caring role can contribute to job satisfaction (53). However, roles 
with increased workload and limited patient interaction can contribute to pharmacy 
professionals experiencing job-related stress and decreased job satisfaction (54). In 
this doctoral research, pharmacy professionals also perceived several benefits to 
providing a PMHS, such as preventing patient harm, and correcting medicines-
related errors. Such perceived benefits may also be a motivator for maintaining a 
service that is not funded. Motivators for providing a PMHS, such as job satisfaction, 
perceived positive outcomes, and embedding the service within the wider 
organisation, accord with theoretical explanations for the maintenance of behaviour 
(55). For example, a systematic review of behaviour theories suggests that 
behavioural maintenance motives include enjoyment of behaviour and satisfaction 
with outcomes, and that the maintenance of behaviours is facilitated if there is an 
alignment between the behaviour (i.e., providing a PMHS) and one’s environment 
(i.e., support of the wider organisation) (55).   
 
Some Trusts reported previously operating a helpline that had been 
discontinued. The main reason for closure was a lack of resources/funding, which, 
as established above, was the main reason why Trusts do not adopt this service in 
the first place. Relatedly, some pharmacy professionals described the difficulty in 
obtaining funding due to the low number of enquiries received by the service. This 
suggests a difficult situation where the numbers of enquiries are too small to justify 
additional funding/resources, yet without additional funding/resources, the number 
of callers is unlikely to increase (i.e., not enough resources to promote the service 
and provide for the increased workload). Therefore, many PMHS may be unable to 




The findings from Studies 1, 3, and 4 suggest that the reach of PMHS could 
be improved. The median number of PMHS enquiries per Trust was just five per 
week, which accords with findings from previous studies (56-58). Five enquiries per 
week is less than might be expected when considering the number of discharges 
that occur at NHS Trusts (59), and that approximately 44% of individuals may 
experience medicines-related problems following discharge (60, 61). Relatedly, 
pharmacy professionals in the qualitative study (Study 4) also described that they 




include under-promotion of the service, and lack of availability of the service 
(including not being available out-of-hours).  
 
The reach of PMHS was explored further, whereby the characteristics of 
PMHS enquirers was examined through a systematic review of nineteen studies. 
Comparing PMHS enquiry data to Hospital Episode Statistics (HES) data, the 
findings showed that users of PMHS are broadly representative of hospital patients 
regarding gender, but not age. The age difference may suggest that PMHS are 
particularly valued as a source of support by people who are at heightened risk with 
their medicines, since there is an association between age and polypharmacy (62). 
 
The findings also showed that there is variability across Trusts as to who can 
use PMHS (e.g., not all Trusts allow outpatients or carers to use the service), which 
is another factor that will affect the reach of PMHS. Relatedly, some Trusts provide 
their PMHS to members of the public as well as patients and carers of their own 
Trust. Given that the promotion of PMHS to patients at NHS Trusts in England is 
often limited, and helplines are typically under-funded and under-resourced, it may 
be premature to also make the service available to members of the public. Members 
of the public have the options of seeking medicines-related support from other 
sources, such as NHS 111 and community pharmacies. However, this highlights 
that the public more widely also have a need to seek support regarding their 
medicines, and that consideration is needed as to how best to support everyone, 




The effectiveness of PMHS was examined in Studies 1, 2, 4, and 5. 
However, these studies all explore perceived benefits rather than hard outcomes 
(e.g., readmissions, symptoms, disease recurrence). This is because two of the 
studies were qualitative, and one of the other studies relied upon existing data 
(systematic review), which primarily comprised service user satisfaction survey 
data. These studies were designed and conducted for this doctorate since, at the 
start of the doctorate, there was a lack of high-quality research on this topic. 
Additionally, these studies have provided the foundations for further research. For 
example, this doctoral research has provided evidence of the lack of studies 





Across the PhD studies, the main perceived benefits of PMHS were avoiding 
or preventing harm to patients, improving patient medication adherence, providing 
patients with reassurance, helping to optimise patients’ medicines, supporting 
patients’ discharge, reducing the burden upon other healthcare services (e.g., 
primary care), and providing a mechanism for fixing issues before the result in 
formal complaints to the Trust. The findings from interviews with service users 
corroborated these findings, and added more depth. The findings illustrate how 
PMHS provide support during the uncertain transition of care period from hospital to 
home, when patients and carers often feel vulnerable because support is less 
available. Participants described how PMHS met their need for timely and easily 
accessible support, and quick resolution of their issues. PMHS were perceived as 
best-placed to answer enquiries that arose from hospital care. Participants 
described feeling reassured from speaking to pharmacy professionals. 
 
A precursor to NHS hospital pharmacy services providing MI to patients was 
hospital pharmacy services providing MI to healthcare professionals. The aim of this 
was to provide evidence-based information to hospital staff who experience barriers 
to searching and appraising the information themselves (e.g., lacking time, and 
lacking expertise in accessing, searching, and appraising resources and evidence). 
Findings from a systematic review of the clinical and economic impact of MI 
services for healthcare professionals, published in 2002, and a recently published 
literature review (63, 64) show that studies have also typically explored enquirer 
opinions of the service. Therefore, similar to the findings of this PhD, the evidence 
regarding the effectiveness of MI services for healthcare professionals is from 
subjective data rather than objective data. Hands et al. conclude their systematic 
review by noting that there is a lack of evidence that MI services for healthcare 
professionals influence patient outcomes (63). This is pertinent, since the same 
conclusion can be drawn regarding PMHS from the findings of this doctoral 
research.  
 
The findings from a recently published qualitative metasummary by Lilleheie 
et al. show that many patients describe the discharge process as an anxious time, 
partly because there is uncertainty as to what to expect following their discharge 
(65). A key finding from this doctoral research was that one of the functions of 
PMHS is to provide reassurance to patients at a time when they are feeling 
vulnerable and anxious. This was seen in both the qualitative study of pharmacy 




experiences of using PMHS (Study 5). Additionally, the systematic review 
examining the effectiveness of MI services for patients and the general public 
(Study 2) found that, on average, 65% of service users reported feeling reassured 
as a consequence of using a PMHS. Delivering reassurance is considered to be a 
core skill for healthcare professionals (66-68). Providing reassurance has the 
potential to improve health outcomes, and there is a wealth of literature showing 
that the impact of reassurance on outcomes is particularly demonstrable in 
individuals with conditions that are defined by subjective symptoms, such as chronic 
pain and irritable bowel syndrome (68-70). Reassurance may therefore be impactful 
when there is uncertainty. This is relevant regarding the effectiveness of PMHS, 
since patients and carers are contacting the service because they are uncertain 
about an aspect of their medicines and are seeking clarification from an expert.  
 
The findings from Study 5, service users’ experiences of using a PMHS, 
suggest that one of the reasons why PMHS result in service users feeling reassured 
is because of the professionalism and characteristics of pharmacy professionals 
who provide the service. Studies show that such characteristics are appreciated 
from pharmacy services more widely. For example, when visiting community 
pharmacies, service users report the importance of characteristics such as 
friendliness, approachability, knowledgeability, being non-judgmental, ability to build 
rapport, and possessing good communication skills (5, 11, 38, 40, 41, 46, 71-74). 
Studies also suggest that service users feel comfortable having discussions with 
pharmacy professionals (72, 75, 76), and that they may feel more comfortable 
discussing issues with pharmacy professionals compared to other healthcare 
professionals (e.g., their GP) (77, 78).  
 
The systematic review of the effectiveness of PMHS also reviewed studies 
that analysed the types of enquiries received to PMHS. The findings showed that 
PMHS may also be effective for correcting medicines-related errors and for 
potentially avoiding medicines-related harm. Medication errors can have significant 
health and economic consequences, such as adverse drug reactions, reduced 
medication efficacy, increased use of healthcare services, and death (79). Learning 
from medicines-related errors in order to implement methods for their reduction is a 
current NHS and worldwide healthcare priority (79). The national standards for 
operating a PMHS include having a mechanism in place to feed back to the Trust 
any medication problems and ‘systems errors’ identified by patients/carers in order 




pharmacies that provide a PMHS adhere to this standard, and whether there are 
specific barriers preventing this from happening. 
 
9.4 How should patients and carers receive support with medicines during the 
transition from secondary to primary care? 
 
One of the main benefits of using a PMHS as perceived by both pharmacy 
professionals who provide PMHS, and service users who use them (Studies 4 and 5 
of this doctoral research), is that PMHS are based at hospitals where the patient 
received care, and so access to relevant resources to deal with the enquiry are 
readily available. A recent study by Badiani et al found that, out of 200 enquiries to 
their PMHS, 75% of enquiries required access to local knowledge in order to 
address the issue (e.g., access to medical records and healthcare professionals 
involved in the patient’s care) (81). Badiani et al. conclude that their findings support 
the value of having a network of local PMHS, rather than a small number of 
centralised services.  
 
Relatedly, in two systematic reviews by Hindi et al., community pharmacists’ 
lack of access to medical records was perceived by the public and healthcare 
professionals as a significant barrier to community pharmacists’ extended roles in 
the wider health-care system (5, 10). Pharmacy professionals also view the transfer 
of information between hospital pharmacy and community pharmacy as poor (82). 
Additionally, patients and the public view community pharmacists’ lack of access to 
relevant health-care providers as another potential barrier to community 
pharmacists being able to help them (10). These findings, along with the findings of 
this doctoral research, suggest that PMHS are best-placed within NHS Trusts where 
patients’ received care, rather than provided by other potential sources of support, 
such as community pharmacies. However, this may no longer be the case if 
community pharmacies also had access to the relevant resources required to 
address service users’ MI queries. Many community pharmacies do now have 
access to patients’ Summary Care Record, which provides them with the patients’ 
list of GP medications (83). However, this list will not include hospital discharge 
medications until it has been updated by the patients’ GP. Therefore, there could be 
a delay for patients seeking support from community pharmacists pertaining to 





In the UK, extending the role of community pharmacists beyond traditional 
dispensing and supply is valued as an opportunity to demonstrate the worth of the 
profession, and to further develop the skills of community pharmacists (84). The 
Royal Pharmaceutical Society’s guidance on discharge and transfer planning 
recommends that community pharmacists, as well as general practitioners and 
patients, are informed about patients’ medicines following hospital discharge, in 
order to prevent adverse events and to reduce readmissions (85, 86). These 
guidelines highlight the potential of technology to improve transfer of medicines-
related information between hospital and community pharmacies.  
 
The new community pharmacist contract for England has outlined plans for 
an essential medicines reconciliation service, the NHS Discharge Medicines 
Service, to come into effect from July 2020 (87, 88). This builds upon the Transfers 
of Care around Medicines (TCAM) services that some NHS Trusts have been 
providing since 2014 (89). TCAM enables NHS Trusts to send referrals to 
nominated community pharmacies regarding patients that need additional support 
with their medicines after leaving hospital. Along with the referral is the ability to 
access the relevant patient’s discharge documentation and records. The community 
pharmacy is then able to accept or reject the referral, and if accepted, will contact 
the patient for a post-discharge support consultation. Two main platforms used for 
TCAM are PharmOutcomes and Refer-to-Pharmacy, and studies have been 
conducted to evidence their benefits (89-92). NHS England has commissioned 
Academic Health Science Networks (AHSNs) to roll out TCAMs to 50% of acute 
Trusts in England by the end of 2020 (89, 93). An evaluation of one TCAM, 
published in 2020, found that patients followed up by a community pharmacist after 
being discharged from hospital were significantly less likely to be readmitted to 
hospital within thirty days (94). However, this was not a randomised controlled trial; 
it was an observational study comparing referred patients who were accepted for 
intervention compared to referred patients who were not accepted for intervention. 
Therefore, the groups were not even matched. This study design is typical of the 
available evidence pertaining to the TCAM scheme (90, 91, 95), and so, higher 
quality research is needed to establish the effectiveness of this scheme for reducing 
readmissions (i.e., a randomised controlled trial). Based upon the limited available 
evidence to date, the AHSN has estimated that TCAM saved the health economy 
more than 50 million pounds in 2018-2019 by reducing the number of hospital 





Since NHS England is aiming to eventually roll out the TCAM scheme to all 
acute Trusts (89), the transfer of patients’ admission and discharge information to 
community pharmacies could mean that community pharmacists may then be in a 
position to obtain the information required to answer medicines-related questions 
from patients and carers following their discharge from secondary care. However, 
this would require all hospital patients’ admission and discharge information being 
available to a nominated community pharmacy, and not just those deemed to be 
high-risk. Therefore, the TCAM scheme would need to be extended to be applicable 
to all patients. An advantage of providing PMHS is that they are available for 
patients regardless as to whether they are considered to be high-risk or not. Another 
advantage of PMHS are that they enable people who are ill to access support from 
their own homes. It is currently unknown whether the TCAM scheme will include the 
option of telephone consultations instead of having to travel to a community 
pharmacy in order to receive support. Additionally, a potential limitation of TCAM is 
that if hospitals do not provide an adequate out-of-hours discharge system, there is 
a risk that out-of-hours discharges will not get referred to the scheme. Out-of-hours 
discharges are also a high-risk for medication errors, meaning that this group of 
patients may not be referred to a scheme that could be particularly beneficial for 
addressing such errors.  
 
There is also the potential that, in the future, pharmacy professionals at GP 
surgeries may also be able to answer MI enquiries from patients following hospital 
discharge, provided that they also have all of the necessary resources. A 
collaborative pilot scheme is currently being conducted by NHS England, Health 
Education England, the Royal College of GPs, the British Medical Association’s GP 
Committee, and the Royal Pharmaceutical Society, to test the role and effectiveness 
of clinical pharmacists in general practice (96). The main aim of this pilot is to 
reduce the burden upon GPs by having practice-based pharmacists available to 
provide medicines-related support to patients. Thus, the improved sharing of 
discharge information from secondary care to primary and community care could 
enable patients to have a choice as to who to contact following hospital discharge if 
they subsequently experience medicines-related problems or would like information 
regarding their medicines. Providing patients with choice around their care is a priority 
for the NHS, so that patients can make informed decisions about their healthcare to 
best meet their needs and preferences (97, 98). An alternative view is that having 
three systems essentially serving the same purpose within different areas of the NHS 




that could be confusing to patients, and that a more efficient solution would be to have 
one system that is adequately resourced.  
 
It is also unlikely that community and GP practice-based pharmacists will be 
in a position to take over full responsibility of dealing with patients’ and carers’ 
medicines-related issues following patients’ hospital discharge. Since TCAM 
currently only applies to acute Trusts, non-acute Trusts (i.e., mental health, 
specialist, and community Trusts) may need to provide their own medicines 
information service to their patients. Also, TCAM will only be useful if hospital 
pharmacists send patients’ information to community pharmacists, and if community 
pharmacists then have the capacity and relevant MI expertise to respond to this 
information. Studies pertaining to other enhanced community pharmacy initiatives, 
such as Medicines Use Reviews and New Medicines Service, suggest that 
community pharmacy staff view providing such additional services as increasing 
their workload in an already pressured, time-limited environment (5-7, 48, 50, 74, 
101, 102). This suggests that community pharmacies may not have the capacity for 
providing a PMHS for discharged hospital patients in addition to their other roles. 
However, the current 5-year Community Pharmacy Contractual Framework has 
committed just over £2.5 billion to expand the role of community pharmacy, and 
support the introduction of clinical services such as TCAM (88). This suggests that, 
in the future, community pharmacy could possibly be better-resourced to support 
patients regarding their medicines than non-funded PMHS provided by NHS Trusts.  
 
Another potential issue for TCAM services is that not all queries to PMHS 
provided by community pharmacies are likely to be answerable, even if community 
pharmacies have access to resources pertaining to patients’ care via resources like 
PharmOutcomes. The Badiani et al. study described above found that, of 200 
enquiries received to their PMHS, 34% required contacting a hospital-based 
healthcare professional involved in the patient’s care (81). Therefore, it seems 
possible that approximately a third of enquiries would need to be transferred back to 
the hospital pharmacy services team in order to provide support to the enquirer. 
However, the finding by Badiani et al. is limited, since it comes from just 200 calls to 
one PMHS, where the evaluation was conducted by the providers of the service. 
This may have resulted in measurement bias, whereby the providers of the service 
coded the enquiries in favour of the service remaining local to hospitals, since they 
have a vested interest in the continuation of the service at the hospital (i.e., it is an 




enquiries that require consultation with a healthcare professional at the hospital 
could have been avoided. The doctoral research has shown that up to 39% of 
enquiries to PLMHS may concern errors. Had the errors not occurred, the enquiries 
to the PMHS would not have been necessary. Similarly, the qualitative study with 
pharmacists showed that helplines are perceived to be a safety net to also provide 
support due to inadequate discharge counselling. Had discharge counselling been 
adequately provided, a further number of enquiries may have been avoided. 
Therefore, the study design by Badiani et al. could be repeated, using researchers 
independent of the service, who not only establish the proportion of enquiries that 
definitely require support from the local hospital, but also take in to account the ones 
that could have been avoided. It could be that the number of enquiries definitely 
requiring support from the hospital where the patient received care is small. In which 
case, this would be a serious challenge to the argument by Badiani et al. that PMHS 
should be provided by each hospital within the UK (81). Arguably, there may no 
longer be a need for hospital-based PMHS, and patients and carers could get 
support with their medicines via a different route (e.g., their community pharmacist, 
or NHS 111). If hospital-based resources are required for some enquiries, a 
collaborative approach could be taken whereby community pharmacies are 
contacted with enquiries initially, and they are then able to contact the relevant 
hospital for additional information if required. This could also provide a mechanism 
for hospitals to conduct improvement projects whereby the content of enquiries are 
used to improve hospital services, therefore potentially reducing the occurrence of 
such enquiries in the future (i.e., enquiries concerning an error, inadequate 
discharge counselling, or inadequate information within the discharge summary).  
 
From the service user perspective, patients and carers would also need to 
be informed as to who to contact with medicines-related queries following hospital 
discharge (i.e., hospital pharmacy or a nominated community pharmacy). Patients’ 
perceptions about the role of community pharmacists suggest that there is 
confusion and lack of awareness over what additional roles are provided by 
community pharmacists, over and above the typical dispensing and supply of 
medicines (44, 103). Otherwise, such a service would suffer the same issue as 
PMHS, whereby their use will be hindered by inadequate promotion. 
 
In summary, although PMHS are often provided sub-optimally, the provision 
of medicines information and support to patients and carers following patients’ 




practice pharmacists are also likely to be limited. Currently, the pharmacy systems 
pertaining to secondary care and primary/community care exist largely 
independently and without reference to one another, and all provide services with 
limited resources. Thus, rather than having a system of multiple poorly funded ways 
for patients and carers to obtain medicines-related support following hospital 
discharge, co-ordinated thinking is needed to explore how best to provide such 
support. For example, a solution could be to devise one adequately funded 
approach that can then be widely promoted to patients and carers. This PhD has 
shown that there are certain characteristics of MI provision that are particularly 
important, and need to be considered when developing such a system. For 
example, the service needs to be timely, easy to access, well-informed about all 
patients’ care, and known about to all patients and carers at the point of discharge.  
 
Through conducting this doctoral research, my view is that all NHS Trusts 
should provide a PMHS (even if it is purely an answerphone service that is checked 
at least once a day), and that the content of enquiries should be used to improve 
hospital services where possible (e.g., reducing medicines-related errors, improving 
discharge counselling, and improving written information given to patients such as 
discharge documentation). Over time, this should reduce the number of enquiries to 
PMHS. Little research has been conducted to show that enquiries to PMHS can 
result in improvements to hospital services. Three studies reported healthcare 
quality improvement projects using data from their PMHS service. Green (104) and 
Hall (105) reported projects whereby helpline calls and experiences of service users 
were used to develop strategies to improve patient safety and discharge. Strategies 
included providing carers with more medicines information prior to discharge, 
highlighting problem areas such as errors to staff, and using types of calls received 
to improve patient information leaflets (e.g., if something is unclear). More recently, 
Bramley et al. conducted and published the findings of a quality improvement 
project for improving written information about medicines in patients’ discharge 
letters (56). This involved analysing the data from calls received in one year 
preceding the change, and reanalysing the calls received in one year after the 
change had been made. They found that, prior to the change, 24% of calls (n = 
98/413) concerned lack of information the discharge letter, and after the change, 
this decreased to 7% of calls (n = 32/475). However, all three of these studies were 
conducted by the providers of their own helpline, and further research is needed to 




content of enquiries to PMHS, and whether such improvements result in a sustained 
decrease in call volume over time.  
 
9.5 Overall strengths and limitations of this doctoral research 
 
The strengths and limitations of each of the five studies were reported in the 
studies’ discussion sections. Next, the overall strengths and limitations of the 
doctoral research as a whole are considered. 
 
9.5.1 Overall strengths of the doctoral research 
 
A strength of this doctoral research is that the RE-AIM framework was used 
throughout the five studies as a uniting framework. With RE-AIM, the emphasis 
upon the importance of translating research findings into practice accords with the 
principles of pragmatism, which aims to produce research findings that are useful 
and have beneficial consequences (106-109). Other frameworks have been 
developed for the purpose of evaluating healthcare interventions and services, such 
as the APEASE criteria, and frameworks proposed by Donabedian, Maxwell, and 
Higginson, to name a few (110-115). However, RE-AIM was chosen since it is the 
only framework that purports to examine the impact of interventions and services. 
Additionally, the RE-AIM framework was a useful tool for examining PMHS, since all 
five of the framework’s dimensions are relevant for examining this particular service. 
At the start of this doctorate, noticeable gaps in the literature were regarding the 
number of Trusts that provide a PMHS, the use of these services, an exploration as 
to how different Trusts provide their PMHS, and evidence regarding their 
effectiveness. RE-AIM acknowledges that the examination of the impact of an 
intervention requires greater understanding than solely focusing upon its 
effectiveness. RE-AIM also acknowledges that it is useful to examine an 
intervention by evaluating both the setting (i.e., NHS Trusts and pharmacy 
professionals who provide the service) and the individual (i.e., patients and carers 
who use the service). Using the RE-AIM framework has therefore ensured that the 
evaluation of PMHS has been more comprehensive than solely focusing upon 
exploring the effectiveness of these services. However, RE-AIM is a detailed 
framework, with each of the five elements comprising sub-elements that are 
considered by the framework’s developers as important to study when examining 
the impact of an intervention or service (116). Due to time and resource constraints, 




there was not enough time to explore the longer-term impact that the advice may 
have had upon service users), and this is discussed further in the Limitations 
section below.  
 
Another strength is that this research used mixed methods, which was 
important in order to address the overarching research question. Studies adopted 
either a quantitative or qualitative approach (Study 1 used a mixed approach, albeit 
weighted towards quantitative). Both quantitative and qualitative approaches have 
strengths and limitations; they enable different questions to be answered, and 
produce different types of knowledge (106, 108, 117, 118). In this research, 
quantitative methods have been useful for providing descriptive data in order to 
understand how many Trusts provide a PMHS, the different ways that PMHS are 
provided, and for whom. Additionally, quantitative methods have been useful for 
evaluating the effectiveness of PMHS, and the types of callers and enquiries, 
through the collation of quantitative data in the two systematic reviews. Qualitative 
methods have been useful for exploring pharmacy professionals’ and service users’ 
perceptions of providing and using PMHS, respectively. This has added a deeper 
layer of understanding to the quantitative data (e.g., understanding why PMHS were 
adopted by NHS Trusts, understanding the reasons why service users find PMHS 
beneficial, and establishing the ways in which PMHS could be improved). Thus, 
quantitative methods have been useful because of their generalisability of findings, 
and qualitative methods have been useful for providing depth and meaning. The 
combination of quantitative and qualitative methods results in what Turner and 
colleagues describe as complementary strengths and non-overlapping weaknesses, 
with the product being superior to that of monomethod research (108, 119). 
 
Another strength of this doctoral research is that data collection tools were 
developed with feedback from members of the public (e.g., individuals who had 
experienced a hospital discharge recently, or carers of such individuals), or 
pharmacists with expertise in MI. The National Institute for Health Research and the 
Health Research Authority define patient and public involvement in research (PPIR) 
as research that is carried out ‘with’ or ‘by’ patients and/or members of the public 
rather than ‘to’, ‘about’ or ‘for’ them (120, 121). PPIR is important because it results 
in service users feeling empowerment and valued, and it can offer unique and 
invaluable insights and expertise, making research more effective and credible 
(122-125). For this research, information sheets and data collection tools were 




professionals, in order to improve their readability and usefulness for collecting 
meaningful data that answered the studies’ research questions. Research suggests 
that PPIR is often not well reported in research articles (126). For example, Mathie 
et al. conducted a UK scoping study to establish the proportion of a selection of 
studies which had evidence of PPIR (126). They found that 51% of studies had 
some evidence of PPIR, and that the extent of this varied widely. Therefore, for 
transparency, publications from this doctoral research have clearly stated the extent 
of PPIR. 
 
Finally, another strength of this doctoral research is the use of checklists and 
tools to enhance the rigour and transparency of the studies. The Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were used 
during the planning, conducting, and reporting of the two systematic reviews 
(Studies 2 and 3) (127-130). The PRISMA guidelines and checklist were developed 
by a group of 29 review authors, methodologists, clinicians, medical editors, and 
consumers, with the aim of improving ways in which authors can ensure the 
transparent and complete reporting of systematic reviews and meta-analyses. Since 
Studies 4 and 5 were qualitative, the consolidated criteria for reporting qualitative 
research (COREQ) and the standards for reporting qualitative research (SRQR) 
were followed (131, 132), as recommended by the British Medical Journal (133). 
Designing, conducting, and reporting research studies is a complex process that 
involves many decisions. Checklists and tools are useful for ensuring that this is 
done systematically, by highlighting what should be done in order to conduct a study 
to a high standard, and to be transparent as to where deviations occur. The use of 
checklists and tools throughout this research have therefore enhanced the 
transparency regarding the decisions made.  
 
9.5.2 Overall limitations of the doctoral research 
 
With hindsight, a limitation of Study 1 is that the survey did not ask 
pharmacy professionals how their PMHS is funded (e.g., through an existing budget 
for medicines information or pharmacy services, or whether there is a specific 
budget just for the PMHS). This quantitative data would have been useful in relation 
to the findings from Study 4, in which interviewed pharmacy professionals described 
having limited resources and staffing to provide their PMHS. Limited resources and 
staffing was a significant issue, which is why Resources was one of the two themes 




not have specific funding for their PMHS would have been a useful addition to this 
qualitative finding. The only published data regarding the proportion of PMHS that 
are funded comes from a study Raynor et al., that was published in 2000 (i.e., that 
85% of 66 PMHS are funded through an existing budget). 
 
Also with hindsight, Study 5 could have been improved had a mixed 
methods approach been applied (108). In order to obtain the necessary Health 
Research Authority approvals in a timely way, Study 5 was designed before 
completing the systematic review examining the effectiveness of medicines 
information services for patients and the general public (Study 2). A 
recommendation for future research from this systematic review was that large, 
multi-site service user satisfaction surveys are needed, since the data primarily 
came from small, single-site service evaluation studies. Had this been known prior 
to designing Study 5, an arguably more useful design would have employed a 
mixed methods approach, in order to make better use of having recruited seven 
NHS trusts to act as participant identification sites. A PMHS satisfaction survey 
could have been posted to consenting PMHS users from the seven sites, with a 
subset of participants selected for further exploration of their experiences using the 
qualitative methods used in Study 5. This design would have filled an important 
knowledge gap, and would not have involved significant extra research time, given 
that the seven sites were already participating in the study. The mixing of 
nomothetic and idiographic approaches within a single study may have resulted in 
the generation of additional recommendations for improving the provision of PMHS 
than are reported in Study 5. Additionally, this design may have overcome a 
limitation of Study 5 in which PMHS providers acted as gatekeepers to participants, 
which likely biased the results (i.e., selection bias). For example, they had the option 
to not advertise the study to enquirers who may have experienced the service 
negatively. In the alternate mixed-methods design, enquirers would tick a box at the 
end of the survey, and include their contact details, if they were interested in 
potentially taking part in an interview to describe their experiences in more depth. 
This may have resulted in a broader picture of the experiences of individuals who 
use PMHS. However, selection bias may have still occurred to some extent for the 
mixed-methods design, given that providers of PMHS would still be required to post 
surveys to enquirers in the first place.  
 
A third limitation is that not all aspects of the RE-AIM framework were 




considered relevant for examining the impact of interventions and services (Reach, 
Effectiveness, Adoption, Implementation, and Maintenance). Each of these five 
elements comprises sub-elements. For example, Maintenance can be explored by 
examining the maintenance of the intervention/service over time, and also the 
longer-term impact that the intervention/service had upon the user. The former was 
examined in this doctoral research (Study 1 and Study 4), yet the latter was not. For 
this doctoral research, Implementation primarily focused upon comparing current 
practice to national standards. However, other aspects of Implementation not 
evaluated during this research were the consistency of delivery of PMHS as 
intended, the time and cost of the intervention, and adaptations made to the 
intervention. Similarly, the reach of PMHS could have been more thoroughly 
examined in this doctoral research. According to the developers of the RE-AIM 
framework, aspects of Reach include the percentage and representativeness of 
individuals who are willing to participate in a given programme (134). The evaluation 
of the reach of PMHS throughout this doctoral research has relied upon examining 
the average number of calls received to PMHS (Study 1), pharmacy professionals’ 
views as to who can use their service and why (Studies 1 and 4), and a systematic 
review examining the characteristics of enquirers of PMHS, comparing the data to 
relevant Hospital Episode Statistics data (Study 3). The latter is the only one from 
this research that therefore examined the reach of PMHS as defined by its 
developers. The data collected from the other two studies has still been useful, 
however, as proxy measures for reach (i.e., the low number of enquiries received 
suggests that the service could be used more, and knowledge regarding who can 
and cannot use PMHS helps to define what reach actually is). 
 
Relatedly, although the RE-AIM framework has been useful for examining 
five constructs that are conceptualised as being important for understanding the 
impact of interventions, there may be other constructs that are also relevant to the 
impact of interventions. For example, the APEASE criteria for evaluating 
interventions has some facets that overlap with RE-AIM, although an element of 
APEASE that does not overtly form part of RE-AIM is Acceptability (110). If an 
intervention is not considered to be acceptable, its use may be negatively affected, 
which will limit its impact. For APEASE, Acceptability refers to the extent to which an 
intervention is judged to be appropriate by relevant stakeholders. This could be a 
useful facet to examine in order to consider ways to improve PMHS, and to explore 
whether relevant stakeholders can think of better ways of supporting patients and 




framework seemed more relevant for the purposes of this research than the 
APEASE criteria, since there are useful elements pertaining to the evaluation of 
PMHS that are within RE-AIM but that are not within APEASE (e.g., adoption and 
reach). Additionally, at the time of choosing a framework for the research, the 
APEASE criteria was not evidence-based, and only a few studies had used it. This 
was another reason why RE-AIM was chosen, given that it was developed in 1999 
and has been widely used (1, 135). Acceptability was included in this doctoral 
research to some extent, as an element of effectiveness (i.e., in the systematic 
review examining the effectiveness of PMHS (Study 2) and the qualitative study of 
service users’ experiences of using a PMHS (Study 5)). 
 
A further limitation is that the doctoral research did not seek to establish 
whether compliance with the national standards for providing a PMHS results in 
improved effectiveness, nor whether the effectiveness of PMHS varies across sites 
irrespective of compliance to the standards. For example, even if all standards are 
met, the quality of the information provided to patients and carers may vary 
depending upon the skills and knowledge of the pharmacist they speak to, and the 
amount of time that pharmacists are able to give to dealing with the enquiry. Such 
potential variability was not examined within this doctoral research, yet it may have 
a significant impact upon the effectiveness of PMHS (e.g., whether the advice was 
understood, whether the advice was followed, and whether following the advice led 
to improved health and wellbeing).  
 
9.6 Ideas for future research 
 
Out of all the studies that could be conducted, a study examining the cost-
effectiveness of PMHS would likely have the most impact in terms of evidencing that 
PMHS are both needed and worthwhile (136). Therefore, a randomised controlled 
trial (including an economic evaluation) would be the ideal future project in terms of 
strength of evidence regarding the effectiveness and cost-effectiveness of PMHS. 
Since approximately 50% of NHS Trusts do not provide a PMHS, a stepped-wedge 
design could be appropriate in order to look at the progressive introduction of the 
helpline to patients at those sites that do not currently provide one (137, 138). A 
stepped-wedge design is becoming increasingly used to evaluate healthcare 
services that are already being provided but where the evidence for the 
effectiveness of the service is limited. It is particularly useful for evaluating 




routinely collected. This design could therefore be suitable in this respect for 
evaluating PMHS. However, conducting such a study is unlikely to be feasible due 
to the cost of recruiting sufficient Trusts to measure what is likely to be a small effect 
on hard outcomes (e.g., adherence, symptoms, disease recurrence). Additionally, 
this PhD research found that, on average, NHS Trusts receive five enquiries to their 
PMHS per week, and a stepped-wedge design would therefore be unlikely to see an 
effect, if any exist. However, the number of enquiries per week may increase above 
five, if the promotion of the PMHS within the trial is increased beyond that of extant 
PMHS within the NHS. For example, the range of enquiries received to PMHS, as 
established in Study 1, was 0-50 per week. Therefore, some Trusts received on 
average 50 enquiries per week. Exploratory analysis showed that number of 
promotional methods and number of hours of availability were both significantly 
correlated with number of calls received, suggesting that increasing the number of 
calls may be possible if improvements to helpline availability and promotion are 
made.   
 
Based upon the findings from the five studies conducted for this doctorate, 
and given that most prior studies have been service evaluations whereby providers 
of PMHS have conducted small-scale studies regarding their own service, there are 
many potential avenues for future research pertaining to PMHS. However, there are 
two in particular that would likely have the most impact regarding the provision of 
medicines-related support following hospital discharge. 
 
9.6.1 Future research study 1 
 
A more thorough approach for understanding the reach of PMHS would be 
to follow up a cohort of discharged patients from several Trusts that provide a 
PMHS, in order to explore those patients who subsequently require medicines 
information, and to compare the percentages and characteristics of PMHS users 
with patients who choose alternative sources of support. This study design could 
also provide an opportunity to explore patients’ reasons for not seeking MI via the 
Trusts’ PMHS, which would be useful for establishing further recommendations for 
improving the use of PMHS (i.e., to make the prospect of using them more 
appealing to such patients). This study could seek to address the research 










Potential participants could be asked to complete a survey approximately 
four weeks after they have been discharged from hospital. Four weeks would be 
appropriate, since previous literature suggests that medicines-related problems 
following hospital discharge are typically disclosed within this timeframe (60, 61). At 
the end of the survey, participants could provide their contact details if they would 
be willing to partake in a semi-structured interview to explore their experiences in 
more depth. This latter part of the design would be particularly useful to answer 
research questions 5 and 6 in Box 1.  
 
The survey part of the study could include the Satisfaction with Information 
about Medicines Scale (SIMS) (139), to assess patients’ satisfaction with the overall 
information they received about their medicines during discharge from hospital. The 
SIMS has had its psychometric properties assessed, showing satisfactory reliability 
and validity in patients from eight diagnostic categories (total n = 826) (139). The 
Box 1. Research questions for a hypothetical study to examine the reach of PMHS, and 
medicines information needs following hospital discharge 
1. What percentage of patients experience medicines-related issues in the month following 
hospital discharge?  
2. What types of medicines-related issues do patients experience following hospital 
discharge? 
3. What do recently discharged patients do in order to meet their medicines-related 
needs? 
4. What percentage of recently discharged patients are aware that their hospital operates 
a patient medicines helpline? 
5. What are recently discharged patients’ reason/s for choosing their source of medicines 
information and support? 
6. What are the barriers to seeking medicines information and support via an NHS Trust’s 




SIMS was not used in this doctoral research, since enquiries to PMHS typically 
pertain to one aspect of medication (e.g., administration, dosage, side effects, 
interactions), and the SIMS explores satisfaction with MI more broadly, such as MI 
received during hospital admission (140, 141). Therefore, the SIMS was not 
considered suitable for exploring the satisfaction of using a PMHS, since it was 
likely that only one of its seventeen items would have been relevant to each 
participant who used a PMHS. However, for this future research study, the inclusion 
of a relevant and psychometrically robust tool such as the SIMS would be 
advantageous for establishing gaps regarding people’s satisfaction with their 
medicines, and to help answer a broader question as to what information about 
medicines patients and carers actually need after discharge from hospital. The 
SIMS has been used for establishing what medicines information patients want 
(e.g., (142)), with findings from studies (those that used the SIMS and those that did 
not) suggesting that side effects, interactions, and duration of treatments are 
common information gaps (142-144). Establishing the needs that patients have 
regarding their medicines in a large, multi-site cohort study would be novel and 
informative for developing recommendations for providing services that can cater to 
their needs. 
 
This study design would therefore not only be useful to explore the reach of 
PMHS, but also to add to the evidence-base regarding the lack of MI provided 
during admission to hospital, and the need for MI support following hospital 
discharge. Regarding the latter, research suggests that between 36% and 44% of 
patients discharged from hospital within the UK will experience medicines-related 
problems (60, 61). However, this finding comes from two studies which had small 
sample sizes (n = 27, n = 96) (60, 61), and where one of the studies was conducted 
at just one NHS Trust, thereby limiting the generalisability of the findings (61).  
 
This study design would also be useful for examining patients MI needs and 
MI-seeking behaviours more broadly, rather than solely focusing upon individuals 
who use PMHS (e.g., calculating the percentages who seek medicines-related 
support via other sources such as GPs, community pharmacists, NHS 111, A&E). 
Broadening the scope would highlight how much of an impact medicines-related 
problems following hospital discharge have upon other services, such as primary 
care. Thus, examining what patients do regarding medicines-related problems 
following hospital discharge, and why, could result in strategies to improve patient 




pharmacy teams in secondary and primary care) which may help to reduce the 
demand on other healthcare services such as GPs and A&E, and reduce avoidable 
medicines-related readmissions. The study could also be useful for exploring 
potential differences in MI needs between service users of different Trust types. For 
example, service users of acute Trusts and of mental health Trusts may seek or 
desire support from different services, based upon their perceptions as to what 
services are available to them. Capturing such depth of information is why a mixed-
methods study design, with a qualitative semi-structured interview element, would 
be advantageous. 
 
9.6.2 Future research study 2 
 
Since NHS England has commissioned Academic Health Science Networks 
(AHSNs) to roll out Transfer of Care Around Medicines (TCAM) services to 50% of 
acute Trusts in England by the end of 2020 (89, 93), it may be possible for 
community pharmacists to answer MI queries from patients following their discharge 
from secondary care. However, as described above, having multiple yet poorly 
funded MI services may not be an efficient solution to the problem of supporting 
patients and carers with their medicines following hospital discharge. Currently, only 
half of Trusts provide a PMHS, not all Trusts yet provide the TCAM service, and not 
all GP practices employ a practice-based pharmacist. Moving forward, an important 
aim would be to consider and establish a system that is adequately resourced, 
efficient, and utilised, where patients know who to go to for MI support, and where 
whoever is dealing with the enquiry has all of the information to provide timely help. 
 
Another useful research avenue would therefore be to explore the views of 
relevant stakeholders (e.g., pharmacy professionals, service users, service 
commissioners) regarding how best to provide medicines-related support to patients 
and carers following hospital discharge. For example, focus groups could be 
conducted with hospital MI pharmacists, community pharmacists, chief pharmacists, 
GPs and general practice-based pharmacists, service users, and service 
commissioners, to establish their views regarding the future of PMHS, and also 
community pharmacists being a source of medicines-related support to patients 
following discharge from secondary care. Regarding the latter, such research could 
also explore the barriers and facilitators to achieving this, and seek the views of 
service users regarding the sources of support that they actually want, and the 




of survey methods, this could also provide another opportunity to establish patients’ 
needs regarding medicines information after being discharged from hospital, and a 
discussion with relevant stakeholders as to whether PMHS are currently able to 
provide such information. Ideally, each focus group with pharmacists would 
comprise an equal number of stakeholders. Additionally, each pharmacist type 
could be broken down further, to include hospital MI pharmacists from different NHS 
Trust types (e.g., acute, mental health, specialist), and to include community 
pharmacists from independent and branch pharmacies, in both rural and urban 
areas. Similarly, focus groups with service users could include a range of 
demographic and background characteristics (e.g., different genders and ages, and 
include both patients and carers), and service users from different NHS Trust types 
(e.g., acute, mental health, specialist) and different geographical areas (e.g., rural, 
urban). This would ensure that a wide range of views are captured, which is 
important for ensuring that services are developed to meet people’s needs. 
 
9.7 Recommendations for practice 
 
9.7.1 A system for supporting all patients with their medicines 
 
The findings from this research show that PMHS are valued, and have a 
number of perceived benefits for service users and healthcare organisations. 
Healthcare organisations that currently do not provide an MI service to patients 
should consider whether the evidence is sufficient to merit developing their own 
PMHS. However, the findings from this doctoral research also suggest that 
recommendations must be achievable within a resource-limited context. Therefore, 
it may not be possible for sites that do not currently provide a PMHS to do so. 
Nevertheless, in terms of equity, patients and carers of Trusts that do not provide a 
PMHS may be less able to receive timely and expert help with their medicines 
following their discharge, which could possibly result in them suffering as a 
consequence. Additionally, the same applies to Trusts that do provide a PMHS, but 
which has limited availability and/or is poorly promoted. Ideally, what is needed is a 
service, or co-ordinated system of services, that are available for all patients 
whenever they need help, so that anyone can easily access expert support with 
their medicines. Budget holders/commissioners and senior management within the 
NHS should consider how best to support patients after discharge, and whether this 




to be needed to establish the best way to achieve this, as described in section 9.6, 
above.  
 
9.7.2 Improving existing patient medicines helpline services 
 
Since the focus of this doctoral research is upon PMHS, the following 
recommendations are for those NHS Trusts that currently provide this service.  
It seems likely from the findings of this doctoral research that existing PMHS are 
underused (e.g., on average NHS Trusts receive five enquiries per week, and 
pharmacy professionals who provide PMHS perceive them to be underused). In 
order to increase the impact of PMHS, helpline providers are encouraged to 
consider ways to increase their use. The findings from this doctoral research 
suggest that this may be achievable by improving the access, availability, and 








Box 2. Examples of ways to improve the access, availability, and promotion of patient 
medicines helpline services (PMHS) 
• Increase the number of promotional methods, and/or conduct local improvement 
projects to establish the types of promotional methods that patients and carers 
recommend, and would most likely see and remember. 
• Promote the service at all sites within the organisation, and ensure that 
promotional methods clearly state the purpose of the service, the service’s 
opening times, and types of enquiries that can be made. 
• In order to reduce the cost of promotion, and increase the reach of PMHS, helpline 
providers could promote their service for free by ensuring that their helpline 
number is included within discharge summaries that patients receive. Some 
pharmacy professionals in Study 4 described how this particular promotional 
method resulted in an increased number of enquiries, suggesting that more 
patients who may need this service will learn of its existence. Additionally, ward 
pharmacists could tell their patients and patients’ carers about the PMHS during 
ward rounds, informing them that the details of the service will be available in 
their discharge summaries. 
• Extend the hours of availability, such as providing access to the service beyond 
typical 9–5 working hours (e.g., evenings and weekends). 
• Ensure that helpline staff are available to answer the telephone to receive 
enquiries, rather than relying on answerphones. 
• Provide access to the service by other means in addition to the telephone, such as 




Providers of PMHS are encouraged to use data on types of enquiries to PMHS 
to produce recommendations for improving local hospital services. For example, in the 
systematic review examining the characteristics of the types of enquiries received to 
PMHS (Study 3), six studies reported that enquiries were predominantly about adverse 
effects, and two studies reported that enquiries were predominantly about antimicrobial 
drugs. Therefore, potential projects could involve improving patient leaflets and 
counselling regarding adverse effects and antimicrobial drugs. Additionally, since a 
proportion of PMHS calls may be avoidable (e.g., calls received as a consequence of 
inadequate discharge counselling, and/or calls regarding medicines-related errors), 
PMHS providers could examine the types of calls they receive in order to learn from 
them and improve practice. Over time, certain enquiries (e.g., those regarding errors) 
may be reduced, which may also reduce the burden upon PMHS providers.  This may 
result in fewer resources being needed to provide a PMHS. It would also be useful if 
sites that provide a PMHS were more easily able to share learning from their local 
projects, and their ideas for implementing and maintaining a PMHS within a 
resource-limited context. This could be co-ordinated by regional MI centres, and 
published via the UK Medicines Information network (145). 
 
Providers of PMHS are also encouraged to evaluate the types of enquiries they 
receive by using standardised categories and coding instructions/training (e.g. those 
that were developed by the UK Medicines Information network). This will enable the 
types of enquiries to be more appropriately compared across sites and regions within 
the UK. Relatedly, the wide variety in error rates found across studies in the systematic 
review examining the effectiveness of PMHS (i.e. 8–39%; Study 2) may reflect the use 
of different definitions as to what constitutes a medicines-related error, since the 
definition of an error has been found to have an effect upon rates (146, 147). We 
therefore also recommend that sites use a standardised definition of ‘medicines-
related error’, including a standardised categorisation/coding scheme for collecting and 
analysing enquiry data. 
 
Another recommendation is that PMHS sites conduct service evaluations in 
order to provide a more detailed and standardised profile of enquirers. In the 
systematic review examining the types of enquirers to PMHS (Study 3), no studies 
were found that reported data pertaining to the ethnicity, educational 
level/socioeconomic status and the average number of medicines consumed by 
patient enquirers. This would help to establish how enquirers compare to the local 




to explore whether certain types of patients are less likely to use the service. This 
could result in projects to understand why, and whether more can be done to provide a 
PMHS that is equitable and available for all hospital patients who require support with 




The aim of this doctoral research was to address the following question: 
What is the impact of National Health Service (NHS) patient medicines helpline 
services upon service users and healthcare organisations? The findings show that 
PMHS provide timely medicines-related support to patients and carers following 
hospital discharge, and that PMHS are perceived as effective and valued from the 
perspectives of pharmacy professionals who provide them, and patients and carers 
who use them. However, the examination of the effectiveness of PMHS is limited by 
primarily consisting of subjective experiences and perceptions (e.g., survey data, a 
systematic review of service user satisfaction survey data, and two interview 
studies) rather than hard outcomes (e.g., readmission rates, symptoms and disease 
recurrence). Additionally, the RE-AIM framework conceptualises that effectiveness 
alone does not determine a service’s impact. The findings from this doctoral 
research also show that the impact of PMHS is hindered by its limited adoption, 
implementation, and reach. The limited adoption, implementation and reach of 
PMHS appear to be a consequence of limited resources and staffing. However, 
despite this, the findings also suggest that, once adopted, PMHS are likely to 
become a relatively stable service for NHS Trusts. PMHS are maintained because 
they are perceived to be beneficial and valued, despite their delivery also being 
perceived as suboptimal.  
 
Based upon the findings of this doctoral research, recommendations have 
been made to improve the delivery of PMHS, in order to provide a more valued and 
efficient service. There will always be limited resources available to provide 
healthcare services, and this is evident not just from the findings of this doctoral 
research, but also the examples provided in this discussion regarding pharmacy 
services and healthcare services more widely. It is therefore important to make the 
most of the resources that are available, and to use them wisely. Thus, one 
recommendation is for pharmacy professionals who provide a PMHS to share their 
learning with the wider MI community regarding ways to provide a PMHS with 




best to provide their service within a resource-limited context. However, since 
PMHS are currently provided suboptimally in terms of the numbers of Trusts that 
provide them and the varying ways that they have been implemented, and since 
research has not been conducted to establish their cost-effectiveness, another 
recommendation is for stakeholders to consider the best way to support patients 
with their medicines following discharge from secondary care. One option may be 
for patients to nominate a local community pharmacy to receive their discharge 
information so that the community pharmacy can be contacted regarding any 
queries. However, research is needed to establish whether this would be an 
improvement upon the current system of support. Therefore, the research 
recommendations from this doctoral research focus upon exploring the future of 
PMHS and establishing the best way to support all patients who need help with their 
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Appendix 1: Survey questions (Study 1) 
Survey 1 questions and answer options 
 
Question Answer type Answer options (if applicable) 
A patient medicines helpline can be defined as: "A telephone line, 
provided or commissioned by an NHS Trust, to enable patients and/or 
their carers to contact a pharmacy professional for medicines-related 
information and advice. It is advertised as being available for this 
purpose. It is specifically for medicines-related information and 
advice, and not for general clinical advice." Do patients and/or carers 
from your NHS Trust have access to a patient medicines helpline, as 
defined above? (This can include a helpline which is run by your Trust, 





   
Questions for Trusts that provide a medicines helpline (either via their own Trust or another Trust) 
   
Some NHS Trusts provide patients with access to a medicines helpline 
which is operated from another Trust. Other NHS Trusts may operate 
one or more patient medicines helpline (e.g., two helplines run from 
different hospitals within a Trust; or a general medicines helpline for 
all patients, and a specialist medicines helpline for patients of a 
particular clinical group). How many patient medicines helplines are 
being operated at your NHS Trust? (Please only include helplines 
which are specifically for patients to access information/advice about 
medicines only, rather than general clinical advice) 
Multiple choice, 
single response 
0 (Patients and carers from my NHS Trust have access to a 







   
Questions for Trusts that provide a patient medicines helpline via another organisation 
   
For whom at your NHS Trust is the patient medicines helpline 




Carers of patients from my NHS Trust. 
Discharged inpatients from my NHS Trust. 
Outpatients from my NHS Trust.  
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Any patient whose medication was prescribed and/or 
dispensed by my NHS Trust. 
A specific clinical group of patients at my NHS Trust (If so, 
please specify in 'Other', below). 
Other (please specify). 
   




Medicines Information Team/Service at another NHS Trust. 
Dispensary at another NHS Trust. 
General Clinical Pharmacy Service at another NHS Trust. 
Specialist Clinical Pharmacy Service at another NHS Trust (If 
so, please specify the type of specialist service in 'Other', 
below). 
Other (please specify). 
   
From approximately what year was the patient medicines helpline 
service available to patients from your NHS Trust? 
Free text box  
   






Other (Please specify). 
   
How is the patient medicines helpline promoted to patients at your 
NHS Trust? (Please tick all that apply) 
Multiple choice, 
multiple response 
Posters in clinical areas around the Trust. 
On the Trust website. 
Leaflet or business card in prescriptions. 
On medicines labels or medicines bag labels. 
On patients' discharge summary. 
Staff routinely tell patients about it (e.g., discharge 
counselling). 
Other (please specify). 
   
Where is the patient medicines helpline promoted? Please tick the 
most relevant statement, below. 
Multiple choice, 
single response 
The helpline is promoted at all sites within the Trust. 
The helpline is promoted at some sites within the Trust. 
The helpline is promoted at none of the sites within the 
Trust. 
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Do the promotional materials for the patient medicines helpline 
advertise the following? (Please tick all that apply) 
Multiple choice, 
multiple response 
Days/times of the week that the helpline is available. 
Examples of types of questions that service users can ask. 
None of the above. 
   
Are any of these other methods of communication advertised to 
patients as alternative ways to get in touch for medicines 




Online web form (e.g., via the Trust website). 
Face-to-face. 
Other (please specify). 
   
How were the promotional methods for the patient medicines 
helpline decided? (Please tick all that apply) 
Multiple choice, 
multiple response 
Patients from my NHS Trust were consulted. 
Recommendations from guidelines / published studies. 
Decided by Pharmacy/MI staff at my Trust. 
Other (please specify) 
   
Please read the following list and tick the options that you consider to 
be a major benefit or a minor benefit of providing a patient medicines 
helpline, based upon your experience. Leave any blank if you do not 
consider them to be a benefit. 
Multiple choice, 
multiple response 
Avoiding harm to patients (e.g., adverse effects, 
interactions). 
Identifying errors. 
Learning from patient experiences. 
Helping the organisation avoid complaints and possible 
litigation. 
Improving patient medication adherence. 
Supporting patient discharge. 
Providing assurance that patients can access professional 
advice at home. 
Improving the patient experience (e.g., patient satisfaction). 
Adhering to the NHS Constitution (e.g., patients have a right 
to information). 
Reducing visits to other healthcare services (e.g., GPs, A&E). 
Reducing medicines-related readmissions. 
Improvement in Trust targets and in national surveys (e.g., 
Adult Inpatient Survey). 
Optimising medicines. 
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Please use the space below if you have suggestions for other benefits 
of providing a patient medicines helpline which aren't on the list 
above. 
Free text box  
   
How do you see patient medicines helplines at NHS Trusts developing 
in the future? (Please consider the future at your Trust, and future 
changes within the NHS as a whole organisation) 
Free text box  
   
If you have any other comments about patient medicines helplines, or 
about the answers you have given in this survey, please use the space 
below. 
Free text box  
   
Questions for Trusts that operate at least one helpline (The majority of questions are asked about each helpline) 
   
Is there an agreement between your NHS Trust and any other NHS 
Trusts so that their patients can access the patient medicines helpline 
being operated at your Trust? If yes, with how many other Trusts is 
there such an agreement? 
Multiple choice, 
single response 






   
For whom is your medicines helpline available? (Please read all 
options and tick all that apply) 
Multiple choice, 
multiple response 
Carers of patients from my NHS Trust. 
Discharged inpatients from my NHS Trust. 
Outpatients from my NHS Trust. 
Any patient whose medication was prescribed and/or 
dispensed by my NHS Trust. 
A specific clinical group of patients at my NHS Trust (If so, 
please specify in 'Other', below). 
Patients from another NHS Trust (e.g., if another Trust 
shares your Medicines Information Team or Pharmacy 
Services). 
Anyone in the local area, regardless of whether they 
are/were a patient or not. 
Anyone who gets in touch, regardless of their location. 
Other (please specify). 
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Medicines Information Team/Service at my NHS Trust. 
Dispensary at my NHS Trust. 
General Clinical Pharmacy Service at my NHS Trust. 
Specialist Clinical Pharmacy Service at my NHS Trust (If so, 
please specify the type of specialist service in 'Other', 
below). 
Other (please specify). 
   
Approximately what year did the patient medicines helpline first start 
taking calls? 
Free text box  
   
On average, how many calls to the patient medicines helpline do you 
receive in a week? (Please provide an estimate if you are unsure) 
Free text box  
   
Does the phone line for the patient medicines helpline allow direct 





   
Is the phone number for the patient medicines helpline a dedicated 





   
What is the charge for calls to the patient medicines helpline? Multiple choice, 
single response 
Calls are charged at a local rate. 
Calls are charged at a premium rate. 
Calls are free. 
   






Other (Please specify) 
   
How is the patient medicines helpline promoted to patients at your 
NHS Trust? (Please tick all that apply) 
Multiple choice, 
multiple response 
Posters in clinical areas around the Trust. 
On the Trust website. 
Leaflet or business card in prescriptions. 
On medicines labels or medicines bag labels. 
On patients' discharge summary. 
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Staff routinely tell patients about it (e.g., discharge 
counselling). 
Other (please specify). 
   
Where is the patient medicines helpline promoted? Please tick the 
most relevant statement, below. 
Multiple choice, 
single response 
The helpline is promoted at all sites within the Trust. 
The helpline is promoted at some sites within the Trust. 
The helpline is promoted at none of the sites within the 
Trust. 
   
Do the promotional materials for the patient medicines helpline 
advertise the following? (Please tick all that apply) 
Multiple choice, 
multiple response 
Days/times of the week that the helpline is available. 
Examples of types of questions that service users can ask. 
None of the above. 
   
Please enter the number of hours per day that the patient medicines 
helpline is advertised as being available, in the relevant spaces below. 












   
Is a pharmacy professional always available to answer calls from 
patients during advertised hours? 
Multiple choice, 
single response 
Yes, and there is also an answerphone service where 
patients can leave a message for out-of-hours calls. 
Yes. 
No, although there is an answerphone service where 
patients can leave a message. 
No. 
   
Are any of these other methods of communication advertised to 
patients as alternative ways to get in touch for medicines 




Online web form (e.g., via the Trust website). 
Face-to-face. 
Other (please specify). 
   
How were the promotional methods for the patient medicines 
helpline decided? (Please tick all that apply) 
Multiple choice, 
multiple response 
Patients from my NHS Trust were consulted. 
Recommendations from guidelines / published studies. 
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Decided by Pharmacy/MI staff at my Trust. 
Other (please specify) 
   
Please read the following list and tick the options that you consider to 
be a major benefit or a minor benefit of providing a patient medicines 
helpline, based upon your experience. Leave any blank if you do not 




Avoiding harm to patients (e.g., adverse effects, 
interactions). 
Identifying errors. 
Learning from patient experiences. 
Helping the organisation avoid complaints and possible 
litigation. 
Improving patient medication adherence. 
Supporting patient discharge. 
Providing assurance that patients can access professional 
advice at home. 
Improving the patient experience (e.g., patient satisfaction). 
Adhering to the NHS Constitution (e.g., patients have a right 
to information). 
Reducing visits to other healthcare services (e.g., GPs, A&E). 
Reducing medicines-related readmissions. 
Improvement in Trust targets and in national surveys (e.g., 
Adult Inpatient Survey). 
Optimising medicines. 
   
Please use the space below if you have suggestions for other benefits 
of providing a patient medicines helpline which aren't on the list 
above. 
Free text box  
   
How do you see patient medicines helplines at NHS Trusts developing 
in the future? (Please consider the future at your Trust, and future 
changes within the NHS as a whole organisation) 
Free text box  
   
If you have any other comments about patient medicines helplines, or 
about the answers you have given in this survey, please use the space 
below. 
Free text box  
   
Questions for Trusts that do not provide a patient medicines helpline (neither via their own Trust, nor outsourced) 
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Has your NHS Trust provided patients with access to a medicines 





   
You answered that your NHS Trust provided patients to a medicines 
helpline in the past. Please could you provide the reason/s why the 
patient medicines helpline service was stopped? 
Free text box  
   
Does your NHS Trust have any plans to provide patients with access to 







   
Research suggests that approximately 50% of Medicines Information 
Centres in the UK do not operate a patient medicines helpline. We are 
interested to learn more about the reasons why some NHS Trusts 
have decided not to operate a helpline. In the space below, we would 
be grateful if you could please provide the reason/s why your Trust 
does not currently operate a patient medicines helpline. 
Free text box  
   
If a patient was to contact the Pharmacy Services team at your NHS 




Answer their query. 
Advise them to contact another service (e.g., their GP). 
Other (Please specify). 
   
How do you see patient medicines helpline services at NHS Trusts 
developing in the future? (Please consider future changes within the 
NHS as a whole organisation) 
Free text box  
   
If you have any other comments about patient medicines helplines, or 
about the answers you have given in this survey, please use the space 
below. 
Free text box  
   
Closing questions, for all respondents 
   
If you are happy to provide your job title, please enter this in the 
space below. 
Free text box  
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If you are happy to provide the name of your NHS Trust, please select 
it from the list below. 
Drop-down list. (List of all NHS Trusts in England, except Ambulance Trusts) 
   
Would you potentially be interested in finding out about other 
research on this particular topic, carried out by the Pharmacy & 
Pharmacology Department at the University of Bath? This will involve 
receiving the occasional email about research being carried out by this 
specific research team only, and does not commit you to taking part. 
You can unsubscribe from receiving the information at any time. If so, 
please enter your email address below. Your email address will only 
be used to inform you of research studies, and will not be given to any 
third parties. Your contact details will not be stored alongside the 
other data you have provided. 
Free text box  
   
Thank you for taking the time to complete this survey – your input is 
greatly appreciated. After reading this page, please click 'Finish', 
below, otherwise your answers will not be saved. Please tick the 
relevant boxes below, and if necessary provide your email address. 
Your email will only be used to inform you of the results and to 
contact you if you are randomly chosen to win the voucher, and will 
not be given to any third parties. Your contact details will not be 
stored alongside the other data you have provided. 
Multiple choice, 
multiple response 
/ free text box 
I would like to be included in the prize draw. 










Survey 2 questions and answer options 
 
Question Answer type Answer options (if applicable) 
Please read the following list and tick the options that you consider to 
be a major benefit or a minor benefit of providing a patient medicines 
helpline, based upon your experience. Leave any blank if you do not 




Avoiding harm to patients (e.g., adverse effects, 
interactions). 
Identifying errors. 
Learning from patient experiences. 
Helping the organisation avoid complaints and possible 
litigation. 
Improving patient medication adherence. 
Supporting patient discharge. 
Providing assurance that patients can access professional 
advice at home. 
Improving the patient experience (e.g., patient satisfaction). 
Adhering to the NHS Constitution (e.g., patients have a right 
to information). 
Reducing visits to other healthcare services (e.g., GPs, A&E). 
Reducing medicines-related readmissions. 
Improvement in Trust targets and in national surveys (e.g., 
Adult Inpatient Survey). 
Optimising medicines. 
   
Please use the space below if you have suggestions for other benefits 
of providing a patient medicines helpline which aren't on the list 
above. 
Free text box  
   
How do you see patient medicines helplines at NHS Trusts developing 
in the future? (Please consider the future at your Trust, and future 
changes within the NHS as a whole organisation) 
Free text box  
   
If you have any other comments about patient medicines helplines, or 
about the answers you have given in this survey, please use the space 
below. 
Free text box  
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Closing questions 
   
If you are happy to provide your job title, please enter this in the 
space below. 
Free text box  
   
If you are happy to provide the name of your NHS Trust, please select 
it from the list below. 
Drop-down list. (List of all NHS Trusts in England, except Ambulance Trusts) 
   
Would you potentially be interested in finding out about other 
research on this particular topic, carried out by the Pharmacy & 
Pharmacology Department at the University of Bath? This will involve 
receiving the occasional email about research being carried out by this 
specific research team only, and does not commit you to taking part. 
You can unsubscribe from receiving the information at any time. If so, 
please enter your email address below. Your email address will only 
be used to inform you of research studies, and will not be given to any 
third parties. Your contact details will not be stored alongside the 
other data you have provided. 
Free text box  
   
Thank you for taking the time to complete this survey – your input is 
greatly appreciated. After reading this page, please click 'Finish', 
below, otherwise your answers will not be saved. Please tick the 
relevant boxes below, and if necessary provide your email address. 
Your email will only be used to inform you of the results and to 
contact you if you are randomly chosen to win the voucher, and will 
not be given to any third parties. Your contact details will not be 
stored alongside the other data you have provided. 
Multiple choice, 
multiple response 
/ free text box 
I would like to be included in the prize draw. 





Appendix 2: Search strategy for EMBASE (Study 2) 
 
#1 'hotline'/exp AND ([embase]/lim OR [embase classic]/lim) 
#2 hotline*:ti,ab OR 'hot$line*':ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#3 helpline*:ti,ab OR 'help$line*':ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#4 'telephone'/exp AND ([embase]/lim OR [embase classic]/lim) 
#5 telephone*:ti,ab OR phone*:ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#6 'e-mail'/exp AND ([embase]/lim OR [embase classic]/lim) 
#7 email*:ti,ab OR 'e-mail*':ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#8 'internet'/exp AND ([embase]/lim OR [embase classic]/lim) 
#9 'internet*':ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#10 online:ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#11 webform*:ti,ab OR 'web$form*':ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#12 webpage*:ti,ab OR 'web$page*':ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#13 website*:ti,ab OR 'web$site*':ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#14 'web$based':ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#15 'mobile application'/exp AND ([embase]/lim OR [embase classic]/lim) 
#16 (((mobile NEXT/2 app):ti,ab) OR ((mobile NEXT/2 apps):ti,ab) OR ((mobile NEXT/2 application*):ti,ab)) 
AND ([embase]/lim OR [embase classic]/lim) 
#17 'mobile device*':ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#18 ('social network*' OR twitter OR tweet* OR facebook OR 'instant messag*' OR 'SMS'):ti,ab AND 
([embase]/lim OR [embase classic]/lim) 
#19 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 
OR #16 OR #17 OR #18 
#20 'pharmacy'/exp AND ([embase]/lim OR [embase classic]/lim) 
#21 'clinical pharmacy'/exp AND ([embase]/lim OR [embase classic]/lim) 
#22 'hospital pharmacy'/exp AND ([embase]/lim OR [embase classic]/lim) 
#23 'pharmacy school'/exp AND ([embase]/lim OR [embase classic]/lim) 
#24 (pharmacy:ti,ab OR pharmacies:ti,ab) AND ([embase]/lim OR [embase classic]/lim) 
#25 'pharmacist'/exp AND ([embase]/lim OR [embase classic]/lim) 
#26 'pharmacy technician'/exp AND ([embase]/lim OR [embase classic]/lim) 
#27 pharmacist*:ti,ab AND ([embase]/lim OR [embase classic]/lim) 
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#28 #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 
#29 ((drug* OR medicine* OR medication*) NEAR/5 (information OR advice OR support OR enquir* OR 
inquir*)):ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#30 #19 AND #28 AND #29 
#31 (telepharmac*:ti,ab OR 'tele$pharmac*':ti,ab) AND ([embase]/lim OR [embase classic]/lim) 
#32 ('epharmac*':ti,ab OR 'e$pharmac*':ti,ab) AND ([embase]/lim OR [embase classic]/lim) 
#33 ((drug* OR medicine* OR medication*) NEAR/5 (hotline* OR hot$line*)):ti,ab AND ([embase]/lim OR 
[embase classic]/lim) 
#34 ((drug* OR medicine* OR medication*) NEAR/5 (helpline* OR help$line)):ti,ab AND ([embase]/lim OR 
[embase classic]/lim) 
#35 ((drug* OR medicine* OR medication*) NEAR/5 'call cent*'):ti,ab AND ([embase]/lim OR [embase 
classic]/lim) 
#36 ((drug* OR medicine* OR medication*) NEAR/5 'information cent*'):ti,ab AND ([embase]/lim OR 
[embase classic]/lim) 
#37 ((drug* OR medicine* OR medication*) NEAR/5 'information service*'):ti,ab AND ([embase]/lim OR 
[embase classic]/lim) 
#38 ((drug* OR medicine* OR medication*) NEAR/5 'information line*'):ti,ab AND ([embase]/lim OR 
[embase classic]/lim) 





Appendix 3: Grey literature search strategy (Study 2) 
 
Appendix S2. Grey literature search strategy 
Godin et al. recommend applying a systematic approach when searching for grey literature (1).  
Following their recommendations, four grey literature sources were searched:  
1) Grey literature databases. OpenGrey and ProQuest database for dissertations and theses were searched 
using the following search terms: ‘medicines information’, ‘medicines helpline’, ‘drug information’, and 
‘drug helpline’.  
2) Google and Google Scholar. The Google search involved evaluating the relevance of all available hits 
when searching for the exact terms ‘patient medicines helpline’, ‘medicines information centre’, ‘drug 
information helpline’, ‘drug information center’, and ‘drug information service’. The Google Scholar search 
involved evaluating the relevance of all available hits when searching for the exact terms ‘patient medicines 
helpline’, ‘medicines information centre’ , ‘drug information helpline’, ‘drug information center’, and ‘drug 
information service’, and then repeating the searches when limiting the terms to appearing in the title only. 
Limiting the search to ‘title only’ was recommended by Haddaway et al. (2), who conducted an evaluation 
using Google Scholar to search for grey literature in seven published systematic reviews. 
3) Targeted websites. Websites of the following UK conferences were searched for conference proceedings: 
UK Medicines Information Practice Development Seminar (1998-2017), Royal Pharmaceutical Society 
Conference (formerly called British Pharmaceutical Conference; 1998-2017), Health Services Research and 
Pharmacy Practice Conference (1998-2018), and International Social Pharmacy Workshop (2004-2018). 
4) Consultation with experts. Where possible, the main author of all included studies that were published 
within the last ten years were contacted, requesting details of any similar research already completed or 







1. Godin K, Stapleton J, Kirkpatrick SI, Hanning RM, Leatherdale ST. Applying systematic review search 
methods to the grey literature: A case study examining guidelines for school-based breakfast programs in 
Canada. Systematic Reviews. 2015;4(1). 
2. Haddaway NR, Collins AM, Coughlin D, Kirk S. The role of Google Scholar in evidence reviews and its 




Appendix 4: Data extraction form (Study 2) 
 
Source of study: 
 
 















Type of service: 
 
 















Appendix 5: Quality assessment and risk of bias table (Study 2) 
 
Supplementary Table. Quality assessment and risk of bias in peer-reviewed published studies 
meeting eligibility criteria for the systematic review. 
First author, Year published Total a RoB b QoR QoSD 
Ansani, 2006 45% (9/20) 67% (4/6) 57% (4/7) 43% (3/7) 
Badiani, 2017 50% (10/20) 50% (3/6) 57% (4/7) 43% (3/7) 
Bramley, 2014 63% (12/19) 40% (2/5) 71% (5/7) 57% (4/7) 
Bramley, 2018 55% (11/20) 50% (3/6) 86% (6/7) 29% (2/7) 
Conner, 1980 41% (7/17) 33% (1/3) 14% (1/7) 57% (4/7) 
Conner, 1982 29% (5/17) 67% (2/3) 29% (2/7) 29% (2/7) 
Joseph, 2004 50% (10/20) 83% (5/6) 71% (5/7) 57% (4/7) 
Marvin, 2011 65% (11/17) 67% (2/3) 71% (5/7) 71% (5/7) 
Maywald, 2004 45% (9/20) 67% (4/6) 57% (4/7) 43% (3/7) 
MeInyk, 2000 30% (6/20) 83% (5/6) 43% (3/7) 29% (2/7) 
MeInyk, 2000 50% (10/20) 67% (4/6) 43% (3/7) 71% (5/7) 
Muhammad, 1998 25% (5/20) 100% (6/6) 14% (1/7) 57% (4/7) 
Olofinjana, 2009 60% (12/20) 50% (3/6) 86% (6/7) 43% (3/7) 
Rutter, 2012 70% (14/20) 67% (4/6) 86% (6/7) 86% (6/7) 
Smith, 1985 45% (9/20) 100% (6/6) 57% (4/7) 71% (5/7) 
Williams, 2018 c 95% (19/20) 17% (1/6) 100% (7/7) 100% (7/7) 
Abbreviations: RoB = risk of bias score (out of a maximum score of 6); QoR = quality of 
reporting score (out of a maximum score of 7); QoSD = quality of study design score (out of a 
maximum score of 7). 
a Quality assessment was measured using the AXIS tool, developed by Downes et al. (2016). 
Depending on the study design, not all items were relevant. This accounts for the different 
possible maximum scores across studies. 
b For the Risk of Bias subscale, the items were reversed so that higher scores in this table 
reflect greater potential for bias.  However, the AXIS total score was calculated without 
reversing the Risk of Bias items, to ensure that the reported total score percentages reflect 
the amount of positively coded items in the tool. This accounts for the apparent discrepancy 
in this table between the total score and the sum of the subscales for each study.  
c The study by Williams et al. (2018) was conducted by the authors of this systematic review. 
Quality assessment and risk of bias for this study was conducted by two postgraduate 







Appendix 6: Search strategy for EMBASE (Study 3) 
 
 
Appendix S1. Search strategy for EMBASE 
 
#1 'hotline'/exp AND ([embase]/lim OR [embase classic]/lim) 
#2 hotline*:ti,ab OR 'hot$line*':ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#3 helpline*:ti,ab OR 'help$line*':ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#4 'telephone'/exp AND ([embase]/lim OR [embase classic]/lim) 
#5 telephone*:ti,ab OR phone*:ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#6 'e-mail'/exp AND ([embase]/lim OR [embase classic]/lim) 
#7 email*:ti,ab OR 'e-mail*':ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#8 'internet'/exp AND ([embase]/lim OR [embase classic]/lim) 
#9 'internet*':ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#10 online:ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#11 webform*:ti,ab OR 'web$form*':ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#12 webpage*:ti,ab OR 'web$page*':ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#13 website*:ti,ab OR 'web$site*':ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#14 'web$based':ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#15 'mobile application'/exp AND ([embase]/lim OR [embase classic]/lim) 
#16 (((mobile NEXT/2 app):ti,ab) OR ((mobile NEXT/2 apps):ti,ab) OR ((mobile NEXT/2 application*):ti,ab)) 
AND ([embase]/lim OR [embase classic]/lim) 
#17 'mobile device*':ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#18 ('social network*' OR twitter OR tweet* OR facebook OR 'instant messag*' OR 'SMS'):ti,ab AND 
([embase]/lim OR [embase classic]/lim) 
#19 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 
OR #16 OR #17 OR #18 
#20 'pharmacy'/exp AND ([embase]/lim OR [embase classic]/lim) 
#21 'clinical pharmacy'/exp AND ([embase]/lim OR [embase classic]/lim) 
#22 'hospital pharmacy'/exp AND ([embase]/lim OR [embase classic]/lim) 
#23 'pharmacy school'/exp AND ([embase]/lim OR [embase classic]/lim) 
#24 (pharmacy:ti,ab OR pharmacies:ti,ab) AND ([embase]/lim OR [embase classic]/lim) 
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#25 'pharmacist'/exp AND ([embase]/lim OR [embase classic]/lim) 
#26 'pharmacy technician'/exp AND ([embase]/lim OR [embase classic]/lim) 
#27 pharmacist*:ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#28 #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 
#29 ((drug* OR medicine* OR medication*) NEAR/5 (information OR advice OR support OR enquir* OR 
inquir*)):ti,ab AND ([embase]/lim OR [embase classic]/lim) 
#30 #19 AND #28 AND #29 
#31 (telepharmac*:ti,ab OR 'tele$pharmac*':ti,ab) AND ([embase]/lim OR [embase classic]/lim) 
#32 ('epharmac*':ti,ab OR 'e$pharmac*':ti,ab) AND ([embase]/lim OR [embase classic]/lim) 
#33 ((drug* OR medicine* OR medication*) NEAR/5 (hotline* OR hot$line*)):ti,ab AND ([embase]/lim OR 
[embase classic]/lim) 
#34 ((drug* OR medicine* OR medication*) NEAR/5 (helpline* OR help$line)):ti,ab AND ([embase]/lim OR 
[embase classic]/lim) 
#35 ((drug* OR medicine* OR medication*) NEAR/5 'call cent*'):ti,ab AND ([embase]/lim OR [embase 
classic]/lim) 
#36 ((drug* OR medicine* OR medication*) NEAR/5 'information cent*'):ti,ab AND ([embase]/lim OR 
[embase classic]/lim) 
#37 ((drug* OR medicine* OR medication*) NEAR/5 'information service*'):ti,ab AND ([embase]/lim OR 
[embase classic]/lim) 
#38 ((drug* OR medicine* OR medication*) NEAR/5 'information line*'):ti,ab AND ([embase]/lim OR 
[embase classic]/lim) 






Appendix 7: Grey literature search strategy (Study 2) 
 
Appendix S2. Grey literature search strategy 
Godin et al. recommend applying a systematic approach when searching for grey literature (1).  
Following their recommendations, four grey literature sources were searched:  
1) Grey literature databases. OpenGrey and ProQuest database for dissertations and theses were searched 
using the following search terms: ‘medicines information’, ‘medicines helpline’, ‘drug information’, and 
‘drug helpline’.  
2) Google and Google Scholar. The Google search involved evaluating the relevance of all available hits 
when searching for the exact terms ‘patient medicines helpline’, ‘medicines information centre’, ‘drug 
information helpline’, ‘drug information center’, and ‘drug information service’. The Google Scholar search 
involved evaluating the relevance of all available hits when searching for the exact terms ‘patient medicines 
helpline’, ‘medicines information centre’ , ‘drug information helpline’, ‘drug information center’, and ‘drug 
information service’, and then repeating the searches when limiting the terms to appearing in the title only. 
Limiting the search to ‘title only’ was recommended by Haddaway et al. (2), who conducted an evaluation 
using Google Scholar to search for grey literature in seven published systematic reviews. 
3) Targeted websites. Websites of the following UK conferences were searched for conference proceedings: 
UK Medicines Information Practice Development Seminar (1998-2017), Royal Pharmaceutical Society 
Conference (formerly called British Pharmaceutical Conference; 1998-2017), Health Services Research and 
Pharmacy Practice Conference (1998-2018), and International Social Pharmacy Workshop (2004-2018). 
4) Consultation with experts. Where possible, the main author of all included studies that were published 
within the last ten years were contacted, requesting details of any similar research already completed or 







1. Godin K, Stapleton J, Kirkpatrick SI, Hanning RM, Leatherdale ST. Applying systematic review search 
methods to the grey literature: A case study examining guidelines for school-based breakfast programs in 
Canada. Systematic Reviews. 2015;4(1). 
2. Haddaway NR, Collins AM, Coughlin D, Kirk S. The role of Google Scholar in evidence reviews and its 
applicability to grey literature searching. PLoS One. 2015;10(9). 
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Appendix 8: Data extraction form (Study 3) 
 
Source of study: 
 
 















Type of service: 
 
 















Appendix 9: Participant characteristics (Study 4) 
 
Supplementary Table 1. Participant characteristics (detailed) 
Participant 
number 
Gender Job title 
Years employed 




NHS Trust type 
P1 Female Lead MI Pharmacist 35 8 Acute 
P2 Female Lead MI Pharmacist 6 6 Acute 
P3 Female MI Manager 21 6 Acute 
P4 Male Chief Pharmacist 30 6 Acute 
P5 Male Lead MI Pharmacist 10 4 Acute 
P6 Female Lead MI Pharmacist 14 7 Acute 
P7 Female MI Pharmacist 6 2 Acute 
P8 Male Pharmacist 3 6 months Acute 
P9 Female Chief Pharmacist 18 9 Specialist 
P10 Female Lead MI Pharmacist 7 6 Acute 
P11 Female MI Pharmacist 4 2 Acute 
P12 Female Pharmacist 23 5 Mental health 
P13 Female Senior MI Pharmacist 19 10 Acute 
P14 Female Chief Pharmacist 33 5 Acute 
P15 Female MI Manager 25 10 Acute 
P16 Male Pharmacist 3 9 months Mental health 
P17 Female Lead MI Technician 26 3.5 Integrated 
P18 Female Chief Pharmacist 37 4 Integrated 
P19 Female MI Pharmacist 3 1 Acute 
P20 Female Lead Pharmacist 20 12 Specialist 
P21 Female Lead MI Pharmacist 15 1.5 Acute 
P22 Male Senior MI Pharmacist 19 5 Acute 
P23 Female Lead MI Pharmacist 8 5 Acute 
P24 Female Lead MI Pharmacist 22 7 Acute 
P25 Female Lead MI Pharmacist 7 5.5 Acute 
P26 Female Lead MI Pharmacist 13 5 Acute 
P27 Male Lead MI Pharmacist 15 2 Community 
P28 Female Lead MI Pharmacist 12 3 Acute 
P29 Female MI Pharmacist 21 19 Acute 
P30 Female Senior Pharmacist 28 5 Mental health 
P31 Male Junior Pharmacist 3 2.5 Acute 
P32 Female Lead MI Pharmacist 17 7 Acute 
P33 Male MI Manager 7 2 Acute 
P34 Female Senior MI Pharmacist 6 3 Acute 






Appendix 10: Interview schedule (Study 4) 
 
Q1 To begin, could you please tell me about your role within your NHS Trust’s 
Pharmacy Services? 
Q2 Please could you tell me about your role in relation to the patient medicines 
helpline service? 
 Probe – [For pharmacists, not chief pharmacists] Please could you tell me your 
responsibilities in terms of the patient medicines helpline?  
Probe – [For both pharmacists and chief pharmacists] Did you help to set up the patient 
medicines helpline? If so, please could you describe what your involvement was in 
setting the service up? 
Q3 Please could you describe why your patient medicines helpline service was 
developed? 
 Probe – Research studies? Guidelines? (If so, which?) Awareness of national standards?  
Probe – What do you consider to be the purpose of the patient medicines helpline 
service? (Has its purpose changed over time? If so, in what ways? And Why?) 
Q4 Please could you tell me your thoughts about your patient medicines helpline 
service? 
 For example, meeting its aims.  
Probe - Is there anything you’d like to say about the cost of running the service? 
Probe - Is there anything you’d like to say about how the service may have developed 
since it first began? 
Q5 Please could you tell me what you consider to be the positive aspects of 
operating a patient medicines helpline service? 
 For example… 
Probe – Aspects that are positive for service users.  
Probe – Aspects that are positive for you/the MI team (e.g., learning from adverse 
patient experiences). 
Probe – Aspects that are positive for the hospital/NHS Trust (e.g., learning from adverse 
patient experiences; service improvement initiatives as a result of operating a PMH). 
Probe – Are there any other positive aspects of operating your patient medicines 
helpline which you haven’t mentioned so far? 
Q6 Please could you tell me about any challenges of operating a patient medicines 
helpline service? 
 For example… 
Probe – Aspects that are negative/unhelpful/risks/safety issues for service users. 
Probe – Aspects that are negative/unhelpful for you/the MI team 
Probe – Aspects that are negative/unhelpful for the hospital/NHS Trust. 
Probe – Are there any other challenges of operating your patient medicines helpline 
service which you haven’t mentioned so far? 
Q7 Please can you tell me your thoughts regarding whether the patient medicines 
helpline service meets the needs of patients and carers? 
 For example, their medicines information needs; their support needs. 
Probe – Please could you explain why?/why not? 
Probe – Is there anything you’d like to say about the uptake of the service? 
(If they mention lack of use: Probe - Do you have any suggestions as to why this might 
be? Probe – Lack of promotion; lack of need; use of other services (if so, which?)). 
Probe – Is there anything you’d like to say about the types of patients/people who use 
246 
 
the service?  
Probe – Are there any types of patients/people who you think could benefit from the 
service but who don’t typically use it? (If so, who? And why?) 
(If not already known from previous answers) 
Q8 Can you tell me your thoughts regarding the cost-effectiveness of the patient 
medicines helpline? 
 Probe – (If not already known) Please could you say how your helpline service is funded? 
Q9 Please could you tell me about any aspects of your patient medicines helpline 
service that you think could be improved? 
 Probe - If so, why? / In what way? 
 
For example…. 
Probe – Service user access. (Alternative methods? Online chat? Email? Skype / 
facetime?) 
Probe – Helpline availability. 
Probe – Helpline promotion. 
Probe – Procedures you use (e.g., documenting the calls; use of a SOP). 
Probe –IT systems and technology you use.  
Probe – Service user involvement (e.g., including feedback/satisfaction surveys). 
Probe – Mechanisms to feed back to the Trust any issues/errors which become apparent 
during the operation of the service. 
 
Probe – (If not already mentioned) Are you aware of the national standards which are 
available for operating a patient medicines helpline service? Have you used them to 
develop your service? If so, in what ways? 
Q10 Research suggests that sometimes people contact a patient medicines helpline 
service if there is an error with their medicines. Please could you describe any 
process that occurs if a helpline call reveals that an error has been made with a 
patient’s medicines? 
 Probe – Learning from errors / Service improvement initiatives. 
Q11 In what ways do you think the helpline service could be used to improve 
practice, within Pharmacy Services and the wider organisation? 
 Probe – For example, if data is routinely collected about errors, using that information to 
improve practice. 
Probe – [If not yet known] Based upon the examples you’ve given, are these means of 
improvement used at your hospital to improve practice? 
Q12 What qualities do you perceive to be important in order to provide a successful 
patient medicines helpline service? 
 Probe – (if not obvious) Why are these things important? 
Probe – What staff skills are important? (Training? Standard operating procedures?) 
Q13 How do you see patient medicines helplines at NHS Trusts developing in the 
future? 
 Probe – Developing the service at your NHS Trust, specifically (e.g., additional ways of 
accessing the service; availability of the service; promotion; procedures; IT/technology 
to provide the service; service user involvement). 
Probe – Developments within the UK generally (e.g., move towards regional/shared 
services - Carter Report / 5 year forward review / sustainability and transformation 
plans). 
Probe – Any perceived financial/funding issues in the future. 
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Q14 In what ways is local knowledge needed in order to deal with helpline 
enquiries? By ‘local knowledge’, I mean knowledge that is available at your 
hospital or NHS Trust only (e.g., patient records, local policies and procedures, 
advice from clinicians who cared for the patient). 
 Probe – patient records; access to relevant clinical staff; local policies and procedures. 
Q15 What do you think the impact would be if patient medicines helpline services 
became regional or national in the future, instead of local to hospitals? 
 Probe – Impact of this upon the service / quality of the service / the type of information 
that could be provided? 
Q16 Those are all of the questions that I have about patient medicines helpline 
services. Although, is there anything else which you would like to say about 
patient medicines helpline services, which you feel would be important to 








Appendix 11: Interview schedules (Study 5) 
 
Interview schedule for patients 
 
Q1 For background information, please could you tell me about your recent 
admission/period of care?  
 For example, please could you tell me why you were admitted? / why were you 
receiving care? 
Probe – For how long were you admitted? 
Probe – Please could you tell me about any other hospital admissions you may have 
had recently? (timeframe – past 2 months) 
Q2 Prior to using the helpline service recently, please can you tell me what you would 
typically do if you had a question or concern with your medicines? 
 For example, your GP, or a community pharmacist, or NHS 111 or NHS Direct. 
Probe – Have you used the patient medicines helpline service in the past? If so, what was your 
experience of using the helpline previously? 
Q3 How did you hear about the medicines helpline service? 
Q4 Please could you tell me why you contacted the medicines helpline service on 
[date]? 
 [Additional questions about the medicines issue/query…] 
Probe – Please could you tell me about the medicine or medicines you were concerned 
about? (e.g., what it was; what it is for; what your concerns were).  
Probe – How did you feel about your medicines before you contacted the medicines helpline 
service? 
Probe - What impact (if any) did this issue [use their words] have upon you before you 
contacted the medicines helpline service and spoke to a pharmacist? (e.g., Physical 
symptoms, Anxiety/worry/stress, Inconvenience, Not taking medicines as prescribed) 
Probe – Please can you tell me your thoughts about the seriousness of the issue/situation [use 
their words]? (and why) 
Probe – Was there anything else you contacted the medicines helpline service about? (If so, 
what?) 
[Additional questions about their circumstances…] 
Probe – Can you tell me about anyone who encouraged you to contact the medicines helpline 
service? For example, who this was, and why they encouraged you to do this. 
[Additional questions about other sources of information…] 
Probe – Please can you tell me about any other sources of information that you may have 
considered using? For example, what these were, and why you didn’t use these. Why you 
contacted the medicines helpline instead. (Or if you did use any other sources of information 
before contacting the helpline service, what were your experiences of using them?). What are 
the advantages of the helpline service compared to the other options you considered? 
[If a medicines-related error has been disclosed, go to Q5. If not, go to Q6]  
 
Q5 You said that there was an error with your medicines/omission/lack of information 
or instructions [use their words]. Please can you tell me about this? 
 Probe – What was the error/omission/lack of instructions? 
Probe - How did you realise that there was an error/omission/lack of instructions? 
Probe – When did you realise that there was an error/omission/lack of instructions? 
249 
 
Probe - How did you feel when you realised that there was an error/omission/lack of 
instructions? (How did you react?) 
Probe – Has this issue been fully resolved? If so, how? 
Probe - How do you feel about this issue now? 
Q6 Please can you tell me about the conversation you had with the pharmacist when 
you contacted the helpline? 
 Probe - How well did you feel that the pharmacist understood your query/concern/issue? 
Probe - What did they say or do to make you feel this way? 
[If not already known from the previous question…] 
Q7 Please could you describe what information or advice the pharmacist gave you 
when you contacted the helpline service? 
 Probe – How well did you understand the information that the pharmacist gave you during 
the call? (What about your understanding of the information by the end of the call?) 
Probe - Was there anything else that the pharmacist said to you? (If so, what?) 
Probe - How did you feel about the information/advice you received from the pharmacist? 
Probe – Was anything left unresolved? If so, what? Why was it left unresolved? 
Probe – How did you feel directly after using the helpline service? (e.g., worried/anxious, 
reassured, relieved?) If so, why? 
Q8 Please can you tell me your thoughts about the medicines helpline service? 
 For example, could you tell me about … 
– what it was like accessing the service? (e.g., time taken to get through to the service; 
whether you had to call back? (if so, how was this?); whether you had to leave a message and 
someone got back to you? (if so, how was this?))  
– the pharmacist? 
– the time taken to answer your enquiry? 
– the amount of information you received? (e.g., was it enough? Too much?) 
– the advertisements for the service?  
 
Probe - Why were these particular aspects [use their words] helpful to you? 
Probe - Why were these particular aspects [use their words] unhelpful to you? 
 
Could you tell me about any other aspects of the service that you may have found to be either 
helpful or unhelpful? 
Q9 Please can you tell me your thoughts about improving the helpline service? 
 Probe – If you could change the service in any way, to make it more useful for you and other 
people, how would you change it? (And why?) 
[The probes for the previous question may be relevant here] 
 
Can you think about any other useful ways in which you would have liked to communicate 
with the medicines information service? (Why would these be useful?) 
For example, online chat / Skype / email. 
Q10 How have things been for you in the XX weeks since you used the helpline service? 
 Probe – Can you tell me about any other sources that you may have used to get information 
or advice about your medicines, since contacting the medicines helpline service? (For 
example, your GP, another pharmacist, online?) 
[If not already known from the previous questions…] 
Q11 Please can you tell me about any changes to your medicines since you contacted the 
helpline service?  
 For example, can you tell me about how you were taking your medicines before you 
contacted the helpline?  Can you tell me about how you are taking your medicines now?   
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[Check if changes are in accordance with the advice from the pharmacist. If they aren’t, check 
why]. 
Probe – What were your reasons for making this change? 
Probe – What effects (if any) has this change to your medicines had? (e.g., any positive 
effects; any downsides as a result of the change) 
Please can you tell me what you think about the safety of your medicines? (Probe how this 
was before the helpline use compared to afterwards) 
[If not already known from the previous question…] 
Q12 Please can you tell me about any changes to your health since you contacted the 
medicines helpline service? 
 Probe for any positive and negative changes 
Probe - If so, what changes? (If not, do you think there will be changes on your health? If so, in 
what ways?) 
[If not already known from the previous questions…] 
Q13 Please tell me about any other changes you may have experienced since you 
contacted the medicines helpline service? 
 For example, regarding your understanding of your medicines. 
Q14 How do you currently feel about your medicine/s? 
Q15 How do you currently feel about the hospital or NHS Trust where you recently 
received care? 
(If not already known…) 
Q16 What would you have done about this issue [use their words], had the helpline 
service not been available? 
 Probe – Please can you tell me what you think would have happened had you not contacted 
the helpline service? (Try to probe for their thoughts about avoided harm). 
Probe – Please could you tell me the reason why you would’ve instead [use their words, e.g., 
‘gone to your gp’] about this particular issue rather than any other source of support? 
Probe – What would you have done if the helpline service was operated from another NHS 
Trust in the region to the one where you recently received care? (Probe why) 
Probe – What would you have done if the helpline service was a national helpline, instead of 
local to you? (Probe why) 
Q17 Those are all of the questions that I have about your recent use of the patient 
medicines helpline service. Although, is there anything else which you would like to 
say about your use of the medicines helpline service, which you feel would be 
important to share at this point? 
 
 
Interview schedule for carers 
 
Q1 Prior to using the helpline service recently, please can you tell me what you would 
typically do if you had a question or concern about medicines? 
 For example, a GP, or a community pharmacist, or NHS 111 or NHS Direct. 
Probe – Have you used the patient medicines helpline service in the past? If so, what was your 
experience of using the helpline previously? 
Q2 How did you hear about the medicines helpline service? 
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Q3 Could you please tell me why you contacted the medicines helpline service on 
[date]? 
 [Additional questions about the medicines issue/query…] 
Probe – How did you feel about the medicines before you contacted the medicines helpline 
service? 
Probe – What impact (if any) did this issue [use their words] have before you contacted the 
medicines helpline service and spoke to a pharmacist? 
Probe – Please can you tell me your thoughts about the seriousness of the issue/situation [use 
their words]? (and why) 
Probe – Was there anything else you contacted the medicines helpline service about? (If so, 
what?) 
[Additional questions about other sources of information…] 
Probe – Please can you tell me about any other sources of information that you may have 
considered using? For example, what these were, and why you didn’t contact these. Why you 
contacted the medicines helpline instead. (Or if you did use any other sources of information 
before contacting the helpline service, what were your experiences of using them?). What are 
the advantages of the helpline service compared to the other options you considered? 
[If a medicines-related error has been disclosed, go to Q4. If not, go to Q5]  
Q4 You said that there was an error with the patient’s medicines/omission/lack of 
information or instructions [use their words]. Please can you tell me about this? 
 Probe – What was the error/omission/lack of instructions? 
Probe - How did you realise that there was an error/omission/lack of instructions? 
Probe – When did you realise that there was an error/omission/lack of instructions? 
Probe - How did you feel when you realised that there was an error/omission/lack of 
instructions? (How did you react?) 
Probe – Has this issue been fully resolved? If so, how? 
Probe - How do you feel about this issue now? 
Q5 Please can you tell me about the conversation you had with the pharmacist when 
you contacted the helpline? 
 Probe - How well did you feel that the pharmacist understood your query/concern/issue? 
Probe - What did they say or do to make you feel this way? 
[If not already known from the previous question…] 
Q6 Please could you describe what information or advice the pharmacist gave you 
when you contacted the helpline service? 
 Probe – How well did you understand the information that the pharmacist gave you during 
the call? (What about your understanding of the information by the end of the call?) 
Probe - Was there anything else that the pharmacist said to you? (If so, what?) 
Probe - How did you feel about the information/advice you received from the pharmacist? 
Probe – Was anything left unresolved? If so, what? Why was it left unresolved? 
Probe – How did you feel directly after using the helpline service? (e.g., worried/anxious, 
reassured?) If so, why? 
Q7 Please can you tell me your thoughts about the medicines helpline service? 
 For example, could you tell me about … 
– what it was like accessing the service? (e.g., time taken to get through to the service; 
whether you had to call back? (if so, how was this?); whether you had to leave a message and 
someone got back to you? (if so, how was this?))  
– the pharmacist? 
– the time taken to answer your enquiry? 
– the amount of information you received? (e.g., was it enough? Too much?) 




Probe - Why were these particular aspects [use their words] helpful to you? 
Probe - Why were these particular aspects [use their words] unhelpful to you? 
 
Could you tell me about any other aspects of the service that you may have found to be either 
helpful or unhelpful? 
Q8 Please can you tell me your thoughts about improving the helpline service? 
 Probe – If you could change the service in any way, to make it more useful for you and other 
people, how would you change it? (and why?) 
[The probes for the previous question may be relevant here] 
 
Can you think about any other useful ways in which you would have liked to communicate 
with the medicines information service? (Why would these be useful?) 
Q9 How have things been in the XX weeks since you used the helpline service? 
 Probe – Can you tell me about any other sources that you may have used to get information 
or advice about the medicines, since contacting the medicines helpline service? (For example, 
a GP, another pharmacist, online?) 
[If not already known from the previous questions…] 
Q10 Please can you tell me about any changes to the medicines since you contacted the 
helpline service? 
 Probe – What were the reasons for making this change? 
Probe – What effects (if any) has this change to the medicines had? (e.g., any positive effects; 
any downsides as a result of the change) 
Please can you tell me what you think about the safety of the medicines? (Probe how this was 
before the helpline use compared to afterwards) 
[If not already known from the previous questions…] 
Q11 Please tell me about any other changes you may have experienced since you 
contacted the medicines helpline service? 
 For example, regarding your understanding of the medicines. 
Q12 How do you currently feel about the medicines being taken by [the person you care 
for]? 
Q13 How do you currently feel about the hospital or NHS Trust? 
(If not already known…) 
Q14 What would you have done about this issue [use their words], had the helpline 
service not been available? 
 Probe – Please can you tell me what you think would have happened had you not contacted 
the helpline service? (Try to probe for their thoughts about avoided harm). 
Probe – Please could you tell me the reason why you would’ve instead [use their words, e.g., 
‘gone to your gp’] about this particular issue rather than any other source of support? 
Probe – What would you have done if the helpline service was operated from another NHS 
Trust in the region to the one where you recently received care? (Probe why) 
Probe – What would you have done if the helpline service was a national helpline, instead of 
local to you? (Probe why) 
Q15 Those are all of the questions that I have about your recent use of the patient 
medicines helpline service. Although, is there anything else which you would like to 
say about your use of the medicines helpline service, which you feel would be 




Appendix 12: Participant characteristics (Study 5) 
Supplementary Table. Participant characteristics (detailed) 
Participant 
number 
Caller type Gender Age range Occupational status NHS Trust type 
P1 Carer Female 50-59 Carer and/or homemaker Acute 
P2 Patient Male 60-69 Retired Acute 
P3 Patient Male 80-89 Retired Acute 
P4 Carer Female 70-79 Retired Acute 
P5 Patient Female 50-59 Unemployed Acute 
P6 Patient Female 60-69 Unemployed Mental Health 
P7 Patient Female 70-79 Retired Acute 
P8 Patient Male 80-89 Retired Acute 
P9 Patient Female 70-79 Retired Acute 
P10 Patient Female 70-79 Retired Acute 
P11 Carer Male 70-79 Retired Acute 
P12 Patient Female 70-79 Retired Acute 
P13 Carer Female 50-59 Retired Acute 
P14 Patient Female 60-69 Retired Acute 
P15 Patient Male 70-79 Retired Acute 
P16 Patient Female 50-59 Employed Acute 
P17 Patient Female 60-69 Employed Acute 
P18 Patient Male 70-79 Retired Acute 
P19 Patient Female 60-69 Retired Acute 
P20 Patient Male 70-79 Retired Acute 
P21 Patient Male 60-69 Retired Acute 
P22 Patient Female 70-79 Retired Acute 
P23 Patient Male 50-59 Retired Acute 
P24 Patient Male 80-89 Retired Acute 
P25 Patient Male 70-79 Retired Acute 
P26 Patient Female 70-79 Retired Acute 
P27 Patient Female 50-59 Employed Acute 
P28 Patient Female 70-79 Retired Acute 
P29 Patient Male 80-89 Retired Specialist 
P30 Carer Male 70-79 Retired Acute 
P31 Patient Male 70-79 Retired Acute 
P32 Carer Female 50-59 Carer and/or homemaker Acute 
P33 Patient Female 70-79 Retired Acute 
P34 Patient Female 60-69 Retired Acute 
P35 Patient Male 40-49 Unemployed Acute 
P36 Carer Female 70-79 Retired Acute 
P37 Patient Male 40-49 Employed Acute 
P38 Patient Female 70-79 Retired Acute 
P39 Patient Male 70-79 Retired Acute 
P40 Patient Female 40-49 Unemployed Acute 
Note. Abbreviations: NHS = National Health Service. 
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